<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US6573099 - Genetic constructs for delaying or repressing the expression of a target gene - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Genetic constructs for delaying or repressing the expression of a target gene"><meta name="DC.contributor" content="Michael Wayne Graham" scheme="inventor"><meta name="DC.contributor" content="Benitec Australia, Ltd." scheme="assignee"><meta name="DC.date" content="1998-6-19" scheme="dateSubmitted"><meta name="DC.description" content="The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto."><meta name="DC.date" content="2003-6-3" scheme="issued"><meta name="DC.relation" content="EP:0242016:A1" scheme="references"><meta name="DC.relation" content="EP:0560156:A2" scheme="references"><meta name="DC.relation" content="US:5034323" scheme="references"><meta name="DC.relation" content="US:5231020" scheme="references"><meta name="DC.relation" content="US:5283184" scheme="references"><meta name="DC.relation" content="US:5583021" scheme="references"><meta name="DC.relation" content="US:5686649" scheme="references"><meta name="DC.relation" content="US:5714323" scheme="references"><meta name="DC.relation" content="WO:1990011682:A1" scheme="references"><meta name="DC.relation" content="WO:1993023551:A1" scheme="references"><meta name="DC.relation" content="WO:1994017194:A1" scheme="references"><meta name="DC.relation" content="WO:1995010607:A1" scheme="references"><meta name="DC.relation" content="WO:1996008558:A1" scheme="references"><meta name="DC.relation" content="WO:1997001952:A1" scheme="references"><meta name="DC.relation" content="WO:1998036083:A1" scheme="references"><meta name="DC.relation" content="WO:1998037213:A1" scheme="references"><meta name="DC.relation" content="WO:1998044138:A1" scheme="references"><meta name="DC.relation" content="WO:1999015682:A2" scheme="references"><meta name="DC.relation" content="WO:1999025853:A1" scheme="references"><meta name="DC.relation" content="WO:1999032619:A1" scheme="references"><meta name="citation_reference" content="Anderson WF, Nature 392:25-30, 1998.*"><meta name="citation_reference" content="Assaad, F.F., et al. (1993), Epigenetic Repeat-Induced Gene Silencing (RIGS) in Arabidopsis. Plant Molecular Biology 22(6): 1067-1085."><meta name="citation_reference" content="Balandin, T., et al. (1997), &quot;Silencing of a beta-1-3-glucanase Transgene is Overcome During Seed Formation&quot;, Plant Molecular Biology 34(1) 125-137."><meta name="citation_reference" content="Balandin, T., et al. (1997), “Silencing of a β-1-3-glucanase Transgene is Overcome During Seed Formation”, Plant Molecular Biology 34(1) 125-137."><meta name="citation_reference" content="Baulcombe, D.C. (1996) RNA as a Target and an Initiator of Post-Transcriptional Gene Silencing in Transgenic Plants, Plant Molecular Biology 32(1-2): 79-88."><meta name="citation_reference" content="Bevec et al. (1994) &quot;Constitutive expression of chimeric Neo-Rev response element transcripts suppresses HIV-1 replication in human CD4+ T lymphocytes.&quot; Human Gene Therapy 5: 193-201."><meta name="citation_reference" content="Bingham, P.M. (1997) &quot;Cosuppression Comes to the Animals&quot;. Cell 90(3): 385-387."><meta name="citation_reference" content="Brigneti, Gianinna et al., &quot;Viral pathogenicity determinants are suppressors of transgene silencing in Nicotiana benthamiana&quot;, The EMBO Journal, 17(22): 6739-6746 (1998)."><meta name="citation_reference" content="Cameron, F.H. and Jennings, P.A. (1991) &quot;Inhibition of Gene Expression by a Short Sense Fragment&quot;. Nucleic Acids Research 19(3): 469-475."><meta name="citation_reference" content="Caplen, Natasha J. et al., &quot;dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA interference&quot;, Gene, 252: 95-105 (2000)."><meta name="citation_reference" content="Chuah et al. (1994)&quot;Inhibition of human immunodeficiencyvirus Type-1 by retroviral vectors expressing antisense- TAR&quot;. Human Gene Therapy 5: 1467-1475."><meta name="citation_reference" content="Cogoni, C., et al. (1994), &quot;Suppression of Gene Expression by Homologous Transgenes&quot;, Antonie Van Leeuwenhoek 65(3): 205-209."><meta name="citation_reference" content="Cogoni, C., et al. (1996), &quot;Transgene Silencing of the al-1 Gene in Vegetative Cells of Neurospora is Mediated by a Cytoplasmic Effector and Does not Depend on DNA-DNA Interactions or DNA Methylation&quot;, The EMBO Journal 15(12): 3153-3163."><meta name="citation_reference" content="Cogoni, C., et al. (1997), &quot;Isolations of Quelling-Defective (qde) Mutants Impaired in Posttranscriptional Transgene-Induced Gene Silencing in Neurospora Crassa&quot;. Proceeding of the National Academy of Sciences of the United States of America 94(19): 10233-10238."><meta name="citation_reference" content="Cogoni, Carlo et al., &quot;Gene silencing in Neurospora crassa requires a protein homologous to RNA-dependent RNA polymerase&quot;, Nature, vol. 399: 166-169 (1999)."><meta name="citation_reference" content="Cogoni, Carlo et al., &quot;Posttranscriptional Gene Silencing in Neurospora by a RecQ DNA Helicase&quot;, Science, 286: 2342-2344 (1999)."><meta name="citation_reference" content="Courtney-Gutterson, et al. (1994), &quot;Modification of Flower Color in Florist&#39;s Chrysanthemum: Production of White-flowering Variety Through Molecular Genetics&quot;, Biotechnology 12(3): 268-271."><meta name="citation_reference" content="Dalmay, Tamas et al., &quot;An RNA-Dependent RNA Polymerase Gene in Arabidopsis Is Required for Posttranscriptional Gene Silencing Mediated by a Transgene but Not by a Virus&quot;, Cell, 101: 543-553 (2000)."><meta name="citation_reference" content="de Carvalho F., et al. (1992), &quot;Suppression of beta-1,3-glucanase Transgene Expression in Homozygous Plants&quot;, The EMBO Journal 11(7): 2595-2602."><meta name="citation_reference" content="de Carvalho F., et al. (1992), “Suppression of β-1,3-glucanase Transgene Expression in Homozygous Plants”, The EMBO Journal 11(7): 2595-2602."><meta name="citation_reference" content="de Carvalho Niebel, F. et al. (1995), &quot;Post-transscriptional Cosuppression of beta-1,3-glucanase Genes Does Not Effect Acculmulation of Transgene Nuclear mRNA&quot;, The Plant Cell 7(3): 347-358."><meta name="citation_reference" content="de Carvalho Niebel, F. et al. (1995), “Post-transscriptional Cosuppression of β-1,3-glucanase Genes Does Not Effect Acculmulation of Transgene Nuclear mRNA”, The Plant Cell 7(3): 347-358."><meta name="citation_reference" content="De Lange, P., et al., (1995), &quot;Suppression of Flavonoid Flower Pigmentation Genes in Petunia Hybrida by the Introduction of Antisense and Sense Genes&quot;, Current Topics in Microbiology and Immunology 197: 57-75."><meta name="citation_reference" content="Depicker, A., et al. (1997), &quot;Post-transcriptional Gene Silencing in Plants&quot;, Current Opinion in Cell Biology 9(3): 373-382."><meta name="citation_reference" content="Ding, Shou Wei, &quot;RNA silencing&quot;, Current Opinion in Biotechnology, 11: 152-156 (2000)."><meta name="citation_reference" content="Domeier, Mary Ellen et al., &quot;A Link Between RNA Interference and Nonsense-Mediated Decay in Caenorhabditis elegans&quot;, Science, 289: 1928-1930 (2000)."><meta name="citation_reference" content="Dorer et al. (1994) &quot;Expansion of transgene repeats cause heterochromatin formation and gene silencing in Drosophilia&quot;. Cell 77: 993-1002."><meta name="citation_reference" content="Dorer, D.R. and Henikoff, S. (1997) Transgene Repear Arrays Interact withDistant Heterochromatin and Cause Silencing in cis and trans. Genetics 147(3)."><meta name="citation_reference" content="Engdahl, H.M., et al. (1997), &quot;A Two Unit Antisense RNA Cassette Test System for Silencing of Target Genes&quot;, Nucleic Acids Research 25(16): 3218-3227."><meta name="citation_reference" content="English, J.J., et al. (1996), &quot;Suppression of Virus Accumulation in Transgenic Plants Exhibiting Silencing of Nuclear Genes&quot;, The Plant Cell 8(2): 179-188."><meta name="citation_reference" content="Fire, A., Xu, S.Q., Montgomery, M.K. Kostas, S.A. Driver, S.E. and Mello, C.C. (1998), &quot;Potent and Specific Genetic Interference by Double-Standard RNA in Caenorhabditis elegans&quot;, Nature, 391 (6669): 806-811."><meta name="citation_reference" content="Fire, Andrew et al., &quot;Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans&quot;, Nature, 391: 806-811 (1998)."><meta name="citation_reference" content="Garrick, D., Fiering, S., Martin, D.I. and Whitelaw, E. (1998), &quot;Repeat-Induced Gene Silencing in Mammals&quot;, Nature Genetics 18(1): 56-59."><meta name="citation_reference" content="Gervaix et al. (1997) &quot;Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades&quot;. Journal of Virology 71(4): 3048-3053."><meta name="citation_reference" content="Gura, Trisha, &quot;A silence that speaks volumes&quot;, Nature, 404: 804-808 (2000)."><meta name="citation_reference" content="Hamilton, A.J., et al. (1998), &quot;A Transgene with Repeated DNA Causes High Frequency, Post-Transcriptional Suppression of ACC-Oxidase Gene Expression in Tomato&quot;, The Plant Journal 15(6): 737-746."><meta name="citation_reference" content="Hamilton, Andrew J. et al., &quot;A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants&quot;, Science, 286: 950-952 (1999)."><meta name="citation_reference" content="Hammond, Scott M. et al., &quot;An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells&quot;, Nature, 404: 293-296 (2000)."><meta name="citation_reference" content="Jorgensen, R. (1990), &quot;Altered Gene Expression in Plants Due to Trans Interactions Between Homologous Genes&quot;, Trends in Biotechnology 8(12): 340-344."><meta name="citation_reference" content="Jorgensen, R.A., et al. (1996), &quot;Chalcone Synthase Cosuppression Phenotypes in Petunia Flowers: Comparison of Sense vs. Antisense Constructs and Single-Copy vs. Complex T-DNA Sequences&quot;, Plant Molecular Biology 31(5): 957-973."><meta name="citation_reference" content="Kappel et al. Current Opinion in Biotechnology 3:548-553 1992.*"><meta name="citation_reference" content="Katsuki, M., et al. (1988), &quot;Conversion of Normal Behavior to Shiverer by Myelin Basic Protein Antisense cDNA in Transgenic Mice&quot;, Science 241(4865): 593-595."><meta name="citation_reference" content="Katsuki, Motoya et al., &quot;Conversion of Normal Behavior to Shiverer by Myelin Basic Protein Antisense cDNA in Transgenic Mice&quot;, Science, 241: 593-595 (1988)."><meta name="citation_reference" content="Knoester, M., et al. (1997), &quot;Modulation of Stress-Inducible Ethylene Biosynthesis by Sense and Antisense Gene Expression in Tobacco&quot;, Plant Science 126(2): 173-183."><meta name="citation_reference" content="Kook, Y.H., et al. (1994), &quot;The Effect of Antisense Inhibition of Urokinase Receptor in Human Squamous Cell Carcinoma on Malignancy&quot;, The EMBO Journal 13(17): 3983-3991."><meta name="citation_reference" content="Kook, Yoon Hoh et al., &quot;The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy&quot;, The EMBO Journal, 13(17): 3983-3991 (1994)."><meta name="citation_reference" content="Kunz, C., et al. (1996), &quot;Developmentally Regulated Silencing and Reactivaation of Tobacco Chitinase Transgene Expression&quot;, The Plant Journal 10(3): 437-450."><meta name="citation_reference" content="Lee et al. (1994)&quot;Inhibition of human immunodeficiency virus type 1 human T cells by a potent Rev response element decoy consisting of 13-nucleotide minimal Rev-binding domain&quot;. Journal of Virology 68(12): 8254-8264."><meta name="citation_reference" content="Lee, K.Y., et al., (1997), &quot;Post-transcriptional Gene Silencing of ACC Synthase in Tomato Results from Cytoplasmic RNA Degradation&quot;, The Plant Journal 12(5): 1127-1137."><meta name="citation_reference" content="Lee, R.C., et al. (1993), The C. elegans Heterochronic Gene lin-4 Encodes Small RNAs with Antisense Complementarity to lin-14. Cell 75: 843-854."><meta name="citation_reference" content="Lindbo, J.A., et al., (1993), &quot;Induction of a Highly Specific Antiviral State in transgenic Plants-Implications for Regulatio of Gene Expression and Virus Resistance&quot;, The Plant Cell 5(12): 1749-1759."><meta name="citation_reference" content="Lindbo, J.A., et al., (1993), “Induction of a Highly Specific Antiviral State in transgenic Plants—Implications for Regulatio of Gene Expression and Virus Resistance”, The Plant Cell 5(12): 1749-1759."><meta name="citation_reference" content="Lindbo, John et al., &quot;Induction of a Highly Specific Antiviral State in Transgenic Plants: Implications for Regulation of Gene Expression and Virus Resistance&quot;, The Plant Cell, 5: 1749-1759 (1993)."><meta name="citation_reference" content="Lisziewicz et al. (1993) &quot;Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS.&quot; Proceedings of the National Academy of Sciences of the United States of America 90: 8000-8004."><meta name="citation_reference" content="Marx, Jean, &quot;Interfering With Gene Expression&quot;, Science, 288: 1370-1372 (2000)."><meta name="citation_reference" content="Matzke, M.A., et al. (1998), &quot;Epigenetic Silencing of Plant Transgenes as a Consequence of Diverse Cellular Defence Responses&quot;, Cellular and Molecular Life Sciences 54(1): 94-103."><meta name="citation_reference" content="Meyer, P. (1996), &quot;Repeat-induced Gene Silencing-Common Mechanisms in Plants and Fungi&quot;, Biological Chemistry Hoppe-Seyler 377(2): 87-95."><meta name="citation_reference" content="Meyer, P. (1996), “Repeat-induced Gene Silencing—Common Mechanisms in Plants and Fungi”, Biological Chemistry Hoppe-Seyler 377(2): 87-95."><meta name="citation_reference" content="Moroni, M.C., et al. (1992) EGF-R Antisense RNA Blocks Expression of the Epidermal Growth Factor Receptor and Suppresses the Transforming Phenotype of a Human Carcinoma Cell Line. Journal of Biological Chemistry 267(4): 2714-2722."><meta name="citation_reference" content="Moroni, Maria Cristina et al., &quot;EGF-R Antisense RNA Blocks Expression of the Epidermal Growth Factor Receptor and Suppresses the Transforming Phenotype of a Human Carcinoma Cell Line&quot;, The Journal of Biological Chemistry, 267(5): 2714-2722 (1992)."><meta name="citation_reference" content="Mueller, E., et al. (1995), &quot;Homology-dependent Resistance-Transgenic Virus Resistance in Plants Related to Homology-Dependent Gene Silencing&quot;, The Plant Journal 7(6): 1001-1013."><meta name="citation_reference" content="Mueller, E., et al. (1995), “Homology-dependent Resistance—Transgenic Virus Resistance in Plants Related to Homology-Dependent Gene Silencing”, The Plant Journal 7(6): 1001-1013."><meta name="citation_reference" content="Napoli, C., et al. (1990), Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible So-Suppression of Homologous Genes in trans, The Plant Cell 2(4): 279-289."><meta name="citation_reference" content="Napoli, Carolyn et al., &quot;Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans&quot;, The Plant Cell, 2: 279-289 (1990)."><meta name="citation_reference" content="Nellen, W. and Lichtenstein C. (1993), &quot;What Makes a Messenger RNA Anti-Sensitive?&quot; Trends in Biochemical Sciences 18(11): 419-423."><meta name="citation_reference" content="Palauqui, J.C., et al. (1997), Systemic Acquired Silencing: Transgene-specific Post-transscriptional Silencing is Transmitted by Grafting from Silenced Stocks to Non-silenced scions, The EMBO Journal 16: 4738-4745."><meta name="citation_reference" content="Palauqui, Jean-Christophe et al., &quot;Systemic acquired silencing: transgene-specific post-transcriptional silencing is transmitted by grafting from silenced stocks to non-silenced scions&quot;, The EMBO Journal, 16(15):-4745 (1997)."><meta name="citation_reference" content="Palauqui, Jean-Christophe et al., &quot;Transgenes are dispensable for the RNA degradation step of cosuppression&quot;, Plant Biology, 95: 9675-9680 (1998)."><meta name="citation_reference" content="Pal-Bhadra, M., Bhadra U. and Birchler, J.A. (1997) &quot;Cosuppression in Drosophila: Gene Silencing of Alcohol Dehydrogenase by White-Adh Tarnsgenes is Polycomb Dependent&quot;. Cell 90(3): 385-387."><meta name="citation_reference" content="Pang, S.Z., et al. (1997), &quot;Nontarget DNA Sequences Reduce the Transgene Length Necessary for RNA-mediated Tospovirus Resistance in Transgenic Plants&quot;, Proceedings of the National Academy of Sciences of the United States of America 94(15): 8261-8266."><meta name="citation_reference" content="Park, Y. et al., &quot;Gene silencing mediated by promoter homology occurs at the level of transcription and results in meiotically heritable alterations in methylation and gene activity&quot;, The Plant Journal, 9: 183-194 (1996)."><meta name="citation_reference" content="Park, Y.D., et al. (1996), &quot;Gene Silencing Mediated by Promotor Homology Occurs at the Level of Transcription and Results in Meiotically Heritable Alterations in Methylation and Gene Activity&quot;, The Plant Journal 9(2): 183-194."><meta name="citation_reference" content="Que, Q., et al. (1998), &quot;Homology-based Control of Gene Expression Patterns in Transgenic Petunia Flowers&quot;, Developmental Genetics 22(1): 100-109."><meta name="citation_reference" content="Romano, N., et al. (1992), &quot;Quelling: Transient Inactivation of Gene Expression in Neurospora Crassa by Transformation with Homologous Sequences&quot;, Molecular Microbiology 6(22): 3343-3353."><meta name="citation_reference" content="Sadiq, M., et al. (1994), &quot;Developmental Regulation of Antisense-mediated Gene Silencing in Dictyostelium&quot;, Antisense Research &amp; Development 4(4): 263-267."><meta name="citation_reference" content="Sijen, T., et al. (1996), &quot;RNA-mediated Virus Resistance-Role of Repeated Transgenes and Delineation of Targeted Regions&quot;, The Plant Cell 8(12): 2277-2294."><meta name="citation_reference" content="Sijen, T., et al. (1996), “RNA-mediated Virus Resistance—Role of Repeated Transgenes and Delineation of Targeted Regions”, The Plant Cell 8(12): 2277-2294."><meta name="citation_reference" content="Singer, M.J., et al. (1995), &quot;Genetic and Epigenetic Inactivation of Repetitive Sequences in Neurospora Crassa: RIP, DNA Methylation, and Quelling&quot;, Current Topics in Microbiology and Immunology 197: 165-177."><meta name="citation_reference" content="Smardon, Anne et al., &quot;EGO-1 is related to RNA-directed RNA polymerase an functions in germ-line development and RNA interference in C. elegans&quot;, Current Biology, 10(4): 169-178 (2000)."><meta name="citation_reference" content="Smith, Neil et al., &quot;Total Silencing by introspliced hairpin RNAs&quot;, Nature, 407: 319-320 (2000)."><meta name="citation_reference" content="Smyth, D.R. (1997), &quot;Gene Silencing: Cosuppression at a Distance&quot;, Current Biology 7(12): R793-795."><meta name="citation_reference" content="Stam, M., et al. (1997), &quot;The Silence of Genes in Transgenic Plants&quot;, Annals of Botany 79(1): 3-12."><meta name="citation_reference" content="Sullenger et al. (1990) &quot;Overexpression of TAR sequences rendered cells resistant to human immundeficiency virus replication&quot;. Cell 63: 8254-8264."><meta name="citation_reference" content="Sullenger et al. (1991 &quot;Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation&quot;. Journal of Virology 65(12): 6811-6816."><meta name="citation_reference" content="Sun et al. (1995) &quot;Resistance to human immunodeficiency virus type 1 infection conferred by trnasduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric transactivation response element constructs&quot;. Proceedings of the National Academy of Sciences of the United States of America 92: 7272-7276."><meta name="citation_reference" content="Tabara, Hiroaki et al., &quot;The rde-1 Gene, RNA Interference, and Transposon Silencing in C. elegans&quot;, Cell, 99: 123-132 (1999)."><meta name="citation_reference" content="Tanzer, M.M., et al. (1997), &quot;Characterization of Post-Transcriptionally Suppressed Transgene Expression that Confers Resistance to Tobacco Etch Virus Infection in Tobacco&quot;, The Plant Cell 9(8): 1411-1423."><meta name="citation_reference" content="Touchette, Nat. Med. 2(1) 7-8, 1996.*"><meta name="citation_reference" content="Tuschl, Thomas et al., &quot;Targeted mRNA degradation by double-stranded RNA in vitro&quot;, Genes &amp; Development, 13: 3191-3197 (1999)."><meta name="citation_reference" content="Vacheret, H. Nussaume, et al. (1997), &quot;A Transciptionally Active State is Required for Post-Transcriptional Silencing (Cosuppresion) of Nitrate Reductase Host Genes and Transgenes&quot;, The Plant Cell 9(8): 1495-1504."><meta name="citation_reference" content="Van der Krol, et al. (1990), &quot;Flavonoid Genes in Petunia: Addition of a Limited Number of Gene Copies May Lead to a Suppression of Gene Expression&quot;, The Plant Cell 2(4): 291-299."><meta name="citation_reference" content="Van der Krol, et al. (1990), &quot;Inhibition of Flower Pigmentation by Antisense CHS Genes: Promoter and Minimal Sequence Requirements for the Antisense Effect&quot;, Plant Molecular Biology 14(4): 457-466."><meta name="citation_reference" content="Verma et al Nature 389:239-242, 1997.*"><meta name="citation_reference" content="Viville, in Transgenic Animals, Houdebine (eds), Harwood academic publishers, France. pp307-321, 1997.*"><meta name="citation_reference" content="Voinnet, Olivier et al., &quot;Systemic Spread of Sequence-Specific Transgene RNA Degradation in Plants Is Initiated by Localized Introduction of Ectopic Promoterless DNA&quot;, Cell, 95: 177-187 (1998)."><meta name="citation_reference" content="Wall RJ Theriogenology 45:57-68, 1996.*"><meta name="citation_reference" content="Wang et al PNAS 94:11563-11566, 1997.*"><meta name="citation_reference" content="Wassenegger, Michael et al., &quot;Signalling in gene silencing&quot;, Elsevier Science, 4(6): 207-209 (1999)."><meta name="citation_reference" content="Waterhouse, Peter et al., &quot;Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA&quot;, Plant Biology, 95: 13959-13964 (1998)."><meta name="citation_reference" content="Wianny, Florence et al., &quot;Specific interference with gene function by double-stranded RNA in early mouse development&quot;, Nature Cell Biology, 2: 70-75 (2000)."><meta name="citation_reference" content="Zamore, Phillip D. et al., &quot;RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals&quot;, Cell, 101: 25-33 (2000)."><meta name="citation_patent_number" content="US:6573099"><meta name="citation_patent_application_number" content="US:09/100,812"><link rel="canonical" href="http://www.google.com/patents/US6573099"/><meta property="og:url" content="http://www.google.com/patents/US6573099"/><meta name="title" content="Patent US6573099 - Genetic constructs for delaying or repressing the expression of a target gene"/><meta name="description" content="The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto."/><meta property="og:title" content="Patent US6573099 - Genetic constructs for delaying or repressing the expression of a target gene"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("npTtU9q3NrCisQS874CYCA"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("IRL"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("npTtU9q3NrCisQS874CYCA"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("IRL"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us6573099?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US6573099"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=CWtgBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS6573099&amp;usg=AFQjCNGMDQ3N0YMK0ZM1Olmx_Q0XDLs-7Q" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US6573099.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US6573099.pdf"></a><a class="appbar-application-grant-link" data-label="Application" href="/patents/US20020168707"></a><a class="appbar-application-grant-link" data-selected="true" data-label="Grant" href="/patents/US6573099"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US6573099" style="display:none"><span itemprop="description">The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are...</span><span itemprop="url">http://www.google.com/patents/US6573099?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US6573099 - Genetic constructs for delaying or repressing the expression of a target gene</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US6573099 - Genetic constructs for delaying or repressing the expression of a target gene" title="Patent US6573099 - Genetic constructs for delaying or repressing the expression of a target gene"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US6573099 B2</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 09/100,812</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Jun 3, 2003</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Jun 19, 1998</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Mar 20, 1998</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US8048670">US8048670</a>, </span><span class="patent-bibdata-value"><a href="/patents/US8053419">US8053419</a>, </span><span class="patent-bibdata-value"><a href="/patents/US8067383">US8067383</a>, </span><span class="patent-bibdata-value"><a href="/patents/US8431547">US8431547</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20020168707">US20020168707</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20030159161">US20030159161</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20040180439">US20040180439</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20040266005">US20040266005</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20050250208">US20050250208</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20120135517">US20120135517</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20130298264">US20130298264</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">09100812, </span><span class="patent-bibdata-value">100812, </span><span class="patent-bibdata-value">US 6573099 B2, </span><span class="patent-bibdata-value">US 6573099B2, </span><span class="patent-bibdata-value">US-B2-6573099, </span><span class="patent-bibdata-value">US6573099 B2, </span><span class="patent-bibdata-value">US6573099B2</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Michael+Wayne+Graham%22">Michael Wayne Graham</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Benitec+Australia,+Ltd.%22">Benitec Australia, Ltd.</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US6573099.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6573099.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6573099.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (20),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (101),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (265),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (43),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (15)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/6573099&usg=AFQjCNGyA47EyJ-AqUGQK9ngawHdLvUEHA">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D6573099&usg=AFQjCNEkwmY7Id-F9yl9Ed0jBXjAbDytgg">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D6573099B2%26KC%3DB2%26FT%3DD&usg=AFQjCNFz7rXpEVWHbYiTS7m_Ol_KGH8-XQ">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT55103331" lang="EN" load-source="patent-office">Genetic constructs for delaying or repressing the expression of a target gene</invention-title></span><br><span class="patent-number">US 6573099 B2</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA50503303" lang="EN" load-source="patent-office"> <div class="abstract">The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(28)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00001.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00001.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00002.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00002.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00003.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00003.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00004.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00004.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00005.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00005.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00006.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00006.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00007.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00007.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00008.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00008.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00009.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00009.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00010.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00010.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00011.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00011.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00012.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00012.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00013.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00013.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00014.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00014.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00015.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00015.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00016.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00016.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00017.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00017.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00018.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00018.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00019.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00019.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00020.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00020.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00021.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00021.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00022.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00022.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00023.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00023.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00024.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00024.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00025.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00025.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00026.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00026.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00027.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00027.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6573099B2/US06573099-20030603-D00028.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6573099B2/US06573099-20030603-D00028.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(22)</span></span></div><div class="patent-text"><div mxw-id="PCLM8494541" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>What is claimed is: </claim-statement> <div class="claim"> <div num="1" id="US-6573099-B2-CLM-00001" class="claim">
      <div class="claim-text">1. An isolated genetic construct which is capable of delaying, repressing or otherwise reducing the expression of a target gene in an animal cell which is transfected with said genetic construct, wherein said genetic construct comprises at least two copies of a structural gene sequence, wherein said structural gene sequence comprises a nucleotide sequence which is substantially identical to at least a region of said target gene, and wherein said at least two copies of said structural gene sequence are placed operably under the control of a single promoter sequence which is operable in said cell, wherein at least one copy of said structural gene sequence is placed operably in the sense orientation under the control of said promoter sequence.</div>
    </div>
    </div> <div class="claim"> <div num="2" id="US-6573099-B2-CLM-00002" class="claim">
      <div class="claim-text">2. An isolated genetic construct which is capable of delaying, repressing or otherwise reducing the expression of a target gene in an animal cell which is transfected with said genetic construct, wherein said genetic construct comprises at least two copies of a structural gene sequence wherein each copy of said structural gene sequence is separately placed under the control of a promoter which is operable in said cell, and wherein said structural gene sequence comprises a nucleotide sequence which is substantially identical to at least a region of said target gene, wherein at least one copy of said structural gene sequence is placed operably in the sense orientation under the control of an individual promoter sequence.</div>
    </div>
    </div> <div class="claim"> <div num="3" id="US-6573099-B2-CLM-00003" class="claim">
      <div class="claim-text">3. An isolated genetic construct which is capable of delaying, repressing or otherwise reducing the expression of a target gene in an animal cell which is transfected with said genetic construct, wherein said genetic construct comprises at least two copies of a structural gene sequence, wherein said structural gene sequence comprises a nucleotide sequence which is substantially identical to at least a region of said target gene, and wherein said at least two copies of said structural gene sequence are placed operably under the control of a single promoter sequence which is operable in said cell, wherein at least one copy of said structural gene sequence is placed operably in the sense orientation under the control of said promoter sequence and wherein at least one other copy of said structural gene sequence is placed operably in the antisense orientation under the control of said promoter sequence.</div>
    </div>
    </div> <div class="claim"> <div num="4" id="US-6573099-B2-CLM-00004" class="claim">
      <div class="claim-text">4. An isolated genetic construct which is capable of delaying, repressing or otherwise reducing the expression of a target gene in an animal cell which is transfected with said genetic construct, wherein said genetic construct comprises at least two copies of a structural gene sequence and each copy of said structural gene sequence is separately placed under the control of a promoter which is operable in said cell, and wherein said structural gene sequence comprises a nucleotide sequence which is substantially identical to at least a region of said target gene, wherein at least one copy of said structural gene sequence is placed operably in the sense orientation under the control of an individual promoter sequence, and wherein at least one other copy of said structural gene sequence is placed operably in the antisense orientation under the control of another individual promoter sequence.</div>
    </div>
    </div> <div class="claim"> <div num="5" id="US-6573099-B2-CLM-00005" class="claim">
      <div class="claim-text">5. An isolated genetic construct which is capable of delaying, repressing or otherwise reducing the expression of a target gene in an animal cell which is transfected with said genetic construct, wherein said genetic construct comprises at least two copies of a structural gene sequence, wherein said structural gene sequence comprises a nucleotide sequence which is substantially identical to at least a region of said target gene, and wherein said at least two copies of said structural gene sequence are placed operably under the control of a single promoter sequence which is operable in said cell, wherein at least one copy of said structural gene sequence is placed operably in the sense orientation under the control of said promoter sequence, wherein at least one other copy of said structural gene sequence is placed operably in the antisense orientation under the control of said promoter sequence, and wherein said at least one copy of said structural gene sequence that is placed in the sense orientation relative to said promoter and said at least one copy of said structural gene sequence that is placed in the antisense orientation relative to said promoter are spaced from each other by a nucleic acid stuffer fragment.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" id="US-6573099-B2-CLM-00006" class="claim">
      <div class="claim-text">6. An animal cell comprising the genetic construct of any one of claims <b>1</b>-<b>2</b> or <b>3</b>-<b>5</b>.</div>
    </div>
    </div> <div class="claim"> <div num="7" id="US-6573099-B2-CLM-00007" class="claim">
      <div class="claim-text">7. A method of delaying or repressing the expression of a target gene in an animal cell, comprising transfecting said animal cell with a genetic construct, wherein said genetic construct comprises at least two copies of a structural gene sequence, wherein said structural gene sequence comprises a nucleotide sequence which is substantially identical to at least a region of said target gene, and wherein said at least two copies of said structural gene sequence are placed operably under the control of a single promoter sequence which is operable in said cell, wherein at least one copy of said structural gene sequence is placed operably in the sense orientation under the control of said promoter sequence.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="8" id="US-6573099-B2-CLM-00008" class="claim">
      <div class="claim-text">8. The method according to <claim-ref idref="US-6573099-B2-CLM-00007">claim 7</claim-ref>, wherein at least one other copy of said structural gene sequence is placed operably in the antisense orientation under the control of said promoter sequence.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="9" id="US-6573099-B2-CLM-00009" class="claim">
      <div class="claim-text">9. The method according to <claim-ref idref="US-6573099-B2-CLM-00008">claim 8</claim-ref>, wherein said copy of said structural gene sequence that is placed in the sense orientation relative to said promoter and said copy of said structural gene sequence that is placed in the antisense orientation relative to said promoter are spaced from each other by a nucleic acid stuffer fragment.</div>
    </div>
    </div> <div class="claim"> <div num="10" id="US-6573099-B2-CLM-00010" class="claim">
      <div class="claim-text">10. A method of delaying or repressing the expression of a target gene in an animal cell, comprising expressing in said animal cell a genetic construct, wherein said genetic construct comprises at least two copies of a structural gene sequence, wherein each copy of said structural gene sequence is separately placed under the control of a promoter which is operable in said cell, and wherein said structural gene sequence comprises a nucleotide sequence which is substantially identical to at least a region of said target gene, wherein at least one copy of said structural gene sequence is placed operably in the sense orientation under the control of an individual promoter sequence.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="11" id="US-6573099-B2-CLM-00011" class="claim">
      <div class="claim-text">11. The isolated genetic construct according to any one of claims <b>1</b>, <b>2</b> or <b>3</b>-<b>5</b> wherein said region of the target gene is 20 to 30 nucleotides long.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="12" id="US-6573099-B2-CLM-00012" class="claim">
      <div class="claim-text">12. The method according to any one of claims <b>7</b>-<b>9</b> or <b>10</b> wherein said region of the target gene is 20 to 30 nucleotides long.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="13" id="US-6573099-B2-CLM-00013" class="claim">
      <div class="claim-text">13. The isolated genetic construct according to any one of claims <b>1</b>, <b>2</b> or <b>3</b>-<b>5</b>, comprising two copies of said structural gene sequence.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="14" id="US-6573099-B2-CLM-00014" class="claim">
      <div class="claim-text">14. The isolated genetic construct according to any one of claims <b>1</b>, <b>2</b> or <b>3</b>-<b>5</b> wherein said region of the target gene is at least 30 nucleotides long.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="15" id="US-6573099-B2-CLM-00015" class="claim">
      <div class="claim-text">15. The isolated genetic construct according to any one of claims <b>1</b>, <b>2</b> or <b>3</b>-<b>5</b> wherein said structural gene sequence comprises a nucleotide sequence that is identical to said region of said target gene.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="16" id="US-6573099-B2-CLM-00016" class="claim">
      <div class="claim-text">16. The method according to any one of claims <b>7</b>-<b>9</b> or <b>10</b>, wherein said genetic construct comprises two copies of said structural gene sequence.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="17" id="US-6573099-B2-CLM-00017" class="claim">
      <div class="claim-text">17. The method according to any one of claims <b>7</b>-<b>9</b> or <b>10</b>, wherein said region of the target gene is at least 30 nucleotides long.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="18" id="US-6573099-B2-CLM-00018" class="claim">
      <div class="claim-text">18. The method according to any one of claims <b>7</b>-<b>9</b> or <b>10</b>, wherein said structural gene sequence comprises a nucleotide sequence that is identical to said region of said target gene.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="19" id="US-6573099-B2-CLM-00019" class="claim">
      <div class="claim-text">19. An animal cell comprising the genetic construct according to <claim-ref idref="US-6573099-B2-CLM-00011">claim 11</claim-ref>.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="20" id="US-6573099-B2-CLM-00020" class="claim">
      <div class="claim-text">20. An animal cell comprising the genetic construct according to <claim-ref idref="US-6573099-B2-CLM-00013">claim 13</claim-ref>.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="21" id="US-6573099-B2-CLM-00021" class="claim">
      <div class="claim-text">21. An animal cell comprising the genetic construct according to <claim-ref idref="US-6573099-B2-CLM-00014">claim 14</claim-ref>.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="22" id="US-6573099-B2-CLM-00022" class="claim">
      <div class="claim-text">22. An animal cell comprising the genetic construct according to <claim-ref idref="US-6573099-B2-CLM-00015">claim 15</claim-ref>.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES53935361" lang="EN" load-source="patent-office" class="description">
    <heading>FIELD OF THE INVENTION</heading> <p>The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto.</p>
    <heading>BACKGROUND TO THE INVENTION</heading> <p>Controlling metabolic pathways in eukaryotic organisms is desirable for the purposes of producing novel traits therein or introducing novel traits into a particular cell, tissue or organ of said organism. Whilst recombinant DNA technology has provided significant progress in an understanding of the mechanisms regulating eukaryotic gene expression, much less progress has been made in the actual manipulation of gene expression to produce novel traits. Moreover, there are only limited means by which human intervention may lead to a repression, delay or reduction in eukaryotic gene expression.</p>
    <p>Current methods for downregulating gene expression using recombinant DNA technology comprise the introduction of a transgene to the cell which is capable of repressing expression of an endogenous target gene, either transcriptionally or post-transcriptionally. However, the precise mechanism is not known. Moreover, the efficiency of current approaches is low and the results are variable and unpredictable.</p>
    <p>Attempts to improve the accuracy and predictability of methods for regulating gene expression in cells, in particular the repression, delay or reduction in expression of viral target genes in eukaryotic cells, foreign transgenes or other foreign genes introduced into cells, tissues or organs by natural means, or endogenous genes which are expressed to produce undesirable traits for a particular purpose, have been largely unsuccessful possibly due to a lack of knowledge of the precise mechanisms involved. As a consequence, the efficiency of methods currently available remains low and highly variable.</p>
    <p>In work leading up to the present invention, the inventors sought to elucidate the mechanisms involved in down-regulating gene expression in an attempt to provide improved methods therefor. In so doing the inventors have developed a wide range of synthetic genes capable of modulating gene expression in both prokaryotic and eukaryotic cells and genetic constructs comprising same.</p>
    <p>Bibliographic details of the publications referred to by author in this specification are collected at the end of the description. Sequence identity numbers (SEQ ID NOs.) for the nucleotide and amino acid sequences referred to in the specification are defined after the bibliography.</p>
    <p>Throughout this specification and the claims that follow, unless the context requires otherwise, the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.</p>
    <p>As used herein, the term “derived from” shall be taken to indicate that a particular integer or group of integers has originated from the species specified, but has not necessarily been obtained directly from the specified source.</p>
    <heading>SUMMARY OF THE INVENTION</heading> <p>The present invention provides novel synthetic genes and improved genetic constructs comprising same for modifying endogenous or target gene expression in cells, tissues and/or organs which are either transfected or stably transformed therewith.</p>
    <p>Accordingly, one aspect of the present invention provides a synthetic gene which is capable of modifying target gene expression in a cell, tissue or organ of a prokaryotic or eukaryotic organism which is transfected or transformed therewith, wherein said synthetic gene at least comprises a structural gene sequence comprising a nucleotide sequence which is substantially identical to the nucleotide sequence of said target gene or a derivative thereof or a complementary sequence thereto placed operably under the control of a promoter sequence which is operable in said cell, tissue or organ.</p>
    <p>A further aspect of the invention provides a synthetic gene which is capable of modifying the expression of a target gene in a cell, tissue or organ of a prokaryotic or eukaryotic organism which is transfected or transformed therewith, wherein said synthetic gene at least comprises multiple structural gene sequences, wherein each of said structural gene sequences comprises a nucleotide sequence which is substantially identical to the nucleotide sequence of said target gene or a derivative thereof or a complementary sequence thereto and wherein said multiple structural gene sequences are placed operably under the control of a single promoter sequence which is operable in said cell, tissue or organ.</p>
    <p>A third aspect of the present invention provides a synthetic gene which is capable of modifying the expression of a target gene in a cell, tissue or organ of a prokaryote or eukaryote which is transfected or transformed therewith wherein said synthetic gene at least comprises multiple structural gene sequences wherein each of said structural gene sequences is placed operably under the control of a promoter sequence which is operable in said cell, tissue or organ and wherein each of said structural gene sequences comprises a nucleotide sequence which is substantially identical to the nucleotide sequence of said target gene or a derivative thereof or a complementary sequence thereto.</p>
    <p>A further aspect of the present invention provides a genetic construct which is capable of modifying the expression of an endogenous gene or target gene in a transformed or transfected cell, tissue or organ wherein said genetic construct at least comprises the synthetic gene of the invention and one or more origins of replication and/or selectable marker gene sequences.</p>
    <p>A still further aspect of the invention provides a cell, tissue, organ or organism comprising the synthetic genes and genetic constructs described herein.</p>
    <heading>BRIEF DESCRIPTION OF THE DRAWINGS</heading> <p>FIG. 1 is a copy of a diagrammatic representation of the plasmid pEGFP-N 1 MCS.</p>
    <p>FIG. 2 is a copy of a diagrammatic representation of the plasmid pCMV.cass.</p>
    <p>FIG. 3 is a copy of a diagrammatic representation of the plasmid pCR.Bgl-GPP-Bam.</p>
    <p>FIG. 4 is a copy of a diagrammatic representation of the plasmid pCR.SV40L.</p>
    <p>FIG. 5 is a copy of a diagrammatic representation of the plasmid pCMV.SV40L.cass.</p>
    <p>FIG. 6 is a copy of a diagrammatic representation of the plasmid pCR.BEV.1.</p>
    <p>FIG. 7 is a copy of a diagrammatic representation of the plasmid pCR.BEV.2.</p>
    <p>FIG. 8 is a copy of a diagrammatic representation of the plasmid pCR.BEV.3.</p>
    <p>FIG. 9 is a copy of a diagrammatic representation of the plasmid pEGFP.BEV.1.</p>
    <p>FIG. 10 is a copy of a diagrammatic representation of the plasmid pCMV.BEV.2.</p>
    <p>FIG. 11 is a copy of a diagrammatic representation of the plasmid pCMV.VEB.</p>
    <p>FIG. 12 is a copy of a diagrammatic representation of the plasmid pCMV.BEVnt</p>
    <p>FIG. 13 is a copy of a diagrammatic representation of the plasmid pCMV.BEVx2.</p>
    <p>FIG. 14 is a copy of a diagrammatic representation of the plasmid pCMV.BEV.VEB.</p>
    <p>FIG. 15 is a copy of a diagrammatic representation of the plasmid pCMV.BEV.GFP.VEB.</p>
    <p>FIG. 16 is a copy of a diagrammatic representation of the plasmid pCMV.BEV.SV40L-0.</p>
    <p>FIG. 17 is a copy of a diagrammatic representation of the plasmid pCMV.0.SV40L.BEV.</p>
    <p>FIG. 18 is a copy of a diagrammatic representation of the plasmid pCMV.0.SV40L.VEB.</p>
    <p>FIG. 19 is a copy of a diagrammatic representation of the plasmid pCMV.BEV.SV40L.BEV.</p>
    <p>FIG. 20 is a copy of a diagrammatic representation of the plasmid PCMV.BEV.SV40L.VEB.</p>
    <p>FIG. 21 is a copy of a diagrammatic representation of the plasmid pCMVSV40LR.cass.</p>
    <p>FIG. 22 is a copy of a diagrammatic representation of the plasmid pCMV.BEV.SV40LR.</p>
    <p>FIG. 23 is a copy of a diagrammatic representation of the plasmid pCMV.TYR.</p>
    <p>FIG. 24 is a copy of a diagrammatic representation of the plasmid PCMV.TYRLIB.</p>
    <p>FIG. 25 is a copy of a diagrammatic representation of the plasmid pCMV.Lac.</p>
    <p>FIG. 26 is a copy of a diagrammatic representation of the plasmid pCMVLacI.OPRSV1.cass.</p>
    <p>FIG. 27 is a copy of a diagrammatic representation of the plasmid pCMVLacI.OPRSV1.GPP.cass.</p>
    <p>FIG. 28 is a copy of a diagrammatic representation of the plasmid pCMVLacI.TYR.OPRSV1.GFP.</p>
    <heading>DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS</heading> <p>One aspect of the present invention provides a synthetic gene which is capable of modifying the expression of a target gene in a cell, tissue or organ wherein said synthetic gene at least comprises a structural gene comprising a nucleotide sequence which is substantially identical to the nucleotide sequence of said target gene or a derivative thereof or a complementary sequence thereto placed operably under the control of a promoter which is operable in said cell, tissue or organ.</p>
    <p>Reference herein to a “gene” is to be taken in its broadest context and includes:</p>
    <p>(i) a classical genomic gene consisting of transcriptional and/or translational regulatory sequences and/or a coding region and/or non-translated sequences (i.e. introns, 5′- and 3′-untranslated sequences);</p>
    <p>(ii) mRNA or cDNA corresponding to the coding regions (i.e. exons) optionally comprising 5′- or 3′-untranslated sequences linked thereto; or</p>
    <p>(iii) an amplified DNA fragment or other recombinant nucleic acid molecule produced in vitro and comprising all or a part of the coding region and/or 5′- or 3′-untranslated sequences linked thereto.</p>
    <p>The term “gene” is also used to describe synthetic or fusion molecules encoding all or part of a functional product, in particular a sense or antisense mRNA product or a peptide, oligopeptide or polypeptide or a biologically-active protein.</p>
    <p>The term “synthetic gene” refers to a non-naturally occurring gene as hereinbefore defined which preferably comprises at least one or more transcriptional and/or translational regulatory sequences operably linked to a structural gene sequence.</p>
    <p>The term “structural gene” shall be taken to refer to a nucleotide sequence which is capable of being transmitted to produce mRNA and optionally, encodes a peptide, oligopeptide, polypeptide or biologically active protein molecule. Those skilled in the art will be aware that not all mRNA is capable of being translated into a peptide, oligopeptide, polypeptide or protein, for example if the mRNA lacks a functional translation start signal or alternatively, if the mRNA is antisense mRNA. The present invention clearly encompasses synthetic genes comprising nucleotide sequences which are not capable of encoding peptides, oligopeptides, polypeptides or biologically-active proteins. In particular, the present inventors have found that such synthetic genes may be advantageous in modifying target gene expression in cells, tissues or organs of a prokaryotic or eukaryotic organism.</p>
    <p>The term “target gene” shall be taken to refer to any gene, the expression of which is to be modified using the synthetic gene of the invention. Preferred target genes include, but are not limited to viral genes and foreign genes which have been introduced into the cell, tissue or organ or alternatively, genes which are endogenous to the cell, tissue or organ.</p>
    <p>Wherein the target gene is a viral gene, it is particularly preferred that the viral gene encodes a function which is essential for replication or reproduction of the virus, such as but not limited to a DNA polymerase or RNA polymerase gene or a viral coat protein gene, amongst others. In a particularly preferred embodiment, the target gene comprises an RNA polymerase gene derived from a single-stranded (+) RNA virus such as bovine enterovirus (BEV), Sinbis alphavirus or a lentivirus such as, but not limited to, an immunodeficiency virus (e.g. HIV-1) or alternatively, a DNA polymerase derived from a double-stranded DNA virus such as bovine herpesvirus or herpes simplex virus I (HSVI), amongst others.</p>
    <p>Wherein the target gene is a foreign gene, those skilled in the art will be aware that it will have been introduced to the cell, tissue or organ using transformation technology or alternatively, comprise a gene derived from a pathogen which has been introduced to said cell, tissue or organ by naturally-occurring gene transfer processes.</p>
    <p>Particularly preferred foreign target genes include any transgene which has been introduced to the cell, tissue or organ.</p>
    <p>Wherein the target gene is a gene which is endogenous to the cell, tissue or organ, it is particular preferred that its expression is capable of being monitored by a visual assay, enzyme assay or immunoassay. Particularly preferred endogenous target genes are those detected by visual assay means.</p>
    <p>The synthetic genes of the present invention may be derived from naturally-occurring genes by standard recombinant techniques, the only requirement being that the synthetic gene is substantially identical at the nucleotide sequence level to at least a part of the target gene, the expression of which is to be modified. By “substantially identical” is meant that the structural gene sequence of the synthetic gene is at least about 80%-90% identical to 30 or more contiguous nucleotides of the target gene, more preferably at least about 90-95% identical to 30 or more contiguous nucleotides of the target gene and even more preferably at least about 95-99% identical or absolutely identical to 30 or ore contiguous nucleotides of the target gene.</p>
    <p>Generally, a gene of the invention may be subjected to mutagenesis to produce single or multiple nucleotide substitutions, deletions and/or additions without affecting its ability to modify target gene expression. Nucleotide insertional derivatives of the synthetic gene of the present invention include 5′ and 3′ terminal fusions as well as intra-sequence insertions of single or multiple nucleotides. Insertional nucleotide sequence variants are those in which one or more nucleotides are introduced into a predetermined site in the nucleotide sequence although random insertion is also possible with suitable screening of the resulting product.</p>
    <p>Deletional variants are characterised by the removal of one or more nucleocides from the sequence. Substitutional nucleotide variants are those in which at least one nucleotide in the sequence has been removed and a different nucleotide inserted in its place. Such a substitution may be “silent” in that the substitution does not change the amino acid defined by the codon. Alternatively, substituents are designed to alter one amino acid for another similar acting amino acid, or amino acid of like charge, polarity, or hydrophobicity.</p>
    <p>Accordingly, the present invention extends to homologues, analogues and derivatives of the synthetic genes described herein.</p>
    <p>For the present purpose, “homologues” of a gene as hereinbefore defined or of a nucleotide sequence shall be taken to refer to an isolated nucleic acid molecule which is substantially the same as the nucleic acid molecule of the present invention or its complementary nucleotide sequence, notwithstanding the occurrence within said sequence, of one or more nucleotide substitutions, insertions, deletions, or rearrangements.</p>
    <p>“Analogues” of a gene as hereinbefore defined or of a nucleotide sequence set forth herein shall be taken to refer to an isolated nucleic acid molecule which is substantially the same as a nucleic acid molecule of the present invention or its complementary nucleotide sequence, notwithstanding the occurrence of any non-nucleotide constituents not normally present in said isolated nucleic acid molecule, for example caxbohydrates, radiochemicals including radionucleotides, reporter molecules such as, but not limited to DIG, alkaline phosphatase or horseradish peroxidase, amongst others.</p>
    <p>“Derivatives” of a gene as hereinbefore defined or of a nucleotide sequence set forth herein shall be taken to refer to any isolated nucleic acid molecule which contains significant sequence similarity to said sequence or a part thereof. Generally, the nucleotide sequence of the present invention may be subjected to mutagenesis to produce single or multiple nucleotide substitutions, deletions and/or insertions. Nucleotide insertional derivatives of the nucleotide sequence of the present invention include 5′ and 3′ terminal fusions as well as intra-sequence insertions of single or multiple nucleotides or nucleotide analogues. Insertional nucleotide sequence variants are those in which one or more nucleotides or nucleotide analogues are introduced into a predetermined site in the nucleotide sequence of said sequence, although random insertion is also possible with suitable screening of the resulting product being performed. Deletional variants are characterised by the removal of one or more nucleotides from the nucleotide sequence. Substitutional nucleotide variants are those in which at least one nucleotide in the sequence has been removed and a different nucleotide or nucleotide analogue inserted in its place.</p>
    <p>Accordingly, the structural gene component of the synthetic gene may comprise a nucleotide sequence which is at least about 80% identical to at least about 30 contiguous nucleotides of an endogenous target gene, a foreign target gene or a viral target gene present in a cell, tissue or organ or a homologue, analogue, derivative thereof or a complementary sequence thereto.</p>
    <p>Preferred structural gene components of the synthetic gene of the invention comprise at least about 20-30 nucleotides in length derived from a viral DNA polymerase, viral RNA polymerase, viral coat protein or visually-detectable gene, more particularly an RNA polymerase gene derived from a virus selected from the list comprising BEV, Sindbis alphavirus, HIV-1, bovine herpes virus and HSV1 or a visually-detectable gene which is involved in determining pigmentation, cell death or other external phenotype on a cell, tissue, organ or organism, amongst others.</p>
    <p>In a particularly preferred embodiment, the structural gene component of the synthetic gene comprises at least about 20-30 nucleotides in length derived from the BEV RNA-dependent RNA polymerase gene or the murine tyrosinase gene or the <i>Escherichia coli </i>lac repressor gene lacI or a complementary sequence thereto.</p>
    <p>The structural gene component may comprise a nucleotide sequence which encodes an amino acid sequence, with or without a translation start signal (ATG) or a nucleotide sequence which is complementary thereto. Those skilled in the art will be aware that, in the absence of the translation start signal in an appropriate reading frame, the mRNA encoded by the structural gene will not be translated in most eukaryotic and prokaryotic cells.</p>
    <p>Alternatively, the structural gene may comprise a nucleotide sequence which does not encode an amino acid sequence or more commonly, comprises one or more open reading frames which encode one or more peptides, oligopeptides or polypeptides which are unrelated at the amino acid sequence level to the amino acid sequence encoded by the target gene. For example, the mRNA product of the structural gene may be inserted into the synthetic gene of the invention so as to alter or disrupt the reading frame of the structural gene and produce one or more frame shift mutations in the translation product thereof relative to the translation product encoded by the target gene, notwithstanding a substantial identity between the structural gene and the target gene on the one hand and the corresponding mRNA products of the structural gene and the target gene on the other hand. Such effects may be produced by introducing one or two nucleotide substitutions or deletions into the structural gene, relative to the target gene sequence or alternatively, by introducing a translation start codon 5′-ATG-3′ upstream of any nucleotide in the structural gene which occurs at a particular position in a codon of the corresponding target gene such that the position of said nucleotide in the codon of the structural gene is altered.</p>
    <p>Alternatively, the structural gene may encode no amino acid sequence or one or more amino acid sequences which are unrelated to the amino acid sequence encoded by the target gene wherein said structural gene is transcribed in the antisense orientation from the synthetic gene promoter, relative to the direction of transcription of the corresponding target gene. In such circumstances, the mRNA product of the structural gene will comprise a nucleotide sequence which is complementary to the nucleotide sequence in the corresponding region of the mRNA encoded by the target gene.</p>
    <p>The present invention clearly encompasses synthetic genes wherein the structural gene component is operably connected in the sense or antisense orientation to a promoter sequence and irrespective of the capacity of said structural gene to encode an amino acid sequence which is encoded by the target gene. Accordingly, the structural gene component may further comprise 5′-untranslated region and/or 3′-untranslated region and/or intron (e.g. SV40 intron) and/or a coding region derived from the target gene or a complementary nucleotide sequence thereto.</p>
    <p>Reference herein to a “promoter” is to be taken in its broadest context and includes the transcriptional regulatory sequences of a classical genomic gene, including the TATA box which is required for accurate transcription initiation in eukaryotic cells, with or without a CCAAT box sequence and additional regulatory elements (i.e. upstream activating sequences, enhancers and silencers). For expression in prokaryotic cells, such as bacteria, the promoter should at least contain the −35 box and −10 box sequences.</p>
    <p>A promoter is usually, but not necessarily, positioned upstream or 5′, of the structural gene component of the synthetic gene of the invention, the expression of which it regulates. Furthermore, the regulatory elements comprising a promoter are usually positioned within 2 kb of the start site of transcription of the structural gene.</p>
    <p>In the present context, the term “promoter” is also used to describe a synthetic or fusion molecule, or derivative which confers, activates or enhances expression of an isolated nucleic acid molecule, in a cell, such as a plant, animal, insect, fungal, yeast or bacterial cell. Preferred promoters may contain additional copies of one or more specific regulatory elements, to further enhance expression of a structural gene which expression it regulates and/or to alter the spatial expression and/or temporal expression of same. For example, regulatory elements which confer inducibility on the expression of the structural gene may be placed adjacent to a heterologous promoter sequence driving expression of a nucleic acid molecule.</p>
    <p>Placing a structural gene under the regulatory control of a promoter sequence means positioning said molecule such that expression is controlled by the promoter sequence. Promoters are generally positioned 5′ (upstream) to the genes that they control. In the construction of heterologous promoter/structural gene combinations it is generally preferred to position the promoter at a distance from the gene transcription start site that is approximately the same as the distance between that promoter and the gene it controls in its natural setting, i.e., the gene from which the promoter is derived. As is known in the art, some variation in this distance can be accommodated without loss of promoter function. Similarly, the preferred positioning of a regulatory sequence element with respect to a heterologous gene to be placed under its control is defined by the positioning of the element in its natural setting, i.e., the genes from which it is derived. Again, as is known in the art, some variation in this distance can also occur.</p>
    <p>Examples of promoters suitable for use in the synthetic genes of the present invention include viral, fungal, bacterial, animal and plant derived promoters capable of functioning in plant, animal, insect, fungal, yeast or bacterial cells. The promoter may regulate the expression of the structural gene component constitutively, or differentially with respect to cell, the tissue or organ in which expression occurs or, with respect to the developmental stage at which expression occurs, or in response to external stimuli such as physiological stresses, or pathogens, or metal ions, amongst others.</p>
    <p>Preferably, the promoter is capable of regulating expression of a nucleic acid molecule in a eukaryotic cell, tissue or organ, at least during the period of time over which the target gene is expressed therein and more preferably also immediately preceding the commencement of detectable expression of the target gene in said cell, tissue or organ.</p>
    <p>Accordingly, strong constitutive promoters are particularly preferred for the purposes of the present invention or promoters which may be induced by virus infection or the commencement of target gene expression.</p>
    <p>Examples of preferred promoters include the bacteriophage T7 promoter, bacteriophage T3 promoter, SP6 promoter, lac operator-promoter, tac promoter, SV40 late promoter, SV40 early promoter, RSV-LTR promoter, CMV IE promoter and the like.</p>
    <p>Particularly preferred promoters contemplated herein include promoters operable in eukaryotic cells, for example the SV40 early promoter, SV40 late promoter or the CMV IE promoter sequence. Those skilled in the art will readily be aware of additional promoter sequences other than those specifically described.</p>
    <p>In the present context, the terms “in operable connection with” or “operably under the control” or similar shall be taken to indicate that expression of the structural gene is under the control of the promoter sequence with which it is spatially connected; in a cell, tissue, organ or whole organism.</p>
    <p>In a more particularly preferred embodiment of the invention, the synthetic gene according to this aspect of the invention comprises the coding region of the BEV polymerase gene placed in the sense orientation operably under the control of the CMV IE promoter or SV40 late promoter. In an alternative embodiment, the synthetic gene comprises a nucleotide sequence derived from the coding region of the BEV polymerase gene but lacking a translation—start site, placed in the sense orientation in operable connection with the CMV IE promoter or SV40 late promoter. In a further alternative embodiment, the synthetic gene comprises a nucleotide sequence derived from the BEV polymerase gene placed in the antisense orientation relative to the BEV polymerase gene and in operable connection with the CMV IE promoter or the SV40 late promoter sequence.</p>
    <p>For the present purposes, the term “BEV polymerase” as used herein shall be taken to refer to a structural gene, cDNA molecule, genomic gene or nucleotide sequence at least about 30-50 nucleotides in length which is derived from the nucleotide sequence of the bovine enterovirus(BEV) RNA-dependent RNA polymerase gene, including both translatable and non-translatable nucleotide sequences and nucleotide sequences which are complementary to a part of the nucleotide sequence of the full-length BEV RNA-dependent RNA polymerase gene.</p>
    <p>In a further alternative embodiment, the synthetic gene according to this aspect of the invention comprises the coding region of a tyrosinase gene, in particular the murine tyrosinase gene, placed in the sense orientation operably under the control of the CMV IE promoter or SV40 late promoter. As with other embodiments described herein, the synthetic gene (i.e. tyrosinase gene) may lack a functional translation start site or be introduced in the antisense orientation. The present invention clearly encompasses all such embodiments.</p>
    <p>As used herein, the term “tyrosinase gene” shall be taken to refer to a structural gene, cDNA molecule, genomic gene or nucleotide sequence which is capable of encoding the tyrosinase enzyme or a polypeptide fragment thereof or alternatively, a nucleotide sequence which is complementary to said structural gene, cDNA molecule, genomic gene or nucleotide sequence. Particularly preferred tyrosinase genes for use in the performance of the present invention include, but are not limited to, those described by Kwon et at (1988) and homologues, analogues and derivatives thereof and complementary nucleotide sequences thereto.</p>
    <p>In still a further alternative embodiment, the synthetic gene according to this aspect of the invention comprises the coding region of the lacI gene, placed in the sense orientation operably under the control of the CMV IE promoter or SV40 late promoter. As with other embodiments described herein, the synthetic gene (i.e. <i>E. coli </i>lacI gene) may lack a functional translation start site or be introduced in the antisense orientation. The present invention clearly encompasses all such embodiments.</p>
    <p>As used herein, the term “lacI gene” shall be taken to refer to a structural gene, cDNA molecule, genomic gene or nucleotide sequence which is capable of encoding a polypeptide repressor of the lacZ gene which encodes the enzyme β-galactosidase or alternatively, a nucleotide sequence which is complementary to said structural gene, cDNA molecule, genomic gene or nucleotide sequence. Those skilled in the art will be aware that the lac repressor is a DNA-binding protein which acts on the lac operator-promoter sequence. In the presence of one of a variety of β-galactosides, the affinity of the lac repressor for the lac operator-promoter sequence is lowered, thereby allowing RNA polymerase to bind the lac operator-promoter region to activate transcription of the lac operon.</p>
    <p>Standard methods may be used to produce the structural genes of the present invention, in particular the BEV polymerase and tyrosinase genes which are derived from publicly available material. For example, the BEV polymerase and tyrosinase genes may be amplified using the polymerase chain reaction or alternatively, isolated using standard hybridisation techniques known to those skilled in the art.</p>
    <p>For the purposes of nomenclature, the nucleotide sequence of the cDNA encoding murine tyrosinase is publicly available under GenBank Accession No. M20234.</p>
    <p>A second aspect of the present invention provides a synthetic gene which is capable of modifying the expression of a target gene in a cell, tissue or organ, wherein said synthetic gene at least comprises multiple structural gene sequences wherein each of said structural gene sequences comprises a nucleotide sequence which is substantially identical to the nucleotide sequence of the target gene or a derivative thereof or a complementary sequence thereto and wherein said multiple structural gene sequences are placed operably under the control of a single promoter sequence which is operable in said cell, tissue or organ.</p>
    <p>As used herein, the term “multiple structural gene sequences” or similar term shall be taken to refer to any number of structural genes as defined herein which is greater than or equal to two. Accordingly, a multiple structural gene sequence may comprise a tandem repeat or concatemer of two or more identical nucleotide sequences or alternatively, a tandem array or concatemer of non-identical nucleotide sequences, the only requirement being that each of the structural gene sequences contained therein is substantially identical to the target gene sequence or a complementary sequence thereto. In this regard, those skilled in the art will be aware that a cDNA molecule may also be regarded as a multiple structural gene sequence in the context of the present invention, in so far as it comprises a tandem array or concatemer of exon sequences derived from a genomic target gene. Accordingly, cDNA molecules and any tandem array, tandem repeat or concatemer of exon sequences and/or intron sequences and/or 5′-untranslated and/or 3′-untranslated sequences are clearly encompassed by this embodiment of the invention.</p>
    <p>Preferably, the multiple structural gene comprises at least 2-4 individual structural gene sequences, more preferably at least about 4-6 individual structural gene sequences and more preferably at least about 6-8 individual structural gene sequences.</p>
    <p>The optimum number of structural gene sequences which may be involved in the synthetic gene of the present invention will vary considerably, depending upon the length of each of said structural gene sequences, their orientation and degree of identity to each other. For example, those skilled in the art will be aware of the inherent instability of palindromic nucleotide sequences in vivo and the difficulties associated with constructing long synthetic genes comprising inverted repeated nucleotide sequences, because of the tendency for such sequences to form hairpin loops and to recombine in vivo. Notwithstanding such difficulties, the optimum number of structural gene sequences to be included in the synthetic genes of the present invention may be determined empirically by those skilled in the art, without any undue experimentation and by following standard procedures such as the construction of the synthetic gene of the invention using recombinase deficient cell lines, reducing the number of repeated sequences to a level which eliminates or minimises recombination events and by keeping the total length of the multiple structural gene sequence to an acceptable limit, preferably no more than 5-10 kb, more preferably no more than 2-5 kb and even more preferably no more than 0.5-2.0 kb in length.</p>
    <p>In an alternative embodiment, each structural gene contained within the multiple structural gene unit of the subject synthetic gene may comprise a nucleotide sequence which is substantially identical to a different target gene in the same organism. Such an arrangement may be of particular utility when the synthetic gene is intended to provide protection against a pathogen in a cell, tissue or organ, in particular a viral pathogen, by modifying the expression of viral target genes. For example, the multiple structural gene may comprise nucleotide sequences which are substantially identical to two or more target genes selected from the list comprising DNA polymerase, RNA polymerase and coat protein or other target gene which is essential for viral infectivity, replication or reproduction. However, it is preferred with this arrangement that the structural gene units are selected such that the target genes to which they are substantially identical are normally expressed at approximately the same time (or later) in an infected cell, tissue or organ as (than) the multiple structural gene of the subject synthetic gene is expressed under control of the promoter sequence. This means that the promoter controlling expression of the multiple structural gene will usually be selected to confer expression in the cell, tissue or organ over the entire life cycle of the virus when the viral target genes are expressed at different stages of infection.</p>
    <p>The individual structural gene units of the multiple structural gene according to the embodiments described herein may be spatially connected in any orientation relative to each other, for example head-to-head, head-to-tail or tail-to-tail and all such configurations are within the scope of the invention.</p>
    <p>Preferably, the multiple structural gene unit comprises two structural genes in a head-to-tail or head-to-head configuration. More preferably, the multiple structural gene unit comprises two identical or substantially identical structural genes or a homologue, analogue or derivative thereof in a head-to-tail configuration as a direct repeat or alternatively, in a head-to-head configuration as an inverted repeat or palindrome.</p>
    <p>In a particularly preferred embodiment, the multiple structural gene unit comprises two identical or substantially identical structural genes comprising nucleotide sequences derived from the BEV polymerase or tyrosinase gene or a homologue, analogue or derivative thereof, placed in a head-to-head or head-to-tail configuration.</p>
    <p>According to this aspect of the invention, wherein the multiple structural gene or any individual structural gene unit thereof is intended to be both transcribed and translated, a translation start signal may be included at the 5′ end of that open reading frame. In a particularly preferred embodiment, the structural gene unit which is positioned nearer the 5′ end of the synthetic gene comprises an in-frame translation start signal of facilitate translation of the first open reading frame of the multiple structural gene in a cell, tissue or organ into which the synthetic gene is introduced. Those skilled in the art will be aware that it is also possible to produce a fusion polypeptide from such an arrangement provided that the individual structural gene units are positioned such that their open reading frames are in-frame with respect to each other or alternatively, the individual structural gene units are separated by intron/exon splice boundary sequences such that splicing of the mRNA product of the synthetic gene produces a translatable mRNA wherein the said open reading frames are in-frame with respect to each other. Such embodiments are clearly contemplated by the present invention. Intron/exon splice junction sequences are well-known in the art and the skilled person would readily be able to introduce such sequences to the 5′- and 3′- ends of a structural gene unit of the synthetic genes described herein.</p>
    <p>The individual structural genes comprising the multiple structural gene unit may be further spatially separated by the addition of a linker molecule or “stuffer fragment” there between. The stuffer fragment may comprise any combination of nucleotide or amino acid residues, carbohydrate molecules or oligosaccharide molecules or carbon atoms or a homologue, analogue or derivative thereof which is capable of being linked covalently to a nucleic acid molecule.</p>
    <p>Preferably, embodiment, the stuffer fragment comprises a sequence of nucleotides or a homologue, analogue or derivative thereof.</p>
    <p>More preferably, the stuffer fragment comprises a sequence of nucleotides of at least about 10-50 nucleotides in length, even more preferably at least about 50-100 nucleotides in length and still more preferably at least about 100-500 nucleotides in length.</p>
    <p>Wherein the multiple structural gene unit comprises intron/exon splice junction sequences, the stuffer fragment may serve as an intron sequence placed between the 3′-splice site of the structural gene nearer the 5′-end of the gene and the 5′- splice site of the next downstream structural gene. Alternatively, wherein it is desirable for more than two adjacent structural genes to be translated, the stuffer fragment placed there between should not include an in-frame translation stop codon, absent intron/exon splice junction sequences at both ends of the stuffer fragment or the addition of a translation start codon at the 5′ end of each structural gene unit, as will be obvious to those skilled in the art.</p>
    <p>Preferred stuffer fragments are those which encode detectable marker proteins or biologically-active analogues and derivatives thereof, for example luciferase, β-galacturonase, β-galactosidase, chloramphenicol acetyltransferase or green fluorescent protein, amongst others.</p>
    <p>According to this embodiment, the detectable marker or an analogue or derivative thereof serves to indicate the expression of the synthetic gene of the invention in a cell, tissue or organ by virtue of its ability to confer a specific detectable phenotype thereon, preferably a visually-detectable phenotype.</p>
    <p>In a more particularly preferred embodiment of the invention, the multiple structural gene comprises an interrupted direct repeat or interrupted palindrome comprising two identical or substantially-identical BEV polymerase structural gene sequences or alternatively, two identical or substantially-identical tyrosinase structural gene sequences or a homologue, analogue or derivative thereof separated by a stuffer fragment comprising a nucleotide sequence which encodes green-fluorescent protein or a biologically-active analogue or derivative thereof.</p>
    <p>As used herein, the term “green fluorescent protein” or “GFP” shall be taken to refer to a protein, polypeptide or peptide which is capable of producing a strong green fluorescence when excited with near ultraviolet radiation or blue light or a homologue, analogue or derivative thereof. Accordingly, the term “GPP gene” shall be taken to refer to a nucleotide sequence which is capable of encoding GFP or a complementary nucleotide sequence thereto. Particularly preferred GFPs and GFP genes according to the present invention are derived from the jellyfish <i>Aequoria victoria </i>as described by Prasher et al (1992) or in International Patent Publication No. WO 95/07463, amongst others.</p>
    <p>A further aspect of the invention provides for each structural gene of the multiple structural gene unit to be placed operably under the control of a separate promoter sequence.</p>
    <p>According to this embodiment, the promoters controlling expression of the structural gene unit are preferably different promoter sequences, to reduce competition there between for cellular transcription factors and RNA polymerases. Preferred promoters are selected from those referred to supra.</p>
    <p>Those skilled in the art will know how to modify the arrangement or configuration of the individual structural genes as described supra to regulate their expression from separate promoter sequences.</p>
    <p>In a particularly preferred embodiment, the multiple structural gene unit comprises two or more BEV polymerase structural genes or two or more tyrosinase structural genes wherein each of said structural genes is placed operably in connection with a different promoter sequence. More particularly preferred, the multiple structural gene unit comprises two BEV polymerase structural genes or two tyrosinase structural genes positioned as inverted repeats or direct repeats wherein one of said structural genes is placed operably in connection with the CMV IE promoter. Even more preferably, at least one of the BEV polymerase structural genes or tyrosinase genes comprising the multiple structural gene is presented in the sense orientation and comprises a translation start signal to facilitate translation of nrRNA encoded therefrom.</p>
    <p>Those skilled in the art will be aware that the structural genes comprising the multiple structural gene unit according to this aspect of the invention are expressed as physically-distinct mRNA species and, as a consequence, wherein said mRNA species are translated, no fusion polypeptide will be produced there between. However, the present invention clearly extends to synthetic gene which comprises two or more structural genes operably connected to a first promoter sequence and one or more structural genes operably connected to one or more additional promoter sequences.</p>
    <p>The synthetic genes described supra are capable of being modified further, for example by the inclusion of marker nucleotide sequences encoding a detectable marker enzyme or a functional analogue or derivative thereof, to facilitate detection of the synthetic gene in a cell, tissue or organ in which it is expressed. According to this embodiment, the marker nucleotide sequences will be present in a translatable format and expressed, for example as a fusion polypeptide with the translation product(s) of any one or more of the structural genes or alternatively as a non-fusion polypeptide.</p>
    <p>Alternatively or in addition, the synthetic genes described supra may further comprise one or more transcription termination sequences placed at the 3′-end of the transcriptional unit of the synthetic gene sequence.</p>
    <p>The term “terminator” refers to a DNA sequence at the end of a transcriptional unit which signals termination of transcription. Terminators are 3′-non-translated DNA sequences containing a polyadenylation signal, which facilitates the addition of polyadenylate sequences to the 3′-end of a primary transcript. Terminators active in cells derived from viruses, yeasts, moulds, bacteria, insects, birds, mammals and plants are known and described in the literature. They may be isolated from bacteria, fungi, viruses, animals and/or plants.</p>
    <p>Examples of terminators particularly suitable for use in the synthetic genes of the present invention include the SV40 polyadenylation signal, the HSV TK polyadenylation signal, the CYC1 terminator, ADH terminator, SPA terminator, nopaline synthase (NOS) gene terminator of <i>Agrobacterium tumefaciens</i>, the terminator of the Cauliflower mosaic virus (CaMV) 35S gene, the zein gene terminator from <i>Zea mays</i>, the Rubisco small subunit gene (SSU) gene terminator sequences, subclover stunt virus (SCSV) gene sequence terminators, any rho-independent <i>E. coli </i>terminator, or the lacZ alpha terminator, amongst others.</p>
    <p>In a particularly preferred embodiment, the terminator is the SV40 polyadenylation signal or the HSV TK polyadenylation signal which are operable in animal cells, tissues and organs or the lacZ alpha terminator which is active in prokaryotic cells.</p>
    <p>Those skilled in the art will be aware of additional promoter sequences and terminator sequences which may be suitable for use in performing the invention. Such sequences may readily be used without any undue experimentation.</p>
    <p>The synthetic genes of the present invention may be introduced to a suitable cell, tissue or organ without modification as linear DNA in the form of a genetic construct, optionally contained within a suitable carrier, such as a cell, virus particle or liposome, amongst others. To produce a genetic construct, the synthetic gene of the invention is inserted into a suitable vector or episome molecule, such as a bacteriophage vector, viral vector or a plasmid, cosmid or artificial chromosome vector which is capable of being maintained and/or replicated and/or expressed in the host cell, tissue or organ into which it is subsequently introduced.</p>
    <p>Accordingly a further aspect of the invention provides a genetic construct which at least comprises the synthetic gene according to any one or more of the embodiments described herein and one or more origins of replication and/or selectable marker gene sequences.</p>
    <p>Usually, an origin of replication or a selectable marker gene suitable for use in bacteria is physically-separated from those genetic sequences contained in the genetic construct which are intended to be expressed or transferred to a eukaryotic cell, or integrated into the genome of a eukaryotic cell.</p>
    <p>In a particularly preferred embodiment, the origin of replication is functional in a bacterial cell and comprises the pUC or the ColE1 origin or alternatively the origin of replication is operable in a eukaryotic cell, tissue and more preferably comprises the 2 micron (2 μm) origin of replication or the SV40 origin of replication.</p>
    <p>As used herein, the term “selectable marker gene” includes any gene which confers a phenotype on a cell in which it is expressed to facilitate the identification and/or selection of cells which are transfected or transformed with a genetic construct of the invention or a derivative thereof.</p>
    <p>Suitable selectable marker genes contemplated herein include the ampicillin-resistance gene (Amp<sup>r</sup>), tetracycline-resistance gene (Tc<sup>r</sup>), bacterial kanamycin-resistance gene (Kan<sup>r</sup>), is the zeocin resistance gene (Zeocin is a drug of bleomycin family which is trademark of InVitrogen Corporation), the AURI-C gene which confers resistance to the antibiotic aureobasidin A, phosphinothricin-resistance gene, neomycin phosphotransferase gene (nptII), hygromycin-resistance gene, β-glucuronidase (GUS) gene, chloramphenicol acetyltransferase (CAT) gene, green fluorescent protein- encoding gene or the luciferase gene, amongst others.</p>
    <p>Preferably, the selectable marker gene is the nptII gene or Kan<sup>r </sup>gene or green fluorescent protein (GFP)-encoding gene.</p>
    <p>Those skilled in the art will be aware of other selectable marker genes useful in the performance of the present invention and the subject invention is not limited by the nature of the selectable marker gene.</p>
    <p>The present invention extends to all genetic constructs essentially as defined herein, which include further genetic sequences intended for the maintenance and/or replication of said genetic construct in prokaryotes and/or the integration of said genetic construct or a part thereof into the genome of a eukaryotic cell or organism.</p>
    <p>The present invention further extends to an isolated cell, tissue or organ comprising the synthetic gene described herein or a genetic construct comprising same. Any standard means may be used for their introduction including cell mating, transformation or transfection procedures known to those skilled in the art or described by Ausubel et al. (1992).</p>
    <p>The present invention is further described by reference to the following non-limiting Examples.</p>
    <heading>EXAMPLE 1</heading> <heading>Base Plasmids</heading> <heading>Plasmid pEGFP-N1 MCS</heading> <p>Plasmid pEGFP-N1 MCS (FIG. 1; Clontech) contains the CMV IE promoter operably connected to an open reading frame encoding a red-shifted variant of wild-type green fluorescent protein (GFP; Prasher et al., 1992; Chalfie et al., 1994; Inouye and Tsuji, 1994), which has been optimised for brighter fluorescence. The specific GFP variant encoded by pEGFP-N1 MCS has been disclosed by Cormack et al. (1996). Plasmid pEGFP-N1 MCS contains a multiple cloning site comprising Bg/II and BamHI sites and many other restriction endonuclease cleavage sites, located between the CMV IE promoter and the GFP open reading frame. Structural genes cloned into the multiple cloning site will be expressed at the transcriptional level if they lack a functional translation start site, however such structural gene sequences will not be expressed at the protein level (i.e. translated). Structural gene sequences inserted into the multiple cloning site which comprise a functional translation start site will be expressed as GFP fusion polypeptides if they are cloned in-frame with the GFP-encoding sequence. The plasmid further comprises an SV40 polyadenylation signal downstream of the GFP open reading frame to direct proper processing of the 3′-end of mRNA transcribed from the CMV-IE promoter sequence. The plasmid further comprises the SV40 origin of replication functional in animal cells; the neomycin-resistance gene comprising SV40 early promoter (SV40 EP in FIG. 1) operably connected to the neomycin/kanamycin-resistance gene derived from Tn5 (Kan/neo in FIG. 1) and the HSV thymidine kinase polyadenylation signal (HSV TK poly (A) in FIG. <b>1</b>), for selection of transformed cells on kamanycin, neomycin or G418; the pUC19 origin of replication which is functional in bacterial cells (pUC Ori in FIG. <b>1</b>); and the fl origin of replication for single-stranded DNA production (fl Ori in FIG. <b>1</b>).</p>
    <heading>pCMVLacI</heading> <p>Plasmid pCMVLacI is a commercially-obtainable mammalian expression vector (Stratagene) comprising the lacI gene encoding the lac repressor and a gene coding for hygromycin resistance (Hyg<sup>r</sup>).</p>
    <heading>Plasmid pOPRSVI/MCS</heading> <p>Plasmid pOPRSVI/MCS is a commercially-obtainable mammalian expression vector (Stratagene), comprising the OPRSV1 promoter sequence (a modified RSV-LTR promoter), SV40 intron sequence, lac operator sequence, multiple cloning site and thymidine kinase (TK) gene transcription terminator sequence [i.e. TK poly(A) signal].</p>
    <heading>Plasmid pSVL</heading> <p>Plasmid pSVL is commercially-obtainable from Pharmacia and serves as a source of the SV40 late promoter sequence. The nucleotide sequence of pSVL is also publicly available as GenBank Accession Number U13868.</p>
    <heading>Plasmid pCMV.cass</heading> <p>Plasmid pCMV.cass (FIG. 2) is an expression cassette for driving expression of a structural gene sequence under control of the CMV-IE promoter sequence. Plasmid pCMV.cass was derived from pEGFP-N1 MCS by deletion of the GFP open reading frame as follows: Plasmid pEGFP-N1 MCS was digested with PinAI and Not I, blunt-ended using PfuI polymerase and then re-ligated. Structural gene sequences are cloned into pCMV.cass using the multiple cloning site, which is identical to the multiple cloning site of pEGFP-N1 MCS, except it lacks the PinAI site.</p>
    <heading>Plasmid pCR2.1</heading> <p>Plasmid pCR2.1 is commercially available from Stratagene and comprises the lacZ promoter sequence and lacZ-α transcription terminator, with a cloning site for the insertion of structural gene sequences there between. Plasmid pCR2.1 is designed to clone nucleic acid fragments by virtue of the A-overhang frequently synthesized by Taq polymerase during the polymerase chain reaction. The plasmid further comprises the ColE1 and fl origins of replication and kanamycin-resistance and ampicillin-resistance genes.</p>
    <heading>Plasmid pCR.Bgl-GFP-Bam</heading> <p>Plasmid pCR.Bgl-GFP-Bam (FIG. 3) comprises an internal region of the GFP open reading frame derived from plasmid pEGFP-N1 MCS (FIG. 1) placed operably under the control of the lacZ promoter. To produce this plasmid, a region of the GFP open reading frame was amplified from pEGFP-N1 MCS using the amplification primers Bgl-GFP (SEQ ID NO:5) and GFP-Bam (SEQ ID NO:6) and cloned into plasmid pCR2.1. The internal GFP-encoding region in plasmid pCR.Bgl-GFP-Bam lacks functional translational start and stop codons.</p>
    <heading>Plasmid pCR.SV40L</heading> <p>Plasmid pCR.SV40L (FIG. 4) comprises the SV40 late promoter derived from plasmid pSVL (GenBank Accession No. U13868; Pharmacia), cloned into pCR2.1 (Stratagene). To produce this plasmid, the SV40 late promoter was amplified using the primers SV40-1 (SEQ ID NO:7) and SV40-2 (SEQ ID NO:8) which comprise Sal I cloning sites to facilitate sub-cloning of the amplified DNA fragment into pCMV.cass. SEQ ID No. 7 also contains a synthetic poly (A) site at the 5′ end, such that the amplicification product comprises the synthetic poly(A) site at the 5′ end of the SV40 promoter sequence.</p>
    <heading>Plasmid pCMV.SV40L.cass</heading> <p>Plasmid pCMV.SV40L.cass (FIG. 5) comprises the synthetic poly A site and the SV40 late promoter sequence from plasmid pCR.SV40L (FIG. <b>4</b>), sub-cloned as a Sal I fragment, into the Sal I site of plasmid pCMV.cass (FIG. <b>2</b>), such that the CMV-IE promoter and SV40 late promoter sequences are capable of directing transcription in the same direction. Accordingly, the synthetic poly(A) site at the 5′ end of the SV40 promoter sequence is used as a transcription terminator for structural genes expressed from the CMV IE promoter in this plasmid, which also provides for the insertion of said structural gene via the multiple cloning site present between the SV40 late promoter and the synthetic poly(A) site (FIG. <b>5</b>). The multiple cloning sites are located behind the CMV-IE and SV40 late promoters, including BamHI and BglII sites.</p>
    <heading>EXAMPLE 2</heading> <heading>BEV Polymerase-containing Genes</heading> <heading>Plasmid pCR.BEV.1</heading> <p>The BEV RNA-dependent RNA polymerase coding region was amplified as a 1,385 bp DNA fragment from a full-length cDNA clone encoding same, using the primers designated BEV-1 (SEQ ID NO:1) and BEV-2 (SEQ ID NO:2), under standard amplification conditions. The amplified DNA contained a 5′-Bgl II restriction enzyme site, derived from the BEV-1 primer sequence and a 3′BamHI restriction enzyme site, derived from the BEV-2 primer sequence. Additionally, as the BEV-1 primer sequence contains a translation start signal 5′-ATG-3′ engineered at positions 15-17 of SEQ ID NO:1, the amplified BEV polymerase structural gene comprises the start site in-frame with BEV polymerase-encoding nucleotide sequences, Thus, the amplified BEV polymerase structural gene comprises the ATG start codon immediately upstream (i.e. juxtaposed) to the BEV polymerase-encoding sequence. There is no translation stop codon in the amplified DNA.</p>
    <p>The amplified BEV polymerase structural gene was cloned into plasmid pCR2.1 to produce pCR.BEV.1 (FIG. <b>6</b>).</p>
    <heading>Plasmid pCR.BEV.2</heading> <p>The complete BEV polymerase coding region was amplified from a full-length cDNA clone encoding same, using primers BEV-1 (SEQ ID NO:1) and BEV-3 (SEQ ID NO:3). Primer BEV-3 comprises a BamHI restriction enzyme site at positions 5 to 10 inclusive of SEQ ID NO:3 and the complement of a translation stop signal at positions 11 to 13 of SEQ ID NO:3. As a consequence, an open reading frame comprising a translation start signal and translation stop signal, contained between the Bgl II and BamHI restriction sites. The amplified fragment was cloned into pCR2.1 to produce plasmid pCR2.BEV.2 (FIG. <b>7</b>).</p>
    <heading>Plasmid pCR.BEV.3</heading> <p>A non-translatable BEV polymerase structural gene was amplified from a full-length BEV polymerase cDNA clone using the amplification primers BEV-3 (SEQ ID NO:3) and BEV4 (SEQ ID NO:4). Primer BEV-4 comprises a BglII cloning site at positions 5-10 of SEQ ID NO:4 and sequences downstream of this BglII site are homologous to nucleotide sequences of the BEV polymerase gene. There is no fictional ATG start codon in the amplified DNA product of primers BEV-3 and 13BV4. The BEV polymerase is expressed as part of a polyprotein and, as a consequence, there is no ATG translation start site in this gene. The amplified DNA was cloned into plasmid pCR2.1 to yield plasmid pCR.BEV.3 (FIG. <b>8</b>).</p>
    <heading>EXAMPLE 3</heading> <heading>Synthetic Genes Comprising a BEV Polymerase Structural Gene Operably Connected to the CMV-IE Promoter Sequence</heading> <heading>Plasmid pEGFP.BEV.1</heading> <p>Plasmid pEGFP.BEV.1 (FIG. 9) is capable of expressing the BEV polymerase structural gene as a GFP fusion polypeptide under the control of the CMV-IE promoter sequence. To produce plasmid pEGFP.BEV.1, the BEV polymerase sequence from pCR.BEV.1 (FIG. 6) was cloned as a BglII-to-BamHI fragment into BglII/BamHI-digested pEGFP-N1 MCS (FIG. <b>1</b>).</p>
    <heading>Plasmid pCMV.BEV.2</heading> <p>Plasmid pCMV.BEV.2 (FIG. 10) is capable of expressing the entire BEV polymerase open reading frame under the control of CMV-IE promoter sequence. To produce pCMV.BEV.2, the BEV polymerase sequence from pCR.BEV.2 (FIG. 7) was sub-cloned in the sense orientation as a BglII-to-BamHI fragment into BglII/BamHI-digested pCMV.cass (FIG. <b>2</b>).</p>
    <heading>Plasmid pCMV.VEB</heading> <p>Plasmid pCMV.VEB (FIG. 11) expresses an antisense BEV polymerase mRNA under the control of the CMV-IE promoter sequence. To produce plasmid pCMV.VEB, the BEV polymerase sequence from pCR.BEV.2 (FIG. 7) was sub-cloned in the antisense orientation as a BglII-to-BamHI fragment into BglII/BamHI-digested pCMV.cass (FIG. <b>2</b>).</p>
    <heading>Plasmid pCMV.BEVnt</heading> <p>Plasmid pCMV.BEVnt (FIG. 12) expresses a non-translatable BEV polymerase structural gene in the sense orientation under the control of the CMV-IE promoter sequence. To produce pCMV.BEVnt, the BEV polymerase sequence from pCR.BEV.3 (FIG. 8) was sub-cloned in the sense orientation as a BglII-to-BamHI fragment into BglII/BamHI-digested pCMV.cass (FIG. <b>2</b>).</p>
    <heading>Plasmid pCMV.BEVx2</heading> <p>Plasmid pCMV.BEVx2 (FIG. 13) comprises a direct repeat of a complete BEV polymerase open reading frame under the control of the CMV-IE promoter sequence. In eukaryotic cells at least, the open reading frame located nearer the CMV-IE promoter is translatable. To produce pCMV.BEVx2, the BEV polymerase structural gene from plasmid pCR.BEV.2 (FIG. 7) was sub-cloned in the sense orientation as a BglII-to-BamHI fragment into BamHI-digested pCMV.BEV.2 (FIG. <b>10</b>), immediately downstream of the BEV polymerase structural gene already present therein.</p>
    <heading>Plasmid pCMV.BEV.VEB</heading> <p>Plasmid pCMV.BEV.VEB (FIG. 14) comprises an inverted repeat or palindrome of a complete BEV polymerase open reading frame under the control of the CMV-IE promoter sequence. In eukaryotic cells at least, the open reading frame located nearer the CMV-IE promoter is translatable. To produce pCMV.BEV.VEB, the BEV polymerase structural gene from plasmid pCR.BEV.2 (FIG. 7) was sub-cloned in the antisense orientation as a BglII-to-BamHI fragment into BamHI-digested pCMV.BEV.2 (FIG. <b>10</b>), immediately downstream of the BEV polymerase structural gene already present therein.</p>
    <heading>Plasmid pCMV.BEV.GFP.VEB</heading> <p>Plasmid pCMV.BEV.GFP.VEB (FIG. 15) is similar to plasmid pCMV.BEV.VEB except that the BEV structural gene inverted repeat or palindrome is interrupted by the insertion of a GFP open reading frame (stuffer fragment) therein. To produce plasmid pCMV.BEV.GFP.VEB, the GFP stuffer fragment from pCR.Bgl-GFP-Bam (FIG. 3) was first sub-cloned in the sense orientation as a BglII-to-BamHI fragment into BamHI-digested pCMV.BEV.2 (FIG. 7) to produce an intermediate plasmid pCMV.BEV.GFP wherein the BEV polymerase-encoding and GFP-encoding sequences are contained within the same 5′-BglII-to-BamHI-3′ fragment. The BEV polymerase structural gene from pCMV.BEV.2 (FIG. 7) was then cloned in the antisense orientation as a BglII-to-BamHI fragment into BamHI-digested pCMV.BEV.GFP. The BEV polymerase structural gene nearer the CMV-IE promoter sequence in plasmid pCMV.BEV.GFP.VEB is capable of being translated, at least in eukaryotic cells.</p>
    <heading>EXAMPLE 4</heading> <heading>Synthetic Genes Comprising BEV Polymerase Structural Genes Operably Connected to Multiple Promoter Sequences</heading> <heading>Plasmid pCMV.BEV.SV40L-O</heading> <p>Plasmid pCMV.BEV.SV40L-O (FIG. 16) comprises a translatable BEV polymerase structural gene derived from plasmid pCR.BEV.2 (FIG. 7) inserted in the sense orientation between the CMV-IE promoter and the SV40 late promoter sequences of plasmid pCMV.SV40L.cass (FIG. <b>5</b>). To produce plasmid pCMV.BEV.SV40L-O, the BEV polymerase structural gene was sub-cloned as a BglII-to-BamHI fragment into BglII-digested pCMV.SV40L.cass DNA.</p>
    <heading>Plasmid pCMV.O.SV40L.BEV</heading> <p>Plasmid pCMV.O.SV40L.BEV (FIG. 17) comprises a translatable BEV polymerase structural gene derived from plasmid pCR.BEV.2 (FIG. 7) cloned downstream of tandem CMV-IE promoter and SV40 late promoter sequences present in plasmid pCMV.SV40L.cass (FIG. <b>5</b>). To produce plasmid pCMV.O.SV40L.BEV, the BEV polymerase structural gene was sub-cloned in the sense orientation as a BglII-to-BamHI fragment into BamHI-digested pCMV.SV40L.cass DNA.</p>
    <heading>Plasmid pCMV.O.SV40L.VEB</heading> <p>Plasmid pCMV.O.SV40L.VEB (FIG. 18) comprises an antisense BEV polymerase structural gene derived from plasmid pCR.BEV.2 (FIG. 7) cloned downstream of tandem CMV-IE promoter and SV40 late promoter sequences present in plasmid pCMV.SV40L.cass (FIG. <b>5</b>). To produce plasmid pCMV.O.SV40L.VEB, the BEV polymerase structural gene was sub-cloned in the antisense orientation as a BglII-to-BamHI fragment into BamHI-digested pCMV.SV40L.cass DNA.</p>
    <heading>Plasmid pCMV.BEV.SV40L.BEV</heading> <p>Plasmid pCMV.BEV.SV40L.BEV(FIG. 19) comprises a multiple structural gene unit comprising two BEV polymerase structural genes placed operably and separately under control of the CMV-IE promoter and SV40 late promoter sequences. To produce plasmid pCMV.BEV.SV40L.BEV, the translatable BEV polymerase structural gene present in pCR.BEV.2 (FIG. 7) was sub-cloned in the sense orientation as a BglII-to-BamHI fragment behind the SV40 late promoter sequence present in BamHI-digested pCMV.BEV.SV40L-O (FIG. <b>16</b>).</p>
    <heading>Plasmid pCMV.BEV.SV40L.VEB</heading> <p>Plasmid pCMV.BEV.SV40L.VEB (FIG. 20) comprises a multiple structural gene unit comprising two BEV polymerase structural genes placed operably and separately under control of the CMV-IE promoter and SV40 late promoter sequences. To produce plasmid pCMV.BEV.SV40L.VEB, the translatable BEV polymerase structural gene present in pCR.BEV.2 (FIG. 7) was sub-cloned in the antisense orientation as a BglII-to-BamHI fragment behind the SV40 late promoter sequence present in BamHI-digested pCMV.BEV.SV40L-O(FIG. <b>16</b>). In this plasmid, the BEV polymerase structural gene is expressed in the sense orientation under control of the CMV-IE promoter to produce a translatable mRNA, whilst the BEV polymerase structural gene is also expressed under control of the SV40 promoter to produce an antisense mRNA species.</p>
    <heading>Plasmid pCMV.SV40LR.cass</heading> <p>Plasmid pCMV.SV40LR.cass (FIG. 21) comprises the SV40 late promoter sequence derived from plasmid pCR.SV40L (FIG. <b>4</b>), sub-cloned as a SalI fragment into the SalI site of the plasmid pCMV.cass (FIG. <b>2</b>), such that the CMV-IE or the SV40 late promoter may drive transcription of a structural gene or a multiple structural gene unit, in the sense or antisense orientation, as desired. A multiple cloning site is positioned between the opposing CMV-IE and SV40 late promoter sequences in this plasmid to facilitate the introduction of a structural gene sequence. In order for expression of a structural gene sequence to occur from this plasmid, it must be introduced with its own transcription termination sequence located at the 3′ end, because there are no transcription termination sequences located between the opposing CMV-IE and SV40 late promoter sequences in this plasmid. Preferably, the structural gene sequence or multiple structural gene unit which is to be introduced into pCMV.SV40LR.cass will comprise both a 5′ and a 3′ polyadenylation signal as follows:</p>
    <p>(i) where the structural gene sequence or multiple structural gene unit is to be expressed in the sense orientation from the CMV IE promoter sequence and/or in the antisense orientation from the SV40 late promoter, the 5′ polyadenylation signal will be in the antisense orientation and the 3′ polyadenylation signal will be in the sense orientation; and</p>
    <p>(ii) where the structural gene sequence or multiple structural gene unit is to be expressed in the antisense orientation from the CMV IE promoter sequence and/or in the sense orientation from the SV40 late promoter, the 5′ polyadenylation signal will be in the sense orientation and the 3′ polyadenylation signal will be in the antisense orientation.</p>
    <p>Alternatively or in addition, suitably-oriented terminator sequences may be placed at the 5′-end of the CMV and SV40L promoters, as shown in FIG. <b>21</b>.</p>
    <p>Alternatively, plasmid pCMV.SV40LR.cass is further modified to produce a derivative plasmid which comprises two polyadenylation signals located between the CMV IE and SV40 late promoter sequences, in appropriate orientations to facilitate expression of any structural gene located therebetween in the sense or antisense orientation from either the CMV IE promoter or the SV40 promoter sequence. The present invention clearly encompasses such derivatives.</p>
    <heading>Plasmid pCMV.BEV.SV40LR</heading> <p>Plasmid pCMV.BEV.SV40LR (FIG. 22) comprises a structural gene comprising the entire BEV polymerase open reading frame placed operably and separately under control of opposing CMV-IE promoter and SV40 late promoter sequences, thereby potentially producing BEV polymerase transcripts at least from both strands of the full-length BEV polymerase structural gene. To produce plasmid pCMV.BEV.SV40LR, the translatable BEV polymerase structural gene present in pCR.BEV.2 (FIG. 7) was sub-cloned, as a BglII-to-BamHI fragment, into the unique BglII site of plasmid pCMV.SV40LR.cass (FIG. <b>21</b>), such that the BEV open reading frame is present in the sense orientation relative to the CMV-IE promoter sequence.</p>
    <p>Those skilled in the art will recognise that it is possible to generate a plasmid wherein the BEV polymerase fragment from pCR.BEV.2 is inserted in the antisense orientation, relative to the CMV IE promoter sequence, using this cloning strategy. The present invention further encompasses such a genetic construct.</p>
    <heading>EXAMPLE 5</heading> <heading>Synthetic Genes and Genetic Constructs Comprising the Tyrosinase Open Reading Frame</heading> <heading>Isolation of the Tyrosinase Open Reading Frame</heading> <p>The tyrosinase structural gene is isolated by polymerase chain reaction, from mRNA derived from murine cells, using the following oligonucleotide primers under standard polymerase chain reaction conditions:</p>
    <p>Tyr 5′ (forward primer; SEQ ID NO:9):</p>
    <p>5′-CCCGGGGCTTAGTGTAAAACAGGCTGAGAG-3′; and</p>
    <p>Tyr 3′ (reverse primer; SEQ ID NO:10):</p>
    <p>5′-CCCGGGCAAATCCCAGTCATTTCTTAGAAAC-3′.</p>
    <p>Nucleotide residues 1 to 6 in each primer represent a SmaI cloning site. Nucleotides 7 to 30 of primer Tyr 5′ correspond to the 5′-end of the murine tyrosinase cDNA sequence disclosed in GenBank Accession No. M20234 (Kwon et al, 1988). Nucleotides 7 to 31 of primer Tyr 3′ correspond to the complement of the nucleotide sequence of the 3′-end of the murine tyrosinase cDNA sequence.</p>
    <heading>Plasmid pCR.tyr</heading> <p>Plasmid pCR.tyr is produced by sub-cloning the amplified tyrosinase structural gene into plasmid pCR2.1 (Example 1), substantially according to the manufacturer's protocol. Plasmid pCR.tyr can be used as a base plasmid to produce a range of genetic constructs designed to express the tyrosinase structural gene or a multiple structural gene unit comprising same, under the control of one or more promoter sequences.</p>
    <heading>Plasmid pCMV.TYR</heading> <p>Plasmid pCMV.TYR (FIG. 23) comprises the complete mouse tyrosinase cDNA sequence placed operably in connection, in the sense orientation, with the CMV-IE promoter sequence and upstream of the SV40 polyadenylation sequence. To produce pCMV.TYR, the fill-length mouse tyrosinase cDNA sequence was excised from plasmid pCRtyr by digestion with SmaI and then ligated, into the SmaI cloning site of pCMV.cass (FIG. <b>2</b>). Clones possessing the tyrosinase structural gene in the sense orientation relative to the CMV-IE promoter were then selected.</p>
    <heading>Plasmid pCMV.TYRLIB</heading> <p>Plasmid pCMV.TYRLIB (FIG. 24) comprises a structural gene or multiple structural gene unit which comprises one or more tyrosinase gene fragments of 100 to 200 base pairs in length each, placed operably in connection with the CMV-IE promoter sequence and upstream of the SV40 polyadenylation signal. To produce pCMV.TYRLIB, blunt-ended fragments of the tyrosinase gene are ligated into SmaI-digested, dephosphorylated plasmid pCMV.cass DNA (FIG. <b>2</b>). The tyrosinase gene fragments are produced, for example, by sonication or mechanical shearing and end-repair using T4 DNA polymerase. Accordingly, the structural gene insert in plasmid pCMV.TYRLIB is variable and an representative library of pCMV.TYRLIB plasmids, covering the complete tyrosinase gene sequence, may be produced using such procedures. The present invention clearly encompasses such representative libraries. Those skilled in the art will recognise that such procedures are also useful for structural genes other than tyrosinase and, as a consequence, the present invention clearly extends to synthetic genes and genetic constructs wherein the structural gene present in pCMV.TYRLIB is a structural gene other than a tyrosinase gene fragment.</p>
    <heading>EXAMPLE 6</heading> <heading>Synthetic Genes and Genetic Constructs Comprising the lacI Open Reading Frame</heading> <heading>Plasmid pCMV.Lac</heading> <p>Plasmid pCMV.Lac (FIG. 25) contains a CMV IE promoter driving expression of the lac repressor protein encoded by the <i>Escherichia coli </i>lacI gene. Accordingly, the open reading frame of the LacI gene is cloned in the sense orientation with respect to the CMV IE promoter sequence in this plasmid. This construct also contains the selectable marker for neomycin resistance.</p>
    <p>To produce plasmid pCMV.Lac, the lacI gene was excised from plasmid pCMV.LacI (Stratagene) by digestion with HindIII and BsaBI and then ligated, in the sense orientation, into the multiple cloning site (MCS) of plasmid pCMV.cass (FIG. 2) which had been digested with HindIII and SmaI.</p>
    <heading>Plasmid pCMVLacI.OPRSV1.cass</heading> <p>Plasmid pCMVLacI.OPRSV1.cass (FIG. 26) is a dual expression construct in which the CMV-IE promoter drives expression of the LacI structural gene to produce the lac repressor protein and the OPRSVI promoter drives the expression of a second structural gene or multiple structural gene unit placed operably under control of lac repressor protein.</p>
    <p>To produce plasmid pCMVLac.OPRSV1.cass, a DNA fragment comprising the OPRSVI promoter, SV40 intron, lac operator sequence, multiple cloning site (MCS) and TK poly(A) sequence was excised from plasmid pOPRSVI/MCS (Stratagene), by digestion with SnaB1 and Asel restriction enzymes, then end-filled using PfuI polymerase and ligated into the end-filled BglII cloning site of plasmid pCMVLacI (Stratagene).</p>
    <heading>EXAMPLE 7</heading> <heading>Synthetic Genes and Genetic Constructs Comprising the lacI and Green Fluorescent Protein (GFP)Open Reading Frames</heading> <heading>Plasmid pCMVLacI.OPRSV1.GFP.cass</heading> <p>Plasmid pCMVLacI.OPRSVI.GFP.cass (FIG. 27) is designed such that a structural gene or multiple structural gene unit can be fused to the 3′ untranslated region of the lacI gene, by cloning directly into the unique BsaB1 cloning site which is located after the lacI stop codon and before an SV40 polyadenylation signal. Alternatively, the BSAB1 site may be modified to facilitate cloning, for example by the addition of linkers or adaptors. This construct also contains the antibiotic selectable marker for hygromycin resistance.</p>
    <p>To produce plasmid pCMVLacI.OPRSVI.GFP.cass, the enhanced GFP coding sequence was excised from plasmid PEGFP-N1 MCS (FIG. 1) by digestion with XhoI and NotI and the DNA fragment thus produced was ligated into the XhoI and NotI cloning sites of the multiple cloning site present in plasmid pCMVLacI.OPRSVI.cass (FIG. <b>26</b>).</p>
    <heading>EXAMPLE 8</heading> <heading>Synthetic Genes and Genetic Constructs Comprising the lacI and Green Fluorescent Protein (GFP) and Tyrosinase Open Reading Frames</heading> <heading>Plasmid pCMVLacI.TYR.OPRSV1.GFP</heading> <p>Plasmid pCMVLacI.TYR.OPRSV/1.GFP (FIG. 28) is a dual construct in which the CMV IE promoter drives expression of the lacI gene and the mRNA of the mouse tyrosinase cDNA or a fragment thereof, whilst the OPRSVI promoter drives expression of GFP operably under control of the lacI gene. The construct is designed such that the mouse tyrosinase gene is fused to the 3′ untranslated region of the lacI gene via a unique BsaB1cloning site. This cloning site is located after the stop codon of the lad coding sequence, but before the SV40 polyadenylation signal. The construct also contains the hygromycin-resistance gene as a selection marker.</p>
    <p>To produce plasmid pCMVLacI.TYR.OPRSV1.GFP, the complete tyrosinase gene present in plasmid pCR.tyr (Stratagene; Example 1) is isolated from host cells, digested with SmaI and ligated into BsaB1-digested and dephosphorylated plasmid pCMVLacI.OPRSVI.GFP.cass DNA (FIG. <b>27</b>).</p>
    <heading>Equivalents</heading> <p>Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.</p>
    <heading>References</heading> <p>1. Ausubel, F. M. et al.(1987) In: Current Protocols in Molecular Biology, Wiley Interscience (ISBN 047140338).</p>
    <p>2. Chalfie, M. et al (1994) <i>Science </i>263: 802-805.</p>
    <p>3. Cormack, B. et al (1996) <i>Gene </i>173: 33-38.</p>
    <p>4. Inouye, S. and Tsuji, F. I. (1994) <i>FEBS Leas. </i>341: 277-280.</p>
    <p>5. Kwon, B. S. et al. (1988) <i>Biochem. Biophys. Res. Comm. </i>153:1301-1309.</p>
    <p>6. Prasher, D. C. et al. (1992) <i>Gene </i>111: 229-233.</p>
    <p>
      <sequence-cwu id="SEQLST-1"> <sequence-list-new-rules> <s100> <s160>10</s160> </s100> <s200> <s210>1</s210> <s211>38</s211> <s212>DNA</s212> <s213>Artificial sequence</s213> <s220> <s223>Primer Bev-1</s223> </s220> </s200> <s400> 1
cggcagatct aacaatggca ggacaaatcg agtacatc                             38
</s400> <s200> <s210>2</s210> <s211>31</s211> <s212>DNA</s212> <s213>Artificial sequence</s213> <s220> <s223>Primer Bev-2</s223> </s220> </s200> <s400> 2
cccgggatcc tcgaaagaat cgtaccactt c                                    31
</s400> <s200> <s210>3</s210> <s211>29</s211> <s212>DNA</s212> <s213>Artificial sequence</s213> <s220> <s223>Primer Bev-3</s223> </s220> </s200> <s400> 3
gggcggatcc ttagaaagaa tcgtaccac                                       29
</s400> <s200> <s210>4</s210> <s211>28</s211> <s212>DNA</s212> <s213>Artificial sequence</s213> <s220> <s223>Primer Bev-4</s223> </s220> </s200> <s400> 4
cggcagatct ggacaaatcg agtacatc                                        28
</s400> <s200> <s210>5</s210> <s211>26</s211> <s212>DNA</s212> <s213>Artificial sequence</s213> <s220> <s223>Primer Bgl-GFP</s223> </s220> </s200> <s400> 5
agatctgtaa acggccacaa gttcag                                          26
</s400> <s200> <s210>6</s210> <s211>26</s211> <s212>DNA</s212> <s213>Artificial sequence</s213> <s220> <s223>Primer GFP-Bam</s223> </s220> </s200> <s400> 6
ggatccttgt acagctcgtc catgcc                                          26
</s400> <s200> <s210>7</s210> <s211>74</s211> <s212>DNA</s212> <s213>Artificial sequence</s213> <s220> <s223>Primer SV40-1</s223> </s220> </s200> <s400> 7
gtcgacaata aaatatcttt attttcatta catctgtgtg ttggtttttt gtgtgatttt     60
tgcaaaagcc tagg                                                       74
</s400> <s200> <s210>8</s210> <s211>31</s211> <s212>DNA</s212> <s213>Artificial sequence</s213> <s220> <s223>Primer SV40-2</s223> </s220> </s200> <s400> 8
gtcgacgttt agagcagaag taacacttcc g                                    31
</s400> <s200> <s210>9</s210> <s211>30</s211> <s212>DNA</s212> <s213>Artificial sequence</s213> <s220> <s223>Forward Primer Tyr 5′</s223> </s220> </s200> <s400> 9
cccggggctt agtgtaaaac aggctgagag                                      30
</s400> <s200> <s210>10</s210> <s211>31</s211> <s212>DNA</s212> <s213>Artificial sequence</s213> <s220> <s223>Reverse Primer Tyr 3′</s223> </s220> </s200> <s400> 10
cccgggcaaa tcccagtcat ttcttagaaa c                                    31
</s400> </sequence-list-new-rules> </sequence-cwu> </p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5034323">US5034323</a></td><td class="patent-data-table-td patent-date-value">Mar 30, 1989</td><td class="patent-data-table-td patent-date-value">Jul 23, 1991</td><td class="patent-data-table-td ">Dna Plant Technology Corporation</td><td class="patent-data-table-td ">Transformation of petunia cells with plasmids of Agrobacterium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5231020">US5231020</a></td><td class="patent-data-table-td patent-date-value">Mar 29, 1990</td><td class="patent-data-table-td patent-date-value">Jul 27, 1993</td><td class="patent-data-table-td ">Dna Plant Technology Corporation</td><td class="patent-data-table-td ">Genetic engineering of novel plant phenotypes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5283184">US5283184</a></td><td class="patent-data-table-td patent-date-value">Apr 17, 1991</td><td class="patent-data-table-td patent-date-value">Feb 1, 1994</td><td class="patent-data-table-td ">Dna Plant Technology Corporation</td><td class="patent-data-table-td ">Genetic engineering of novel plant phenotypes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5583021">US5583021</a></td><td class="patent-data-table-td patent-date-value">Jul 7, 1994</td><td class="patent-data-table-td patent-date-value">Dec 10, 1996</td><td class="patent-data-table-td ">The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University</td><td class="patent-data-table-td ">Genetic engineering</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5686649">US5686649</a></td><td class="patent-data-table-td patent-date-value">Jan 19, 1995</td><td class="patent-data-table-td patent-date-value">Nov 11, 1997</td><td class="patent-data-table-td ">The Rockefeller University</td><td class="patent-data-table-td ">Suppression of plant gene expression using processing-defective RNA constructs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5714323">US5714323</a></td><td class="patent-data-table-td patent-date-value">Mar 1, 1994</td><td class="patent-data-table-td patent-date-value">Feb 3, 1998</td><td class="patent-data-table-td ">The University Of Medecine And Dentistry Of New Jersey</td><td class="patent-data-table-td ">Over expression of single-stranded molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0242016A1?cl=en">EP0242016A1</a></td><td class="patent-data-table-td patent-date-value">Jan 19, 1987</td><td class="patent-data-table-td patent-date-value">Oct 21, 1987</td><td class="patent-data-table-td ">Agricultural Genetics Company Limited</td><td class="patent-data-table-td ">Modification of plant viruses or their effects</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0560156A2?cl=en">EP0560156A2</a></td><td class="patent-data-table-td patent-date-value">Mar 1, 1993</td><td class="patent-data-table-td patent-date-value">Sep 15, 1993</td><td class="patent-data-table-td ">Bayer Ag</td><td class="patent-data-table-td ">Pseudorabies virus polynucleotids and their use in the production of virus-resistant eucaryotic cells</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1990011682A1?cl=en">WO1990011682A1</a></td><td class="patent-data-table-td patent-date-value">Aug 18, 1989</td><td class="patent-data-table-td patent-date-value">Oct 18, 1990</td><td class="patent-data-table-td ">Dna Plant Techn Corp</td><td class="patent-data-table-td ">Genetic engineering of novel plant phenotypes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1993023551A1?cl=en">WO1993023551A1</a></td><td class="patent-data-table-td patent-date-value">May 13, 1993</td><td class="patent-data-table-td patent-date-value">Nov 25, 1993</td><td class="patent-data-table-td ">Zeneca Ltd</td><td class="patent-data-table-td ">Co-ordinated inhibition of plant gene expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1994017194A1?cl=en">WO1994017194A1</a></td><td class="patent-data-table-td patent-date-value">Jan 6, 1994</td><td class="patent-data-table-td patent-date-value">Aug 4, 1994</td><td class="patent-data-table-td ">Gregoria N Acedo</td><td class="patent-data-table-td ">Nematode-resistant transgenic plants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1995010607A1?cl=en">WO1995010607A1</a></td><td class="patent-data-table-td patent-date-value">Oct 14, 1994</td><td class="patent-data-table-td patent-date-value">Apr 20, 1995</td><td class="patent-data-table-td ">Anthony C Hunt</td><td class="patent-data-table-td ">Antisense oligonucleotide generators</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1996008558A1?cl=en">WO1996008558A1</a></td><td class="patent-data-table-td patent-date-value">Sep 12, 1994</td><td class="patent-data-table-td patent-date-value">Mar 21, 1996</td><td class="patent-data-table-td ">Hope City</td><td class="patent-data-table-td ">Modulation of drug radiation resistant genes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1997001952A1?cl=en">WO1997001952A1</a></td><td class="patent-data-table-td patent-date-value">Jun 28, 1996</td><td class="patent-data-table-td patent-date-value">Jan 23, 1997</td><td class="patent-data-table-td ">Dna Plant Techn Corp</td><td class="patent-data-table-td ">Delayed ripening tomato plants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1998036083A1?cl=en">WO1998036083A1</a></td><td class="patent-data-table-td patent-date-value">Feb 12, 1998</td><td class="patent-data-table-td patent-date-value">Aug 20, 1998</td><td class="patent-data-table-td ">Angell Susan Mary</td><td class="patent-data-table-td ">Methods and means for gene silencing in transgenic plants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1998037213A1?cl=en">WO1998037213A1</a></td><td class="patent-data-table-td patent-date-value">Feb 23, 1998</td><td class="patent-data-table-td patent-date-value">Aug 27, 1998</td><td class="patent-data-table-td ">Danisco</td><td class="patent-data-table-td ">Antisense intron inhibition of starch branching enzyme expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1998044138A1?cl=en">WO1998044138A1</a></td><td class="patent-data-table-td patent-date-value">Mar 27, 1998</td><td class="patent-data-table-td patent-date-value">Oct 8, 1998</td><td class="patent-data-table-td ">Cambridge Advanced Tech</td><td class="patent-data-table-td ">Improvements relating to the specificity of gene expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1999015682A2?cl=en">WO1999015682A2</a></td><td class="patent-data-table-td patent-date-value">Sep 22, 1998</td><td class="patent-data-table-td patent-date-value">Apr 1, 1999</td><td class="patent-data-table-td ">David Charles Baulcombe</td><td class="patent-data-table-td ">Gene silencing materials and methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1999025853A1?cl=en">WO1999025853A1</a></td><td class="patent-data-table-td patent-date-value">Nov 16, 1998</td><td class="patent-data-table-td patent-date-value">May 27, 1999</td><td class="patent-data-table-td ">Christopher L Baszczynski</td><td class="patent-data-table-td ">Targeted manipulation of herbicide-resistance genes in plants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1999032619A1?cl=en">WO1999032619A1</a></td><td class="patent-data-table-td patent-date-value">Dec 21, 1998</td><td class="patent-data-table-td patent-date-value">Jul 1, 1999</td><td class="patent-data-table-td ">Carnegie Inst Of Washington</td><td class="patent-data-table-td ">Genetic inhibition by double-stranded rna</td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Anderson WF, Nature 392:25-30, 1998.*</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Assaad, F.F., et al. (1993), Epigenetic Repeat-Induced Gene Silencing (RIGS) in Arabidopsis. Plant Molecular Biology 22(6): 1067-1085.</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Balandin, T., et al. (1997), "<a href='http://scholar.google.com/scholar?q="Silencing+of+a+beta-1-3-glucanase+Transgene+is+Overcome+During+Seed+Formation"'>Silencing of a beta-1-3-glucanase Transgene is Overcome During Seed Formation</a>", Plant Molecular Biology 34(1) 125-137.</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Balandin, T., et al. (1997), "<a href='http://scholar.google.com/scholar?q="Silencing+of+a+%CE%B2-1-3-glucanase+Transgene+is+Overcome+During+Seed+Formation"'>Silencing of a β-1-3-glucanase Transgene is Overcome During Seed Formation</a>", Plant Molecular Biology 34(1) 125-137.</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Baulcombe, D.C. (1996) RNA as a Target and an Initiator of Post-Transcriptional Gene Silencing in Transgenic Plants, Plant Molecular Biology 32(1-2): 79-88.</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bevec et al. (1994) "<a href='http://scholar.google.com/scholar?q="Constitutive+expression+of+chimeric+Neo-Rev+response+element+transcripts+suppresses+HIV-1+replication+in+human+CD4%2B+T+lymphocytes."'>Constitutive expression of chimeric Neo-Rev response element transcripts suppresses HIV-1 replication in human CD4+ T lymphocytes.</a>" Human Gene Therapy 5: 193-201.</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bingham, P.M. (1997) "<a href='http://scholar.google.com/scholar?q="Cosuppression+Comes+to+the+Animals"'>Cosuppression Comes to the Animals</a>". Cell 90(3): 385-387.</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Brigneti, Gianinna et al., "<a href='http://scholar.google.com/scholar?q="Viral+pathogenicity+determinants+are+suppressors+of+transgene+silencing+in+Nicotiana+benthamiana"'>Viral pathogenicity determinants are suppressors of transgene silencing in Nicotiana benthamiana</a>", The EMBO Journal, 17(22): 6739-6746 (1998).</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Cameron, F.H. and Jennings, P.A. (1991) "<a href='http://scholar.google.com/scholar?q="Inhibition+of+Gene+Expression+by+a+Short+Sense+Fragment"'>Inhibition of Gene Expression by a Short Sense Fragment</a>". Nucleic Acids Research 19(3): 469-475.</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Caplen, Natasha J. et al., "<a href='http://scholar.google.com/scholar?q="dsRNA-mediated+gene+silencing+in+cultured+Drosophila+cells%3A+a+tissue+culture+model+for+the+analysis+of+RNA+interference"'>dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA interference</a>", Gene, 252: 95-105 (2000).</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Chuah et al. (1994)"<a href='http://scholar.google.com/scholar?q="Inhibition+of+human+immunodeficiencyvirus+Type-1+by+retroviral+vectors+expressing+antisense-+TAR"'>Inhibition of human immunodeficiencyvirus Type-1 by retroviral vectors expressing antisense- TAR</a>". Human Gene Therapy 5: 1467-1475.</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Cogoni, C., et al. (1994), "<a href='http://scholar.google.com/scholar?q="Suppression+of+Gene+Expression+by+Homologous+Transgenes"'>Suppression of Gene Expression by Homologous Transgenes</a>", Antonie Van Leeuwenhoek 65(3): 205-209.</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Cogoni, C., et al. (1996), "<a href='http://scholar.google.com/scholar?q="Transgene+Silencing+of+the+al-1+Gene+in+Vegetative+Cells+of+Neurospora+is+Mediated+by+a+Cytoplasmic+Effector+and+Does+not+Depend+on+DNA-DNA+Interactions+or+DNA+Methylation"'>Transgene Silencing of the al-1 Gene in Vegetative Cells of Neurospora is Mediated by a Cytoplasmic Effector and Does not Depend on DNA-DNA Interactions or DNA Methylation</a>", The EMBO Journal 15(12): 3153-3163.</td></tr><tr><td class="patent-data-table-td ">14</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Cogoni, C., et al. (1997), "<a href='http://scholar.google.com/scholar?q="Isolations+of+Quelling-Defective+%28qde%29+Mutants+Impaired+in+Posttranscriptional+Transgene-Induced+Gene+Silencing+in+Neurospora+Crassa"'>Isolations of Quelling-Defective (qde) Mutants Impaired in Posttranscriptional Transgene-Induced Gene Silencing in Neurospora Crassa</a>". Proceeding of the National Academy of Sciences of the United States of America 94(19): 10233-10238.</td></tr><tr><td class="patent-data-table-td ">15</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Cogoni, Carlo et al., "<a href='http://scholar.google.com/scholar?q="Gene+silencing+in+Neurospora+crassa+requires+a+protein+homologous+to+RNA-dependent+RNA+polymerase"'>Gene silencing in Neurospora crassa requires a protein homologous to RNA-dependent RNA polymerase</a>", Nature, vol. 399: 166-169 (1999).</td></tr><tr><td class="patent-data-table-td ">16</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Cogoni, Carlo et al., "<a href='http://scholar.google.com/scholar?q="Posttranscriptional+Gene+Silencing+in+Neurospora+by+a+RecQ+DNA+Helicase"'>Posttranscriptional Gene Silencing in Neurospora by a RecQ DNA Helicase</a>", Science, 286: 2342-2344 (1999).</td></tr><tr><td class="patent-data-table-td ">17</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Courtney-Gutterson, et al. (1994), "<a href='http://scholar.google.com/scholar?q="Modification+of+Flower+Color+in+Florist%27s+Chrysanthemum%3A+Production+of+White-flowering+Variety+Through+Molecular+Genetics"'>Modification of Flower Color in Florist's Chrysanthemum: Production of White-flowering Variety Through Molecular Genetics</a>", Biotechnology 12(3): 268-271.</td></tr><tr><td class="patent-data-table-td ">18</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Dalmay, Tamas et al., "<a href='http://scholar.google.com/scholar?q="An+RNA-Dependent+RNA+Polymerase+Gene+in+Arabidopsis+Is+Required+for+Posttranscriptional+Gene+Silencing+Mediated+by+a+Transgene+but+Not+by+a+Virus"'>An RNA-Dependent RNA Polymerase Gene in Arabidopsis Is Required for Posttranscriptional Gene Silencing Mediated by a Transgene but Not by a Virus</a>", Cell, 101: 543-553 (2000).</td></tr><tr><td class="patent-data-table-td ">19</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">de Carvalho F., et al. (1992), "<a href='http://scholar.google.com/scholar?q="Suppression+of+beta-1%2C3-glucanase+Transgene+Expression+in+Homozygous+Plants"'>Suppression of beta-1,3-glucanase Transgene Expression in Homozygous Plants</a>", The EMBO Journal 11(7): 2595-2602.</td></tr><tr><td class="patent-data-table-td ">20</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">de Carvalho F., et al. (1992), "<a href='http://scholar.google.com/scholar?q="Suppression+of+%CE%B2-1%2C3-glucanase+Transgene+Expression+in+Homozygous+Plants"'>Suppression of β-1,3-glucanase Transgene Expression in Homozygous Plants</a>", The EMBO Journal 11(7): 2595-2602.</td></tr><tr><td class="patent-data-table-td ">21</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">de Carvalho Niebel, F. et al. (1995), "<a href='http://scholar.google.com/scholar?q="Post-transscriptional+Cosuppression+of+beta-1%2C3-glucanase+Genes+Does+Not+Effect+Acculmulation+of+Transgene+Nuclear+mRNA"'>Post-transscriptional Cosuppression of beta-1,3-glucanase Genes Does Not Effect Acculmulation of Transgene Nuclear mRNA</a>", The Plant Cell 7(3): 347-358.</td></tr><tr><td class="patent-data-table-td ">22</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">de Carvalho Niebel, F. et al. (1995), "<a href='http://scholar.google.com/scholar?q="Post-transscriptional+Cosuppression+of+%CE%B2-1%2C3-glucanase+Genes+Does+Not+Effect+Acculmulation+of+Transgene+Nuclear+mRNA"'>Post-transscriptional Cosuppression of β-1,3-glucanase Genes Does Not Effect Acculmulation of Transgene Nuclear mRNA</a>", The Plant Cell 7(3): 347-358.</td></tr><tr><td class="patent-data-table-td ">23</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">De Lange, P., et al., (1995), "<a href='http://scholar.google.com/scholar?q="Suppression+of+Flavonoid+Flower+Pigmentation+Genes+in+Petunia+Hybrida+by+the+Introduction+of+Antisense+and+Sense+Genes"'>Suppression of Flavonoid Flower Pigmentation Genes in Petunia Hybrida by the Introduction of Antisense and Sense Genes</a>", Current Topics in Microbiology and Immunology 197: 57-75.</td></tr><tr><td class="patent-data-table-td ">24</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Depicker, A., et al. (1997), "<a href='http://scholar.google.com/scholar?q="Post-transcriptional+Gene+Silencing+in+Plants"'>Post-transcriptional Gene Silencing in Plants</a>", Current Opinion in Cell Biology 9(3): 373-382.</td></tr><tr><td class="patent-data-table-td ">25</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ding, Shou Wei, "<a href='http://scholar.google.com/scholar?q="RNA+silencing"'>RNA silencing</a>", Current Opinion in Biotechnology, 11: 152-156 (2000).</td></tr><tr><td class="patent-data-table-td ">26</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Domeier, Mary Ellen et al., "<a href='http://scholar.google.com/scholar?q="A+Link+Between+RNA+Interference+and+Nonsense-Mediated+Decay+in+Caenorhabditis+elegans"'>A Link Between RNA Interference and Nonsense-Mediated Decay in Caenorhabditis elegans</a>", Science, 289: 1928-1930 (2000).</td></tr><tr><td class="patent-data-table-td ">27</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Dorer et al. (1994) "<a href='http://scholar.google.com/scholar?q="Expansion+of+transgene+repeats+cause+heterochromatin+formation+and+gene+silencing+in+Drosophilia"'>Expansion of transgene repeats cause heterochromatin formation and gene silencing in Drosophilia</a>". Cell 77: 993-1002.</td></tr><tr><td class="patent-data-table-td ">28</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Dorer, D.R. and Henikoff, S. (1997) Transgene Repear Arrays Interact withDistant Heterochromatin and Cause Silencing in cis and trans. Genetics 147(3).</td></tr><tr><td class="patent-data-table-td ">29</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Engdahl, H.M., et al. (1997), "<a href='http://scholar.google.com/scholar?q="A+Two+Unit+Antisense+RNA+Cassette+Test+System+for+Silencing+of+Target+Genes"'>A Two Unit Antisense RNA Cassette Test System for Silencing of Target Genes</a>", Nucleic Acids Research 25(16): 3218-3227.</td></tr><tr><td class="patent-data-table-td ">30</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">English, J.J., et al. (1996), "<a href='http://scholar.google.com/scholar?q="Suppression+of+Virus+Accumulation+in+Transgenic+Plants+Exhibiting+Silencing+of+Nuclear+Genes"'>Suppression of Virus Accumulation in Transgenic Plants Exhibiting Silencing of Nuclear Genes</a>", The Plant Cell 8(2): 179-188.</td></tr><tr><td class="patent-data-table-td ">31</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Fire, A., Xu, S.Q., Montgomery, M.K. Kostas, S.A. Driver, S.E. and Mello, C.C. (1998), "<a href='http://scholar.google.com/scholar?q="Potent+and+Specific+Genetic+Interference+by+Double-Standard+RNA+in+Caenorhabditis+elegans"'>Potent and Specific Genetic Interference by Double-Standard RNA in Caenorhabditis elegans</a>", Nature, 391 (6669): 806-811.</td></tr><tr><td class="patent-data-table-td ">32</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Fire, Andrew et al., "<a href='http://scholar.google.com/scholar?q="Potent+and+specific+genetic+interference+by+double-stranded+RNA+in+Caenorhabditis+elegans"'>Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans</a>", Nature, 391: 806-811 (1998).</td></tr><tr><td class="patent-data-table-td ">33</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Garrick, D., Fiering, S., Martin, D.I. and Whitelaw, E. (1998), "<a href='http://scholar.google.com/scholar?q="Repeat-Induced+Gene+Silencing+in+Mammals"'>Repeat-Induced Gene Silencing in Mammals</a>", Nature Genetics 18(1): 56-59.</td></tr><tr><td class="patent-data-table-td ">34</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Gervaix et al. (1997) "<a href='http://scholar.google.com/scholar?q="Multigene+antiviral+vectors+inhibit+diverse+human+immunodeficiency+virus+type+1+clades"'>Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades</a>". Journal of Virology 71(4): 3048-3053.</td></tr><tr><td class="patent-data-table-td ">35</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Gura, Trisha, "<a href='http://scholar.google.com/scholar?q="A+silence+that+speaks+volumes"'>A silence that speaks volumes</a>", Nature, 404: 804-808 (2000).</td></tr><tr><td class="patent-data-table-td ">36</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hamilton, A.J., et al. (1998), "<a href='http://scholar.google.com/scholar?q="A+Transgene+with+Repeated+DNA+Causes+High+Frequency%2C+Post-Transcriptional+Suppression+of+ACC-Oxidase+Gene+Expression+in+Tomato"'>A Transgene with Repeated DNA Causes High Frequency, Post-Transcriptional Suppression of ACC-Oxidase Gene Expression in Tomato</a>", The Plant Journal 15(6): 737-746.</td></tr><tr><td class="patent-data-table-td ">37</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hamilton, Andrew J. et al., "<a href='http://scholar.google.com/scholar?q="A+Species+of+Small+Antisense+RNA+in+Posttranscriptional+Gene+Silencing+in+Plants"'>A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants</a>", Science, 286: 950-952 (1999).</td></tr><tr><td class="patent-data-table-td ">38</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hammond, Scott M. et al., "<a href='http://scholar.google.com/scholar?q="An+RNA-directed+nuclease+mediates+post-transcriptional+gene+silencing+in+Drosophila+cells"'>An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells</a>", Nature, 404: 293-296 (2000).</td></tr><tr><td class="patent-data-table-td ">39</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Jorgensen, R. (1990), "<a href='http://scholar.google.com/scholar?q="Altered+Gene+Expression+in+Plants+Due+to+Trans+Interactions+Between+Homologous+Genes"'>Altered Gene Expression in Plants Due to Trans Interactions Between Homologous Genes</a>", Trends in Biotechnology 8(12): 340-344.</td></tr><tr><td class="patent-data-table-td ">40</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Jorgensen, R.A., et al. (1996), "<a href='http://scholar.google.com/scholar?q="Chalcone+Synthase+Cosuppression+Phenotypes+in+Petunia+Flowers%3A+Comparison+of+Sense+vs.+Antisense+Constructs+and+Single-Copy+vs.+Complex+T-DNA+Sequences"'>Chalcone Synthase Cosuppression Phenotypes in Petunia Flowers: Comparison of Sense vs. Antisense Constructs and Single-Copy vs. Complex T-DNA Sequences</a>", Plant Molecular Biology 31(5): 957-973.</td></tr><tr><td class="patent-data-table-td ">41</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Kappel et al. Current Opinion in Biotechnology 3:548-553 1992.*</td></tr><tr><td class="patent-data-table-td ">42</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Katsuki, M., et al. (1988), "<a href='http://scholar.google.com/scholar?q="Conversion+of+Normal+Behavior+to+Shiverer+by+Myelin+Basic+Protein+Antisense+cDNA+in+Transgenic+Mice"'>Conversion of Normal Behavior to Shiverer by Myelin Basic Protein Antisense cDNA in Transgenic Mice</a>", Science 241(4865): 593-595.</td></tr><tr><td class="patent-data-table-td ">43</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Katsuki, Motoya et al., "<a href='http://scholar.google.com/scholar?q="Conversion+of+Normal+Behavior+to+Shiverer+by+Myelin+Basic+Protein+Antisense+cDNA+in+Transgenic+Mice"'>Conversion of Normal Behavior to Shiverer by Myelin Basic Protein Antisense cDNA in Transgenic Mice</a>", Science, 241: 593-595 (1988).</td></tr><tr><td class="patent-data-table-td ">44</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Knoester, M., et al. (1997), "<a href='http://scholar.google.com/scholar?q="Modulation+of+Stress-Inducible+Ethylene+Biosynthesis+by+Sense+and+Antisense+Gene+Expression+in+Tobacco"'>Modulation of Stress-Inducible Ethylene Biosynthesis by Sense and Antisense Gene Expression in Tobacco</a>", Plant Science 126(2): 173-183.</td></tr><tr><td class="patent-data-table-td ">45</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kook, Y.H., et al. (1994), "<a href='http://scholar.google.com/scholar?q="The+Effect+of+Antisense+Inhibition+of+Urokinase+Receptor+in+Human+Squamous+Cell+Carcinoma+on+Malignancy"'>The Effect of Antisense Inhibition of Urokinase Receptor in Human Squamous Cell Carcinoma on Malignancy</a>", The EMBO Journal 13(17): 3983-3991.</td></tr><tr><td class="patent-data-table-td ">46</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kook, Yoon Hoh et al., "<a href='http://scholar.google.com/scholar?q="The+effect+of+antisense+inhibition+of+urokinase+receptor+in+human+squamous+cell+carcinoma+on+malignancy"'>The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy</a>", The EMBO Journal, 13(17): 3983-3991 (1994).</td></tr><tr><td class="patent-data-table-td ">47</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kunz, C., et al. (1996), "<a href='http://scholar.google.com/scholar?q="Developmentally+Regulated+Silencing+and+Reactivaation+of+Tobacco+Chitinase+Transgene+Expression"'>Developmentally Regulated Silencing and Reactivaation of Tobacco Chitinase Transgene Expression</a>", The Plant Journal 10(3): 437-450.</td></tr><tr><td class="patent-data-table-td ">48</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lee et al. (1994)"<a href='http://scholar.google.com/scholar?q="Inhibition+of+human+immunodeficiency+virus+type+1+human+T+cells+by+a+potent+Rev+response+element+decoy+consisting+of+13-nucleotide+minimal+Rev-binding+domain"'>Inhibition of human immunodeficiency virus type 1 human T cells by a potent Rev response element decoy consisting of 13-nucleotide minimal Rev-binding domain</a>". Journal of Virology 68(12): 8254-8264.</td></tr><tr><td class="patent-data-table-td ">49</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lee, K.Y., et al., (1997), "<a href='http://scholar.google.com/scholar?q="Post-transcriptional+Gene+Silencing+of+ACC+Synthase+in+Tomato+Results+from+Cytoplasmic+RNA+Degradation"'>Post-transcriptional Gene Silencing of ACC Synthase in Tomato Results from Cytoplasmic RNA Degradation</a>", The Plant Journal 12(5): 1127-1137.</td></tr><tr><td class="patent-data-table-td ">50</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lee, R.C., et al. (1993), The C. elegans Heterochronic Gene lin-4 Encodes Small RNAs with Antisense Complementarity to lin-14. Cell 75: 843-854.</td></tr><tr><td class="patent-data-table-td ">51</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lindbo, J.A., et al., (1993), "<a href='http://scholar.google.com/scholar?q="Induction+of+a+Highly+Specific+Antiviral+State+in+transgenic+Plants-Implications+for+Regulatio+of+Gene+Expression+and+Virus+Resistance"'>Induction of a Highly Specific Antiviral State in transgenic Plants-Implications for Regulatio of Gene Expression and Virus Resistance</a>", The Plant Cell 5(12): 1749-1759.</td></tr><tr><td class="patent-data-table-td ">52</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lindbo, J.A., et al., (1993), "<a href='http://scholar.google.com/scholar?q="Induction+of+a+Highly+Specific+Antiviral+State+in+transgenic+Plants%E2%80%94Implications+for+Regulatio+of+Gene+Expression+and+Virus+Resistance"'>Induction of a Highly Specific Antiviral State in transgenic Plants—Implications for Regulatio of Gene Expression and Virus Resistance</a>", The Plant Cell 5(12): 1749-1759.</td></tr><tr><td class="patent-data-table-td ">53</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lindbo, John et al., "<a href='http://scholar.google.com/scholar?q="Induction+of+a+Highly+Specific+Antiviral+State+in+Transgenic+Plants%3A+Implications+for+Regulation+of+Gene+Expression+and+Virus+Resistance"'>Induction of a Highly Specific Antiviral State in Transgenic Plants: Implications for Regulation of Gene Expression and Virus Resistance</a>", The Plant Cell, 5: 1749-1759 (1993).</td></tr><tr><td class="patent-data-table-td ">54</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lisziewicz et al. (1993) "<a href='http://scholar.google.com/scholar?q="Inhibition+of+human+immunodeficiency+virus+type+1+replication+by+regulated+expression+of+a+polymeric+Tat+activation+response+RNA+decoy+as+a+strategy+for+gene+therapy+in+AIDS."'>Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS.</a>" Proceedings of the National Academy of Sciences of the United States of America 90: 8000-8004.</td></tr><tr><td class="patent-data-table-td ">55</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Marx, Jean, "<a href='http://scholar.google.com/scholar?q="Interfering+With+Gene+Expression"'>Interfering With Gene Expression</a>", Science, 288: 1370-1372 (2000).</td></tr><tr><td class="patent-data-table-td ">56</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Matzke, M.A., et al. (1998), "<a href='http://scholar.google.com/scholar?q="Epigenetic+Silencing+of+Plant+Transgenes+as+a+Consequence+of+Diverse+Cellular+Defence+Responses"'>Epigenetic Silencing of Plant Transgenes as a Consequence of Diverse Cellular Defence Responses</a>", Cellular and Molecular Life Sciences 54(1): 94-103.</td></tr><tr><td class="patent-data-table-td ">57</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Meyer, P. (1996), "<a href='http://scholar.google.com/scholar?q="Repeat-induced+Gene+Silencing-Common+Mechanisms+in+Plants+and+Fungi"'>Repeat-induced Gene Silencing-Common Mechanisms in Plants and Fungi</a>", Biological Chemistry Hoppe-Seyler 377(2): 87-95.</td></tr><tr><td class="patent-data-table-td ">58</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Meyer, P. (1996), "<a href='http://scholar.google.com/scholar?q="Repeat-induced+Gene+Silencing%E2%80%94Common+Mechanisms+in+Plants+and+Fungi"'>Repeat-induced Gene Silencing—Common Mechanisms in Plants and Fungi</a>", Biological Chemistry Hoppe-Seyler 377(2): 87-95.</td></tr><tr><td class="patent-data-table-td ">59</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Moroni, M.C., et al. (1992) EGF-R Antisense RNA Blocks Expression of the Epidermal Growth Factor Receptor and Suppresses the Transforming Phenotype of a Human Carcinoma Cell Line. Journal of Biological Chemistry 267(4): 2714-2722.</td></tr><tr><td class="patent-data-table-td ">60</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Moroni, Maria Cristina et al., "<a href='http://scholar.google.com/scholar?q="EGF-R+Antisense+RNA+Blocks+Expression+of+the+Epidermal+Growth+Factor+Receptor+and+Suppresses+the+Transforming+Phenotype+of+a+Human+Carcinoma+Cell+Line"'>EGF-R Antisense RNA Blocks Expression of the Epidermal Growth Factor Receptor and Suppresses the Transforming Phenotype of a Human Carcinoma Cell Line</a>", The Journal of Biological Chemistry, 267(5): 2714-2722 (1992).</td></tr><tr><td class="patent-data-table-td ">61</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Mueller, E., et al. (1995), "<a href='http://scholar.google.com/scholar?q="Homology-dependent+Resistance-Transgenic+Virus+Resistance+in+Plants+Related+to+Homology-Dependent+Gene+Silencing"'>Homology-dependent Resistance-Transgenic Virus Resistance in Plants Related to Homology-Dependent Gene Silencing</a>", The Plant Journal 7(6): 1001-1013.</td></tr><tr><td class="patent-data-table-td ">62</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Mueller, E., et al. (1995), "<a href='http://scholar.google.com/scholar?q="Homology-dependent+Resistance%E2%80%94Transgenic+Virus+Resistance+in+Plants+Related+to+Homology-Dependent+Gene+Silencing"'>Homology-dependent Resistance—Transgenic Virus Resistance in Plants Related to Homology-Dependent Gene Silencing</a>", The Plant Journal 7(6): 1001-1013.</td></tr><tr><td class="patent-data-table-td ">63</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Napoli, C., et al. (1990), Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible So-Suppression of Homologous Genes in trans, The Plant Cell 2(4): 279-289.</td></tr><tr><td class="patent-data-table-td ">64</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Napoli, Carolyn et al., "<a href='http://scholar.google.com/scholar?q="Introduction+of+a+Chimeric+Chalcone+Synthase+Gene+into+Petunia+Results+in+Reversible+Co-Suppression+of+Homologous+Genes+in+trans"'>Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans</a>", The Plant Cell, 2: 279-289 (1990).</td></tr><tr><td class="patent-data-table-td ">65</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Nellen, W. and Lichtenstein C. (1993), "<a href='http://scholar.google.com/scholar?q="What+Makes+a+Messenger+RNA+Anti-Sensitive%3F"'>What Makes a Messenger RNA Anti-Sensitive?</a>" Trends in Biochemical Sciences 18(11): 419-423.</td></tr><tr><td class="patent-data-table-td ">66</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Palauqui, J.C., et al. (1997), Systemic Acquired Silencing: Transgene-specific Post-transscriptional Silencing is Transmitted by Grafting from Silenced Stocks to Non-silenced scions, The EMBO Journal 16: 4738-4745.</td></tr><tr><td class="patent-data-table-td ">67</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Palauqui, Jean-Christophe et al., "<a href='http://scholar.google.com/scholar?q="Systemic+acquired+silencing%3A+transgene-specific+post-transcriptional+silencing+is+transmitted+by+grafting+from+silenced+stocks+to+non-silenced+scions"'>Systemic acquired silencing: transgene-specific post-transcriptional silencing is transmitted by grafting from silenced stocks to non-silenced scions</a>", The EMBO Journal, 16(15):-4745 (1997).</td></tr><tr><td class="patent-data-table-td ">68</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Palauqui, Jean-Christophe et al., "<a href='http://scholar.google.com/scholar?q="Transgenes+are+dispensable+for+the+RNA+degradation+step+of+cosuppression"'>Transgenes are dispensable for the RNA degradation step of cosuppression</a>", Plant Biology, 95: 9675-9680 (1998).</td></tr><tr><td class="patent-data-table-td ">69</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pal-Bhadra, M., Bhadra U. and Birchler, J.A. (1997) "<a href='http://scholar.google.com/scholar?q="Cosuppression+in+Drosophila%3A+Gene+Silencing+of+Alcohol+Dehydrogenase+by+White-Adh+Tarnsgenes+is+Polycomb+Dependent"'>Cosuppression in Drosophila: Gene Silencing of Alcohol Dehydrogenase by White-Adh Tarnsgenes is Polycomb Dependent</a>". Cell 90(3): 385-387.</td></tr><tr><td class="patent-data-table-td ">70</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pang, S.Z., et al. (1997), "<a href='http://scholar.google.com/scholar?q="Nontarget+DNA+Sequences+Reduce+the+Transgene+Length+Necessary+for+RNA-mediated+Tospovirus+Resistance+in+Transgenic+Plants"'>Nontarget DNA Sequences Reduce the Transgene Length Necessary for RNA-mediated Tospovirus Resistance in Transgenic Plants</a>", Proceedings of the National Academy of Sciences of the United States of America 94(15): 8261-8266.</td></tr><tr><td class="patent-data-table-td ">71</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Park, Y. et al., "<a href='http://scholar.google.com/scholar?q="Gene+silencing+mediated+by+promoter+homology+occurs+at+the+level+of+transcription+and+results+in+meiotically+heritable+alterations+in+methylation+and+gene+activity"'>Gene silencing mediated by promoter homology occurs at the level of transcription and results in meiotically heritable alterations in methylation and gene activity</a>", The Plant Journal, 9: 183-194 (1996).</td></tr><tr><td class="patent-data-table-td ">72</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Park, Y.D., et al. (1996), "<a href='http://scholar.google.com/scholar?q="Gene+Silencing+Mediated+by+Promotor+Homology+Occurs+at+the+Level+of+Transcription+and+Results+in+Meiotically+Heritable+Alterations+in+Methylation+and+Gene+Activity"'>Gene Silencing Mediated by Promotor Homology Occurs at the Level of Transcription and Results in Meiotically Heritable Alterations in Methylation and Gene Activity</a>", The Plant Journal 9(2): 183-194.</td></tr><tr><td class="patent-data-table-td ">73</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Que, Q., et al. (1998), "<a href='http://scholar.google.com/scholar?q="Homology-based+Control+of+Gene+Expression+Patterns+in+Transgenic+Petunia+Flowers"'>Homology-based Control of Gene Expression Patterns in Transgenic Petunia Flowers</a>", Developmental Genetics 22(1): 100-109.</td></tr><tr><td class="patent-data-table-td ">74</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Romano, N., et al. (1992), "<a href='http://scholar.google.com/scholar?q="Quelling%3A+Transient+Inactivation+of+Gene+Expression+in+Neurospora+Crassa+by+Transformation+with+Homologous+Sequences"'>Quelling: Transient Inactivation of Gene Expression in Neurospora Crassa by Transformation with Homologous Sequences</a>", Molecular Microbiology 6(22): 3343-3353.</td></tr><tr><td class="patent-data-table-td ">75</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sadiq, M., et al. (1994), "<a href='http://scholar.google.com/scholar?q="Developmental+Regulation+of+Antisense-mediated+Gene+Silencing+in+Dictyostelium"'>Developmental Regulation of Antisense-mediated Gene Silencing in Dictyostelium</a>", Antisense Research &amp; Development 4(4): 263-267.</td></tr><tr><td class="patent-data-table-td ">76</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sijen, T., et al. (1996), "<a href='http://scholar.google.com/scholar?q="RNA-mediated+Virus+Resistance-Role+of+Repeated+Transgenes+and+Delineation+of+Targeted+Regions"'>RNA-mediated Virus Resistance-Role of Repeated Transgenes and Delineation of Targeted Regions</a>", The Plant Cell 8(12): 2277-2294.</td></tr><tr><td class="patent-data-table-td ">77</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sijen, T., et al. (1996), "<a href='http://scholar.google.com/scholar?q="RNA-mediated+Virus+Resistance%E2%80%94Role+of+Repeated+Transgenes+and+Delineation+of+Targeted+Regions"'>RNA-mediated Virus Resistance—Role of Repeated Transgenes and Delineation of Targeted Regions</a>", The Plant Cell 8(12): 2277-2294.</td></tr><tr><td class="patent-data-table-td ">78</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Singer, M.J., et al. (1995), "<a href='http://scholar.google.com/scholar?q="Genetic+and+Epigenetic+Inactivation+of+Repetitive+Sequences+in+Neurospora+Crassa%3A+RIP%2C+DNA+Methylation%2C+and+Quelling"'>Genetic and Epigenetic Inactivation of Repetitive Sequences in Neurospora Crassa: RIP, DNA Methylation, and Quelling</a>", Current Topics in Microbiology and Immunology 197: 165-177.</td></tr><tr><td class="patent-data-table-td ">79</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Smardon, Anne et al., "<a href='http://scholar.google.com/scholar?q="EGO-1+is+related+to+RNA-directed+RNA+polymerase+an+functions+in+germ-line+development+and+RNA+interference+in+C.+elegans"'>EGO-1 is related to RNA-directed RNA polymerase an functions in germ-line development and RNA interference in C. elegans</a>", Current Biology, 10(4): 169-178 (2000).</td></tr><tr><td class="patent-data-table-td ">80</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Smith, Neil et al., "<a href='http://scholar.google.com/scholar?q="Total+Silencing+by+introspliced+hairpin+RNAs"'>Total Silencing by introspliced hairpin RNAs</a>", Nature, 407: 319-320 (2000).</td></tr><tr><td class="patent-data-table-td ">81</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Smyth, D.R. (1997), "<a href='http://scholar.google.com/scholar?q="Gene+Silencing%3A+Cosuppression+at+a+Distance"'>Gene Silencing: Cosuppression at a Distance</a>", Current Biology 7(12): R793-795.</td></tr><tr><td class="patent-data-table-td ">82</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Stam, M., et al. (1997), "<a href='http://scholar.google.com/scholar?q="The+Silence+of+Genes+in+Transgenic+Plants"'>The Silence of Genes in Transgenic Plants</a>", Annals of Botany 79(1): 3-12.</td></tr><tr><td class="patent-data-table-td ">83</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sullenger et al. (1990) "<a href='http://scholar.google.com/scholar?q="Overexpression+of+TAR+sequences+rendered+cells+resistant+to+human+immundeficiency+virus+replication"'>Overexpression of TAR sequences rendered cells resistant to human immundeficiency virus replication</a>". Cell 63: 8254-8264.</td></tr><tr><td class="patent-data-table-td ">84</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sullenger et al. (1991 "<a href='http://scholar.google.com/scholar?q="Analysis+of+trans-acting+response+decoy+RNA-mediated+inhibition+of+human+immunodeficiency+virus+type+1+transactivation"'>Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation</a>". Journal of Virology 65(12): 6811-6816.</td></tr><tr><td class="patent-data-table-td ">85</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sun et al. (1995) "<a href='http://scholar.google.com/scholar?q="Resistance+to+human+immunodeficiency+virus+type+1+infection+conferred+by+trnasduction+of+human+peripheral+blood+lymphocytes+with+ribozyme%2C+antisense%2C+or+polymeric+transactivation+response+element+constructs"'>Resistance to human immunodeficiency virus type 1 infection conferred by trnasduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric transactivation response element constructs</a>". Proceedings of the National Academy of Sciences of the United States of America 92: 7272-7276.</td></tr><tr><td class="patent-data-table-td ">86</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Tabara, Hiroaki et al., "<a href='http://scholar.google.com/scholar?q="The+rde-1+Gene%2C+RNA+Interference%2C+and+Transposon+Silencing+in+C.+elegans"'>The rde-1 Gene, RNA Interference, and Transposon Silencing in C. elegans</a>", Cell, 99: 123-132 (1999).</td></tr><tr><td class="patent-data-table-td ">87</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Tanzer, M.M., et al. (1997), "<a href='http://scholar.google.com/scholar?q="Characterization+of+Post-Transcriptionally+Suppressed+Transgene+Expression+that+Confers+Resistance+to+Tobacco+Etch+Virus+Infection+in+Tobacco"'>Characterization of Post-Transcriptionally Suppressed Transgene Expression that Confers Resistance to Tobacco Etch Virus Infection in Tobacco</a>", The Plant Cell 9(8): 1411-1423.</td></tr><tr><td class="patent-data-table-td ">88</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Touchette, Nat. Med. 2(1) 7-8, 1996.*</td></tr><tr><td class="patent-data-table-td ">89</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Tuschl, Thomas et al., "<a href='http://scholar.google.com/scholar?q="Targeted+mRNA+degradation+by+double-stranded+RNA+in+vitro"'>Targeted mRNA degradation by double-stranded RNA in vitro</a>", Genes &amp; Development, 13: 3191-3197 (1999).</td></tr><tr><td class="patent-data-table-td ">90</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Vacheret, H. Nussaume, et al. (1997), "<a href='http://scholar.google.com/scholar?q="A+Transciptionally+Active+State+is+Required+for+Post-Transcriptional+Silencing+%28Cosuppresion%29+of+Nitrate+Reductase+Host+Genes+and+Transgenes"'>A Transciptionally Active State is Required for Post-Transcriptional Silencing (Cosuppresion) of Nitrate Reductase Host Genes and Transgenes</a>", The Plant Cell 9(8): 1495-1504.</td></tr><tr><td class="patent-data-table-td ">91</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Van der Krol, et al. (1990), "<a href='http://scholar.google.com/scholar?q="Flavonoid+Genes+in+Petunia%3A+Addition+of+a+Limited+Number+of+Gene+Copies+May+Lead+to+a+Suppression+of+Gene+Expression"'>Flavonoid Genes in Petunia: Addition of a Limited Number of Gene Copies May Lead to a Suppression of Gene Expression</a>", The Plant Cell 2(4): 291-299.</td></tr><tr><td class="patent-data-table-td ">92</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Van der Krol, et al. (1990), "<a href='http://scholar.google.com/scholar?q="Inhibition+of+Flower+Pigmentation+by+Antisense+CHS+Genes%3A+Promoter+and+Minimal+Sequence+Requirements+for+the+Antisense+Effect"'>Inhibition of Flower Pigmentation by Antisense CHS Genes: Promoter and Minimal Sequence Requirements for the Antisense Effect</a>", Plant Molecular Biology 14(4): 457-466.</td></tr><tr><td class="patent-data-table-td ">93</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Verma et al Nature 389:239-242, 1997.*</td></tr><tr><td class="patent-data-table-td ">94</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Viville, in Transgenic Animals, Houdebine (eds), Harwood academic publishers, France. pp307-321, 1997.*</td></tr><tr><td class="patent-data-table-td ">95</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Voinnet, Olivier et al., "<a href='http://scholar.google.com/scholar?q="Systemic+Spread+of+Sequence-Specific+Transgene+RNA+Degradation+in+Plants+Is+Initiated+by+Localized+Introduction+of+Ectopic+Promoterless+DNA"'>Systemic Spread of Sequence-Specific Transgene RNA Degradation in Plants Is Initiated by Localized Introduction of Ectopic Promoterless DNA</a>", Cell, 95: 177-187 (1998).</td></tr><tr><td class="patent-data-table-td ">96</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Wall RJ Theriogenology 45:57-68, 1996.*</td></tr><tr><td class="patent-data-table-td ">97</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Wang et al PNAS 94:11563-11566, 1997.*</td></tr><tr><td class="patent-data-table-td ">98</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Wassenegger, Michael et al., "<a href='http://scholar.google.com/scholar?q="Signalling+in+gene+silencing"'>Signalling in gene silencing</a>", Elsevier Science, 4(6): 207-209 (1999).</td></tr><tr><td class="patent-data-table-td ">99</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Waterhouse, Peter et al., "<a href='http://scholar.google.com/scholar?q="Virus+resistance+and+gene+silencing+in+plants+can+be+induced+by+simultaneous+expression+of+sense+and+antisense+RNA"'>Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA</a>", Plant Biology, 95: 13959-13964 (1998).</td></tr><tr><td class="patent-data-table-td ">100</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Wianny, Florence et al., "<a href='http://scholar.google.com/scholar?q="Specific+interference+with+gene+function+by+double-stranded+RNA+in+early+mouse+development"'>Specific interference with gene function by double-stranded RNA in early mouse development</a>", Nature Cell Biology, 2: 70-75 (2000).</td></tr><tr><td class="patent-data-table-td ">101</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Zamore, Phillip D. et al., "<a href='http://scholar.google.com/scholar?q="RNAi%3A+Double-Stranded+RNA+Directs+the+ATP-Dependent+Cleavage+of+mRNA+at+21+to+23+Nucleotide+Intervals"'>RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals</a>", Cell, 101: 25-33 (2000).</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7217807">US7217807</a></td><td class="patent-data-table-td patent-date-value">Aug 28, 2003</td><td class="patent-data-table-td patent-date-value">May 15, 2007</td><td class="patent-data-table-td ">Rosetta Genomics Ltd</td><td class="patent-data-table-td ">Human immunodeficiency viral nucleotide sequences for use as gene therapeutic tools in prevention of viral infection; gene expression inhibition</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7256329">US7256329</a></td><td class="patent-data-table-td patent-date-value">Jun 27, 2003</td><td class="patent-data-table-td patent-date-value">Aug 14, 2007</td><td class="patent-data-table-td ">Calgene Llc</td><td class="patent-data-table-td ">Comprises nucleotide sequences coding desaturase for insertion of a double bond into a fatty acyl moiety at the twelfth or fifteenth carbon position in fatty acyl chain; improving vegetable oils</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7312376">US7312376</a></td><td class="patent-data-table-td patent-date-value">Feb 22, 2006</td><td class="patent-data-table-td patent-date-value">Dec 25, 2007</td><td class="patent-data-table-td ">Ceres, Inc.</td><td class="patent-data-table-td ">Isolated polynucleotide for regulating expression of a heterologous nucleic acid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7335760">US7335760</a></td><td class="patent-data-table-td patent-date-value">Mar 31, 2006</td><td class="patent-data-table-td patent-date-value">Feb 26, 2008</td><td class="patent-data-table-td ">Ceres, Inc.</td><td class="patent-data-table-td ">encodes a zinc finger, C3HC4 type polypeptide; for making transgenic plants or organisms</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7358068">US7358068</a></td><td class="patent-data-table-td patent-date-value">Sep 12, 2003</td><td class="patent-data-table-td patent-date-value">Apr 15, 2008</td><td class="patent-data-table-td ">Replicor, Inc.</td><td class="patent-data-table-td ">For use as therapeutic agents in viral infections by human and animal viruses and in cancers caused by oncogene viruses; non-sequence complementary mode of action; drug screening</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7429692">US7429692</a></td><td class="patent-data-table-td patent-date-value">Nov 15, 2005</td><td class="patent-data-table-td patent-date-value">Sep 30, 2008</td><td class="patent-data-table-td ">Ceres, Inc.</td><td class="patent-data-table-td ">Using vector comprising nucleotide sequences coding methyltransferase to generate plants with larger seed size; tissue engineering;</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7479555">US7479555</a></td><td class="patent-data-table-td patent-date-value">Jul 13, 2005</td><td class="patent-data-table-td patent-date-value">Jan 20, 2009</td><td class="patent-data-table-td ">Ceres, Inc.</td><td class="patent-data-table-td ">Polynucleotides having a nucleotide sequence that encodes a polypeptide having MOV34 family activity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7485715">US7485715</a></td><td class="patent-data-table-td patent-date-value">Jul 13, 2005</td><td class="patent-data-table-td patent-date-value">Feb 3, 2009</td><td class="patent-data-table-td ">Ceres, Inc.</td><td class="patent-data-table-td ">Polynucleotides, such as cDNA sequences and/or genomic fragments, hereinafter collectively referred to as &quot;Sequence-Determined DNA Fragments&quot; (SDFs), from Arabidopsis thaliana and polypeptides derived therefrom; gene expression and mapping in plants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7517864">US7517864</a></td><td class="patent-data-table-td patent-date-value">Dec 9, 2005</td><td class="patent-data-table-td patent-date-value">Apr 14, 2009</td><td class="patent-data-table-td ">Sirna Therapeutics, Inc.</td><td class="patent-data-table-td ">Study and interfererance, diagnosis and treatment of polyglutamine using short interfering nucleic acid for treatment of dementia or siezures or muscular dystrophy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7524653">US7524653</a></td><td class="patent-data-table-td patent-date-value">May 10, 2004</td><td class="patent-data-table-td patent-date-value">Apr 28, 2009</td><td class="patent-data-table-td ">University Of Pittsburgh - Of The Commonwealth System Of Higher Education</td><td class="patent-data-table-td ">Small interfering RNA libraries and methods of synthesis and use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7538095">US7538095</a></td><td class="patent-data-table-td patent-date-value">Oct 30, 2002</td><td class="patent-data-table-td patent-date-value">May 26, 2009</td><td class="patent-data-table-td ">The Carnegie Institution Of Washington</td><td class="patent-data-table-td ">Genetic inhibition by double-stranded RNA</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7553822">US7553822</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 30, 2003</td><td class="patent-data-table-td patent-date-value">Jun 30, 2009</td><td class="patent-data-table-td ">The United States Of America As Represented By The Department Of Health And Human Services</td><td class="patent-data-table-td ">Compositions and methods for inhibiting translation of a Mect1-MAML2 chimeric gene</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7560438">US7560438</a></td><td class="patent-data-table-td patent-date-value">Oct 30, 2002</td><td class="patent-data-table-td patent-date-value">Jul 14, 2009</td><td class="patent-data-table-td ">The Carnegie Institution Of Washington</td><td class="patent-data-table-td ">Genetic inhibition by double-stranded RNA</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7601888">US7601888</a></td><td class="patent-data-table-td patent-date-value">Mar 21, 2003</td><td class="patent-data-table-td patent-date-value">Oct 13, 2009</td><td class="patent-data-table-td ">Monsanto Technology L.L.C.</td><td class="patent-data-table-td ">Nucleic acid constructs and methods for producing altered seed oil compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7618814">US7618814</a></td><td class="patent-data-table-td patent-date-value">Nov 16, 2003</td><td class="patent-data-table-td patent-date-value">Nov 17, 2009</td><td class="patent-data-table-td ">Rosetta Genomics Ltd.</td><td class="patent-data-table-td ">Microrna-related nucleic acids and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7622633">US7622633</a></td><td class="patent-data-table-td patent-date-value">Oct 30, 2002</td><td class="patent-data-table-td patent-date-value">Nov 24, 2009</td><td class="patent-data-table-td ">Carnegie Institution Of Washington</td><td class="patent-data-table-td ">Introducing ribonucleic acid (RNA) into cell in an amount sufficient to inhibit expression of target gene, wherein RNA comprises a double-stranded structure with an identical nucleotide sequence as compared to portion of target gene</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7655785">US7655785</a></td><td class="patent-data-table-td patent-date-value">Apr 2, 2004</td><td class="patent-data-table-td patent-date-value">Feb 2, 2010</td><td class="patent-data-table-td ">Rosetta Genomics Ltd.</td><td class="patent-data-table-td ">Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7687616">US7687616</a></td><td class="patent-data-table-td patent-date-value">May 14, 2004</td><td class="patent-data-table-td patent-date-value">Mar 30, 2010</td><td class="patent-data-table-td ">Rosetta Genomics Ltd</td><td class="patent-data-table-td ">for therapy that allows inter alia up-regulation of a disease-related target gene of novel GAM oligonucleotides of the present invention, by countering the activity of a GAM oligonucleotides which naturally inhibits expression of that target gene</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7691995">US7691995</a></td><td class="patent-data-table-td patent-date-value">Jul 12, 2002</td><td class="patent-data-table-td patent-date-value">Apr 6, 2010</td><td class="patent-data-table-td ">University Of Massachusetts</td><td class="patent-data-table-td ">Engineered RNA precursors encoded in plasmids and/or other vectors; simple, low cost technique utilizing DNA molecule production; host cells, transgenes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7704688">US7704688</a></td><td class="patent-data-table-td patent-date-value">Mar 22, 2004</td><td class="patent-data-table-td patent-date-value">Apr 27, 2010</td><td class="patent-data-table-td ">Plant Bioscience Limited</td><td class="patent-data-table-td ">Using RNA interference to prevent and treat viral diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7709616">US7709616</a></td><td class="patent-data-table-td patent-date-value">May 16, 2005</td><td class="patent-data-table-td patent-date-value">May 4, 2010</td><td class="patent-data-table-td ">Rosetta Genomics Inc.</td><td class="patent-data-table-td ">Micrornas and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7732417">US7732417</a></td><td class="patent-data-table-td patent-date-value">May 16, 2001</td><td class="patent-data-table-td patent-date-value">Jun 8, 2010</td><td class="patent-data-table-td ">Cold Spring Harbor Laboratory</td><td class="patent-data-table-td ">Methods and compositions for RNA interference using recombinant Dicer and Argonaut</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7732421">US7732421</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 17, 2007</td><td class="patent-data-table-td patent-date-value">Jun 8, 2010</td><td class="patent-data-table-td ">Alcon Research, Ltd.</td><td class="patent-data-table-td ">RNAI-mediated inhibition of tumor necrosis factor α-related conditions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7754697">US7754697</a></td><td class="patent-data-table-td patent-date-value">Aug 22, 2003</td><td class="patent-data-table-td patent-date-value">Jul 13, 2010</td><td class="patent-data-table-td ">Commonwealth Scientific And Industrial Research Organisation</td><td class="patent-data-table-td ">Control of gene expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7759546">US7759546</a></td><td class="patent-data-table-td patent-date-value">Jan 30, 2002</td><td class="patent-data-table-td patent-date-value">Jul 20, 2010</td><td class="patent-data-table-td ">University Of Bath</td><td class="patent-data-table-td ">Methods for modifying plant endosperm</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7777022">US7777022</a></td><td class="patent-data-table-td patent-date-value">May 26, 2004</td><td class="patent-data-table-td patent-date-value">Aug 17, 2010</td><td class="patent-data-table-td ">Rosetta Genomics, Ltd.</td><td class="patent-data-table-td ">Bioinformatically detectable group of novel regulatory viral and viral associated oligonucleotides and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7795233">US7795233</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 15, 2005</td><td class="patent-data-table-td patent-date-value">Sep 14, 2010</td><td class="patent-data-table-td ">Miyagi Ken</td><td class="patent-data-table-td ">double-stranded RNA which is 20 to 30 nucleotides in length; inhibits the expression of a gene encoding human plasma membrane-associated sialidase (NEU3)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7795419">US7795419</a></td><td class="patent-data-table-td patent-date-value">Aug 28, 2006</td><td class="patent-data-table-td patent-date-value">Sep 14, 2010</td><td class="patent-data-table-td ">Rosetta Genomics Ltd.</td><td class="patent-data-table-td ">human microRNA molecules associated with viral infections; used to identify modulators of viral infections</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7795503">US7795503</a></td><td class="patent-data-table-td patent-date-value">Feb 22, 2006</td><td class="patent-data-table-td patent-date-value">Sep 14, 2010</td><td class="patent-data-table-td ">Ceres, Inc.</td><td class="patent-data-table-td ">plant cell containing a regulatory protein that can modulate expression of one or more genes involved in alkaloid biosynthesis in plants; papaverine, narcotine, noscapine, narceine, hydrastine, oripavine</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7795504">US7795504</a></td><td class="patent-data-table-td patent-date-value">Dec 5, 2006</td><td class="patent-data-table-td patent-date-value">Sep 14, 2010</td><td class="patent-data-table-td ">Monsanto Technology Llc</td><td class="patent-data-table-td ">Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7803611">US7803611</a></td><td class="patent-data-table-td patent-date-value">Feb 3, 2006</td><td class="patent-data-table-td patent-date-value">Sep 28, 2010</td><td class="patent-data-table-td ">Benitec, Inc.</td><td class="patent-data-table-td ">RNAi expression constructs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7820632">US7820632</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 13, 2003</td><td class="patent-data-table-td patent-date-value">Oct 26, 2010</td><td class="patent-data-table-td ">City Of Hope</td><td class="patent-data-table-td ">For inhibiting expression of human immunodeficiency virus (HIV); for use in vitro/vivo</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7858625">US7858625</a></td><td class="patent-data-table-td patent-date-value">Jun 24, 2005</td><td class="patent-data-table-td patent-date-value">Dec 28, 2010</td><td class="patent-data-table-td ">Sirna Therapeutics, Inc.</td><td class="patent-data-table-td ">Conjugates and compositions for cellular delivery</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7858769">US7858769</a></td><td class="patent-data-table-td patent-date-value">Feb 9, 2005</td><td class="patent-data-table-td patent-date-value">Dec 28, 2010</td><td class="patent-data-table-td ">Sirna Therapeutics, Inc.</td><td class="patent-data-table-td ">RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional siNA)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7884264">US7884264</a></td><td class="patent-data-table-td patent-date-value">Jan 17, 2007</td><td class="patent-data-table-td patent-date-value">Feb 8, 2011</td><td class="patent-data-table-td ">Biolex Therapeutics, Inc.</td><td class="patent-data-table-td ">Transgenic plant which serves as bioreactor for expression of humanized glycoproteins with reduced fucose and xylose residues</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7888010">US7888010</a></td><td class="patent-data-table-td patent-date-value">May 31, 2005</td><td class="patent-data-table-td patent-date-value">Feb 15, 2011</td><td class="patent-data-table-td ">Asuragen, Inc.</td><td class="patent-data-table-td ">for isolating, enriching, and/or labeling miRNA molecules and for preparing and using arrays or other detection techniques for miRNA analysis; biomarker for lung cancer; analyzing mir-205 expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7888325">US7888325</a></td><td class="patent-data-table-td patent-date-value">Dec 12, 2006</td><td class="patent-data-table-td patent-date-value">Feb 15, 2011</td><td class="patent-data-table-td ">Medical College Of Georgia Research Institute, Inc.</td><td class="patent-data-table-td ">Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7888497">US7888497</a></td><td class="patent-data-table-td patent-date-value">May 14, 2004</td><td class="patent-data-table-td patent-date-value">Feb 15, 2011</td><td class="patent-data-table-td ">Rosetta Genomics Ltd.</td><td class="patent-data-table-td ">Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7893035">US7893035</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 15, 2007</td><td class="patent-data-table-td patent-date-value">Feb 22, 2011</td><td class="patent-data-table-td ">The Board Of Trustees Of The University Of Illinois</td><td class="patent-data-table-td ">Multicistronic constructs with siRNA to inhibit tumors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7893036">US7893036</a></td><td class="patent-data-table-td patent-date-value">Mar 26, 2008</td><td class="patent-data-table-td patent-date-value">Feb 22, 2011</td><td class="patent-data-table-td ">University Of Massachusetts</td><td class="patent-data-table-td ">In vivo production of small interfering RNAs that mediate gene silencing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7906326">US7906326</a></td><td class="patent-data-table-td patent-date-value">Feb 16, 2004</td><td class="patent-data-table-td patent-date-value">Mar 15, 2011</td><td class="patent-data-table-td ">Rosetta Genomics Ltd.</td><td class="patent-data-table-td ">Bioinformatically detectable group of novel regulatory oligonucleotides associated with alzheimer&#39;s disease and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7919245">US7919245</a></td><td class="patent-data-table-td patent-date-value">Aug 11, 2007</td><td class="patent-data-table-td patent-date-value">Apr 5, 2011</td><td class="patent-data-table-td ">Asuragen, Inc.</td><td class="patent-data-table-td ">Methods and compositions involving microRNA</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7923547">US7923547</a></td><td class="patent-data-table-td patent-date-value">Aug 4, 2006</td><td class="patent-data-table-td patent-date-value">Apr 12, 2011</td><td class="patent-data-table-td ">Sirna Therapeutics, Inc.</td><td class="patent-data-table-td ">for antisense therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7956176">US7956176</a></td><td class="patent-data-table-td patent-date-value">Aug 4, 2006</td><td class="patent-data-table-td patent-date-value">Jun 7, 2011</td><td class="patent-data-table-td ">Sirna Therapeutics, Inc.</td><td class="patent-data-table-td ">RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7960359">US7960359</a></td><td class="patent-data-table-td patent-date-value">Aug 10, 2007</td><td class="patent-data-table-td patent-date-value">Jun 14, 2011</td><td class="patent-data-table-td ">Asuragen, Inc.</td><td class="patent-data-table-td ">Methods and compositions involving miRNA and miRNA inhibitor molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7989612">US7989612</a></td><td class="patent-data-table-td patent-date-value">Aug 4, 2006</td><td class="patent-data-table-td patent-date-value">Aug 2, 2011</td><td class="patent-data-table-td ">Sirna Therapeutics, Inc.</td><td class="patent-data-table-td ">Antisense against viral sequence such as hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human papilloma virus (HPV), herpes simplex virus (HSV), or influenza virus</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8003320">US8003320</a></td><td class="patent-data-table-td patent-date-value">Aug 11, 2007</td><td class="patent-data-table-td patent-date-value">Aug 23, 2011</td><td class="patent-data-table-td ">Asuragen, Inc.</td><td class="patent-data-table-td ">Methods and compositions involving MicroRNA</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8008269">US8008269</a></td><td class="patent-data-table-td patent-date-value">Feb 28, 2008</td><td class="patent-data-table-td patent-date-value">Aug 30, 2011</td><td class="patent-data-table-td ">Replicor Inc.</td><td class="patent-data-table-td ">Antiviral oligonucleotides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8008270">US8008270</a></td><td class="patent-data-table-td patent-date-value">Apr 9, 2008</td><td class="patent-data-table-td patent-date-value">Aug 30, 2011</td><td class="patent-data-table-td ">Replicor Inc.</td><td class="patent-data-table-td ">Antiviral oligonucleotides targeting viral families</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8008468">US8008468</a></td><td class="patent-data-table-td patent-date-value">Feb 16, 2006</td><td class="patent-data-table-td patent-date-value">Aug 30, 2011</td><td class="patent-data-table-td ">Benitec, Inc.</td><td class="patent-data-table-td ">RNAi expression constructs with liver-specific enhancer/promoter</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8048670">US8048670</a></td><td class="patent-data-table-td patent-date-value">Jan 15, 2004</td><td class="patent-data-table-td patent-date-value">Nov 1, 2011</td><td class="patent-data-table-td ">Commonwealth Scientific And Industrial Research Organisation</td><td class="patent-data-table-td ">Expression vector comprising promoter elements and which codes complimentary nucleotide sequences of preferential genes for use as therapeutic tool in targeted tissue/cell therapy; gene expression inhibition</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8053419">US8053419</a></td><td class="patent-data-table-td patent-date-value">Apr 8, 2004</td><td class="patent-data-table-td patent-date-value">Nov 8, 2011</td><td class="patent-data-table-td ">Commonwealth Scientific And Industrial Research Organisation</td><td class="patent-data-table-td ">Using RNA interference as therapeutic tool in treatment of metabolic disorders; tissue directed therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8058250">US8058250</a></td><td class="patent-data-table-td patent-date-value">Aug 10, 2007</td><td class="patent-data-table-td patent-date-value">Nov 15, 2011</td><td class="patent-data-table-td ">Asuragen, Inc.</td><td class="patent-data-table-td ">Administering synthetic miRNA or inhibitor as an anticarcinogenic agent that protects noncancerous cells and is effective against chemo- and radiation resistant cancer cells; breast, colon, thyroid and lung cancers; antimetastasis agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8058255">US8058255</a></td><td class="patent-data-table-td patent-date-value">Jun 15, 2009</td><td class="patent-data-table-td patent-date-value">Nov 15, 2011</td><td class="patent-data-table-td ">Applied Biosystems, Llc</td><td class="patent-data-table-td ">Methods and compositions concerning siRNA&#39;s as mediators of RNA interference</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8067163">US8067163</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 9, 2008</td><td class="patent-data-table-td patent-date-value">Nov 29, 2011</td><td class="patent-data-table-td ">National Chung Cheng University</td><td class="patent-data-table-td ">Determination of the biological function of a target gene in a cell</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8067383">US8067383</a></td><td class="patent-data-table-td patent-date-value">Jan 17, 2003</td><td class="patent-data-table-td patent-date-value">Nov 29, 2011</td><td class="patent-data-table-td ">Commonwealth Scientific And Industrial Research Organisation</td><td class="patent-data-table-td ">Synthetic genes and genetic constructs comprising same I</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8067385">US8067385</a></td><td class="patent-data-table-td patent-date-value">Jul 10, 2008</td><td class="patent-data-table-td patent-date-value">Nov 29, 2011</td><td class="patent-data-table-td ">Replicor, Inc.</td><td class="patent-data-table-td ">Antiviral oligonucleotides targeting HBV</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8067390">US8067390</a></td><td class="patent-data-table-td patent-date-value">Feb 29, 2008</td><td class="patent-data-table-td patent-date-value">Nov 29, 2011</td><td class="patent-data-table-td ">The Board Of Regents Of The University Of Texas System</td><td class="patent-data-table-td ">Therapeutic targeting of interleukins using siRNA in neutral liposomes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8071562">US8071562</a></td><td class="patent-data-table-td patent-date-value">Dec 1, 2008</td><td class="patent-data-table-td patent-date-value">Dec 6, 2011</td><td class="patent-data-table-td ">Mirna Therapeutics, Inc.</td><td class="patent-data-table-td ">MiR-124 regulated genes and pathways as targets for therapeutic intervention</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8076071">US8076071</a></td><td class="patent-data-table-td patent-date-value">Sep 14, 2010</td><td class="patent-data-table-td patent-date-value">Dec 13, 2011</td><td class="patent-data-table-td ">City Of Hope</td><td class="patent-data-table-td ">Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8076471">US8076471</a></td><td class="patent-data-table-td patent-date-value">Feb 3, 2006</td><td class="patent-data-table-td patent-date-value">Dec 13, 2011</td><td class="patent-data-table-td ">Benitec, Inc.</td><td class="patent-data-table-td ">RNAi expression constructs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8084422">US8084422</a></td><td class="patent-data-table-td patent-date-value">Apr 4, 2008</td><td class="patent-data-table-td patent-date-value">Dec 27, 2011</td><td class="patent-data-table-td ">Institut National De La Sante Et De La Recherche Medicale (Inserm)</td><td class="patent-data-table-td ">Method of treating insulin resistance with a selective inhibitor of CB2 receptor activity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8084598">US8084598</a></td><td class="patent-data-table-td patent-date-value">Jan 29, 2004</td><td class="patent-data-table-td patent-date-value">Dec 27, 2011</td><td class="patent-data-table-td ">Rosetta Genomics Inc.</td><td class="patent-data-table-td ">Bioionformality detectable group of novel regulatory oligonucleotides and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8097710">US8097710</a></td><td class="patent-data-table-td patent-date-value">Mar 22, 2004</td><td class="patent-data-table-td patent-date-value">Jan 17, 2012</td><td class="patent-data-table-td ">Plant Bioscience Limited</td><td class="patent-data-table-td ">Using short RNA sequences to control endogenous gene expression through post-transcriptional gene silencing; tissue engineering</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8097778">US8097778</a></td><td class="patent-data-table-td patent-date-value">Apr 7, 2009</td><td class="patent-data-table-td patent-date-value">Jan 17, 2012</td><td class="patent-data-table-td ">Monsanto Company</td><td class="patent-data-table-td ">Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8101343">US8101343</a></td><td class="patent-data-table-td patent-date-value">Jul 5, 2002</td><td class="patent-data-table-td patent-date-value">Jan 24, 2012</td><td class="patent-data-table-td ">Commonwealth Scientific And Industrial Research Organisation</td><td class="patent-data-table-td ">protecting against parasites and predators; transgenic organisims</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8106181">US8106181</a></td><td class="patent-data-table-td patent-date-value">Feb 22, 2010</td><td class="patent-data-table-td patent-date-value">Jan 31, 2012</td><td class="patent-data-table-td ">City Of Hope</td><td class="patent-data-table-td ">Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8114980">US8114980</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 16, 2004</td><td class="patent-data-table-td patent-date-value">Feb 14, 2012</td><td class="patent-data-table-td ">Devgen Nv</td><td class="patent-data-table-td ">Transforming caenorhabditis and using as animal model for gene expression inhibition; RNA interference</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8119611">US8119611</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 27, 2009</td><td class="patent-data-table-td patent-date-value">Feb 21, 2012</td><td class="patent-data-table-td ">Medtronic, Inc.</td><td class="patent-data-table-td ">Treatment of neurodegenerative disease through intracranial delivery of SIRNA</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8124753">US8124753</a></td><td class="patent-data-table-td patent-date-value">Jun 29, 2009</td><td class="patent-data-table-td patent-date-value">Feb 28, 2012</td><td class="patent-data-table-td ">The United States Of America As Represented By The Department Of Health And Human Services</td><td class="patent-data-table-td ">Compositions and methods for inhibiting translation of a Mect1-MAML2 chimeric gene</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8124839">US8124839</a></td><td class="patent-data-table-td patent-date-value">Jun 8, 2006</td><td class="patent-data-table-td patent-date-value">Feb 28, 2012</td><td class="patent-data-table-td ">Ceres, Inc.</td><td class="patent-data-table-td ">Identification of terpenoid-biosynthesis related regulatory protein-regulatory region associations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8148345">US8148345</a></td><td class="patent-data-table-td patent-date-value">Apr 13, 2009</td><td class="patent-data-table-td patent-date-value">Apr 3, 2012</td><td class="patent-data-table-td ">Georgia Health Sciences University Research Institute, Inc.</td><td class="patent-data-table-td ">Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8148604">US8148604</a></td><td class="patent-data-table-td patent-date-value">Oct 21, 2005</td><td class="patent-data-table-td patent-date-value">Apr 3, 2012</td><td class="patent-data-table-td ">Venganza Inc.</td><td class="patent-data-table-td ">Methods and materials for conferring resistance to pests and pathogens of plants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8153776">US8153776</a></td><td class="patent-data-table-td patent-date-value">Aug 20, 2007</td><td class="patent-data-table-td patent-date-value">Apr 10, 2012</td><td class="patent-data-table-td ">Cold Spring Harbor Laboratory</td><td class="patent-data-table-td ">Using targeted gene expression inhibition to treat and prevent viral infection</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8163896">US8163896</a></td><td class="patent-data-table-td patent-date-value">Nov 24, 2003</td><td class="patent-data-table-td patent-date-value">Apr 24, 2012</td><td class="patent-data-table-td ">Rosetta Genomics Ltd.</td><td class="patent-data-table-td ">Bioinformatically detectable group of novel regulatory genes and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8168774">US8168774</a></td><td class="patent-data-table-td patent-date-value">Sep 2, 2005</td><td class="patent-data-table-td patent-date-value">May 1, 2012</td><td class="patent-data-table-td ">Commonwealth Scientific And Industrial Research Organisation</td><td class="patent-data-table-td ">Control of gene expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8173611">US8173611</a></td><td class="patent-data-table-td patent-date-value">Nov 14, 2005</td><td class="patent-data-table-td patent-date-value">May 8, 2012</td><td class="patent-data-table-td ">Asuragen Inc.</td><td class="patent-data-table-td ">Methods and compositions involving miRNA and miRNA inhibitor molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8183217">US8183217</a></td><td class="patent-data-table-td patent-date-value">Jul 13, 2005</td><td class="patent-data-table-td patent-date-value">May 22, 2012</td><td class="patent-data-table-td ">Commonwealth Scientific And Industrial Research Organisation</td><td class="patent-data-table-td ">Methods and means for obtaining modified phenotypes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8202846">US8202846</a></td><td class="patent-data-table-td patent-date-value">Nov 23, 2004</td><td class="patent-data-table-td patent-date-value">Jun 19, 2012</td><td class="patent-data-table-td ">Cold Spring Harbor Laboratory</td><td class="patent-data-table-td ">Methods and compositions for RNA interference</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8202979">US8202979</a></td><td class="patent-data-table-td patent-date-value">May 23, 2003</td><td class="patent-data-table-td patent-date-value">Jun 19, 2012</td><td class="patent-data-table-td ">Sirna Therapeutics, Inc.</td><td class="patent-data-table-td ">siNA molecule comprising a double-stranded structure that down-regulates expression of a target nucleic acid, wherein said siNA molecule does not require a 2&#39;-hydroxyl group containing ribonucleotide; treating viral diseases such as SARS (severe acute respiratory syndrome virus), herpes, hepatitis, HIV</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8222388">US8222388</a></td><td class="patent-data-table-td patent-date-value">Nov 16, 2007</td><td class="patent-data-table-td patent-date-value">Jul 17, 2012</td><td class="patent-data-table-td ">Ceres, Inc.</td><td class="patent-data-table-td ">Broadly expressing regulatory regions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8222482">US8222482</a></td><td class="patent-data-table-td patent-date-value">Jan 26, 2007</td><td class="patent-data-table-td patent-date-value">Jul 17, 2012</td><td class="patent-data-table-td ">Ceres, Inc.</td><td class="patent-data-table-td ">Modulating plant oil levels</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8227434">US8227434</a></td><td class="patent-data-table-td patent-date-value">Nov 4, 2004</td><td class="patent-data-table-td patent-date-value">Jul 24, 2012</td><td class="patent-data-table-td ">H. Lee Moffitt Cancer Center &amp; Research Institute, Inc.</td><td class="patent-data-table-td ">Materials and methods for treating oncological disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8232260">US8232260</a></td><td class="patent-data-table-td patent-date-value">Feb 21, 2011</td><td class="patent-data-table-td patent-date-value">Jul 31, 2012</td><td class="patent-data-table-td ">University Of Massachusetts</td><td class="patent-data-table-td ">In vivo production of small interfering RNAs that mediate gene silencing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8232380">US8232380</a></td><td class="patent-data-table-td patent-date-value">Aug 25, 2008</td><td class="patent-data-table-td patent-date-value">Jul 31, 2012</td><td class="patent-data-table-td ">Ceres, Inc.</td><td class="patent-data-table-td ">Shade regulatory regions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8258111">US8258111</a></td><td class="patent-data-table-td patent-date-value">May 8, 2009</td><td class="patent-data-table-td patent-date-value">Sep 4, 2012</td><td class="patent-data-table-td ">The Johns Hopkins University</td><td class="patent-data-table-td ">Compositions and methods related to miRNA modulation of neovascularization or angiogenesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8258285">US8258285</a></td><td class="patent-data-table-td patent-date-value">Dec 17, 2004</td><td class="patent-data-table-td patent-date-value">Sep 4, 2012</td><td class="patent-data-table-td ">Plant Bioscience Limited</td><td class="patent-data-table-td ">RNA molecules and vectors for gene silencing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8263569">US8263569</a></td><td class="patent-data-table-td patent-date-value">May 30, 2008</td><td class="patent-data-table-td patent-date-value">Sep 11, 2012</td><td class="patent-data-table-td ">Plant Biosciences Limited</td><td class="patent-data-table-td ">Gene silencing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8263573">US8263573</a></td><td class="patent-data-table-td patent-date-value">Sep 23, 2011</td><td class="patent-data-table-td patent-date-value">Sep 11, 2012</td><td class="patent-data-table-td ">Commonwealth Scientific And Industrial Research Organisation</td><td class="patent-data-table-td ">Delivery of dsRNA to arthropods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8273866">US8273866</a></td><td class="patent-data-table-td patent-date-value">Nov 24, 2003</td><td class="patent-data-table-td patent-date-value">Sep 25, 2012</td><td class="patent-data-table-td ">Merck Sharp &amp; Dohme Corp.</td><td class="patent-data-table-td ">Chemically synthesized doubled stranded micro-RNA (miRNA) molecule; nucleic acids with a pyrimidine modification</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8283329">US8283329</a></td><td class="patent-data-table-td patent-date-value">Sep 28, 2007</td><td class="patent-data-table-td patent-date-value">Oct 9, 2012</td><td class="patent-data-table-td ">The Carnegie Institution Of Washington</td><td class="patent-data-table-td ">Genetic inhibition of double-stranded RNA</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8293718">US8293718</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 16, 2010</td><td class="patent-data-table-td patent-date-value">Oct 23, 2012</td><td class="patent-data-table-td ">Novartis Ag</td><td class="patent-data-table-td ">Organic compositions to treat HSF1-related diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8298794">US8298794</a></td><td class="patent-data-table-td patent-date-value">Oct 8, 2009</td><td class="patent-data-table-td patent-date-value">Oct 30, 2012</td><td class="patent-data-table-td ">Ceres, Inc.</td><td class="patent-data-table-td ">Cinnamyl-alcohol dehydrogenases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8299235">US8299235</a></td><td class="patent-data-table-td patent-date-value">Dec 17, 2004</td><td class="patent-data-table-td patent-date-value">Oct 30, 2012</td><td class="patent-data-table-td ">Plant Bioscience Limited</td><td class="patent-data-table-td ">RNA molecules and vectors for gene silencing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8329463">US8329463</a></td><td class="patent-data-table-td patent-date-value">Jul 19, 2010</td><td class="patent-data-table-td patent-date-value">Dec 11, 2012</td><td class="patent-data-table-td ">MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.</td><td class="patent-data-table-td ">RNA interference mediating small RNA molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8329890">US8329890</a></td><td class="patent-data-table-td patent-date-value">Nov 23, 2010</td><td class="patent-data-table-td patent-date-value">Dec 11, 2012</td><td class="patent-data-table-td ">University Of Iowa Research Foundation</td><td class="patent-data-table-td ">SiRNA-mediated gene silencing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8329989">US8329989</a></td><td class="patent-data-table-td patent-date-value">Sep 28, 2009</td><td class="patent-data-table-td patent-date-value">Dec 11, 2012</td><td class="patent-data-table-td ">Monsanto Technology Llc</td><td class="patent-data-table-td ">Soybean plant with altered oil content (more oleic, less saturated fat); cooking oil, salad oil, shortening, lecithin, nontoxic plastics, printing inks, lubricants, waxes, hydraulic fluids, electric transformer fluids, solvents, cosmetics, hair care products and biodiesel</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8334374">US8334374</a></td><td class="patent-data-table-td patent-date-value">May 17, 2012</td><td class="patent-data-table-td patent-date-value">Dec 18, 2012</td><td class="patent-data-table-td ">Commonwealth Scientific And Industrial Research Organisation</td><td class="patent-data-table-td ">Methods and means for obtaining modified phenotypes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8349607">US8349607</a></td><td class="patent-data-table-td patent-date-value">Jul 23, 2009</td><td class="patent-data-table-td patent-date-value">Jan 8, 2013</td><td class="patent-data-table-td ">Plant Bioscience Limited</td><td class="patent-data-table-td ">Gene silencing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8361714">US8361714</a></td><td class="patent-data-table-td patent-date-value">Sep 12, 2008</td><td class="patent-data-table-td patent-date-value">Jan 29, 2013</td><td class="patent-data-table-td ">Asuragen, Inc.</td><td class="patent-data-table-td ">Micrornas differentially expressed in cervical cancer and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8362231">US8362231</a></td><td class="patent-data-table-td patent-date-value">Jan 6, 2010</td><td class="patent-data-table-td patent-date-value">Jan 29, 2013</td><td class="patent-data-table-td ">Max-Planck-Gesellschaft zur Föderung der Wissenschaften E.V.</td><td class="patent-data-table-td ">RNA interference mediating small RNA molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8362322">US8362322</a></td><td class="patent-data-table-td patent-date-value">Oct 26, 2007</td><td class="patent-data-table-td patent-date-value">Jan 29, 2013</td><td class="patent-data-table-td ">Ceres, Inc.</td><td class="patent-data-table-td ">Modulating lignin in plants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8372968">US8372968</a></td><td class="patent-data-table-td patent-date-value">Aug 7, 2009</td><td class="patent-data-table-td patent-date-value">Feb 12, 2013</td><td class="patent-data-table-td ">MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.</td><td class="patent-data-table-td ">RNA interference mediating small RNA molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8383599">US8383599</a></td><td class="patent-data-table-td patent-date-value">May 16, 2008</td><td class="patent-data-table-td patent-date-value">Feb 26, 2013</td><td class="patent-data-table-td ">Cold Spring Harbor Laboratory</td><td class="patent-data-table-td ">Methods and compositions for RNA interference</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8389487">US8389487</a></td><td class="patent-data-table-td patent-date-value">Jan 25, 2010</td><td class="patent-data-table-td patent-date-value">Mar 5, 2013</td><td class="patent-data-table-td ">Ann &amp; Robert Lurie Children&#39;s Hospital of Chicago</td><td class="patent-data-table-td ">siRNA-mediated gene silencing of synuclein</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8394628">US8394628</a></td><td class="patent-data-table-td patent-date-value">Oct 4, 2010</td><td class="patent-data-table-td patent-date-value">Mar 12, 2013</td><td class="patent-data-table-td ">University Of Massachusetts</td><td class="patent-data-table-td ">RNA sequence-specific mediators of RNA interference</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8415320">US8415320</a></td><td class="patent-data-table-td patent-date-value">Jul 10, 2012</td><td class="patent-data-table-td patent-date-value">Apr 9, 2013</td><td class="patent-data-table-td ">Commonwealth Scientific And Industrial Research Organisation</td><td class="patent-data-table-td ">Delivery of dsRNA to arthropods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8420391">US8420391</a></td><td class="patent-data-table-td patent-date-value">Oct 4, 2010</td><td class="patent-data-table-td patent-date-value">Apr 16, 2013</td><td class="patent-data-table-td ">University Of Massachusetts</td><td class="patent-data-table-td ">RNA sequence-specific mediators of RNA interference</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8431547">US8431547</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 7, 2011</td><td class="patent-data-table-td patent-date-value">Apr 30, 2013</td><td class="patent-data-table-td ">Commonwealth Scientific And Industrial Research Organisation</td><td class="patent-data-table-td ">Synthetic genes and genetic constructs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8445237">US8445237</a></td><td class="patent-data-table-td patent-date-value">Jul 12, 2010</td><td class="patent-data-table-td patent-date-value">May 21, 2013</td><td class="patent-data-table-td ">MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.</td><td class="patent-data-table-td ">RNA interference mediating small RNA molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8450106">US8450106</a></td><td class="patent-data-table-td patent-date-value">Feb 1, 2010</td><td class="patent-data-table-td patent-date-value">May 28, 2013</td><td class="patent-data-table-td ">The Ohio State University Research Foundation</td><td class="patent-data-table-td ">Oncolytic virus</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8455633">US8455633</a></td><td class="patent-data-table-td patent-date-value">Aug 4, 2010</td><td class="patent-data-table-td patent-date-value">Jun 4, 2013</td><td class="patent-data-table-td ">Rosetta Genomics Ltd.</td><td class="patent-data-table-td ">Viral and viral associated mirnas and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8461416">US8461416</a></td><td class="patent-data-table-td patent-date-value">Jun 28, 2011</td><td class="patent-data-table-td patent-date-value">Jun 11, 2013</td><td class="patent-data-table-td ">Venganza, Inc.</td><td class="patent-data-table-td ">Methods and materials for conferring resistance to pests and pathogens of plants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8465914">US8465914</a></td><td class="patent-data-table-td patent-date-value">Jul 2, 2012</td><td class="patent-data-table-td patent-date-value">Jun 18, 2013</td><td class="patent-data-table-td ">Asuragen, Inc.</td><td class="patent-data-table-td ">Method and compositions involving microRNA</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8481506">US8481506</a></td><td class="patent-data-table-td patent-date-value">Dec 5, 2007</td><td class="patent-data-table-td patent-date-value">Jul 9, 2013</td><td class="patent-data-table-td ">Rosetta Genomics, Ltd.</td><td class="patent-data-table-td ">Nucleic acids involved in viral infection</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8481509">US8481509</a></td><td class="patent-data-table-td patent-date-value">Feb 1, 2012</td><td class="patent-data-table-td patent-date-value">Jul 9, 2013</td><td class="patent-data-table-td ">Novartis Ag</td><td class="patent-data-table-td ">Organic compositions to treat HSF1-related diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8481710">US8481710</a></td><td class="patent-data-table-td patent-date-value">Dec 9, 2010</td><td class="patent-data-table-td patent-date-value">Jul 9, 2013</td><td class="patent-data-table-td ">University Of Iowa Research Foundation</td><td class="patent-data-table-td ">RNA interference suppression of neurodegenerative diseases and methods of use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8524879">US8524879</a></td><td class="patent-data-table-td patent-date-value">May 5, 2010</td><td class="patent-data-table-td patent-date-value">Sep 3, 2013</td><td class="patent-data-table-td ">University Of Iowa Research Foundation</td><td class="patent-data-table-td ">RNA interference suppresion of neurodegenerative diseases and methods of use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8530438">US8530438</a></td><td class="patent-data-table-td patent-date-value">Mar 19, 2010</td><td class="patent-data-table-td patent-date-value">Sep 10, 2013</td><td class="patent-data-table-td ">University Of Massachusetts</td><td class="patent-data-table-td ">Vivo production of small interfering RNAs that mediate gene silencing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8541389">US8541389</a></td><td class="patent-data-table-td patent-date-value">Feb 25, 2011</td><td class="patent-data-table-td patent-date-value">Sep 24, 2013</td><td class="patent-data-table-td ">Alcon Research, Ltd.</td><td class="patent-data-table-td ">RNAi-mediated inhibition of tumor necrosis factor α-related conditions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8546349">US8546349</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 26, 2011</td><td class="patent-data-table-td patent-date-value">Oct 1, 2013</td><td class="patent-data-table-td ">Thermo Fisher Scientific Biosciences Inc.</td><td class="patent-data-table-td ">siRNA targeting VEGFA and methods for treatment in vivo</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8552171">US8552171</a></td><td class="patent-data-table-td patent-date-value">Oct 4, 2010</td><td class="patent-data-table-td patent-date-value">Oct 8, 2013</td><td class="patent-data-table-td ">University Of Massachusetts</td><td class="patent-data-table-td ">RNA sequence-specific mediators of RNA interference</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8557785">US8557785</a></td><td class="patent-data-table-td patent-date-value">Mar 23, 2010</td><td class="patent-data-table-td patent-date-value">Oct 15, 2013</td><td class="patent-data-table-td ">University Of Massachusetts</td><td class="patent-data-table-td ">In vivo production of small interfering RNAS that mediate gene silencing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8568971">US8568971</a></td><td class="patent-data-table-td patent-date-value">Sep 24, 2010</td><td class="patent-data-table-td patent-date-value">Oct 29, 2013</td><td class="patent-data-table-td ">Asuragen, Inc.</td><td class="patent-data-table-td ">Methods and compositions involving microRNA</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8580754">US8580754</a></td><td class="patent-data-table-td patent-date-value">Oct 1, 2007</td><td class="patent-data-table-td patent-date-value">Nov 12, 2013</td><td class="patent-data-table-td ">Carnegie Institution Of Washington</td><td class="patent-data-table-td ">Genetic inhibition by double-stranded RNA</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8581039">US8581039</a></td><td class="patent-data-table-td patent-date-value">Jun 28, 2011</td><td class="patent-data-table-td patent-date-value">Nov 12, 2013</td><td class="patent-data-table-td ">Venganza, Inc.</td><td class="patent-data-table-td ">Methods and materials for conferring resistance to pests and pathogens of plants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8598332">US8598332</a></td><td class="patent-data-table-td patent-date-value">Apr 7, 1999</td><td class="patent-data-table-td patent-date-value">Dec 3, 2013</td><td class="patent-data-table-td ">Bayer Cropscience N.V.</td><td class="patent-data-table-td ">Methods and means for obtaining modified phenotypes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8623838">US8623838</a></td><td class="patent-data-table-td patent-date-value">Feb 1, 2012</td><td class="patent-data-table-td patent-date-value">Jan 7, 2014</td><td class="patent-data-table-td ">Novartis Ag</td><td class="patent-data-table-td ">Organic compositions to treat HSF1-related diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8632997">US8632997</a></td><td class="patent-data-table-td patent-date-value">Oct 4, 2010</td><td class="patent-data-table-td patent-date-value">Jan 21, 2014</td><td class="patent-data-table-td ">University Of Massachusetts</td><td class="patent-data-table-td ">RNA sequence-specific mediators of RNA interference</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8633028">US8633028</a></td><td class="patent-data-table-td patent-date-value">Jul 2, 2004</td><td class="patent-data-table-td patent-date-value">Jan 21, 2014</td><td class="patent-data-table-td ">Musc Foundation For Research Development</td><td class="patent-data-table-td ">dsRNA induced specific and non-specific immunity in crustaceans and other invertebrates and biodelivery vehicles for use therein</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8692080">US8692080</a></td><td class="patent-data-table-td patent-date-value">Nov 6, 2012</td><td class="patent-data-table-td patent-date-value">Apr 8, 2014</td><td class="patent-data-table-td ">Monsanto Technology Llc</td><td class="patent-data-table-td ">Soybean transgenic event MON87705 and methods for detection thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8710024">US8710024</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 11, 2012</td><td class="patent-data-table-td patent-date-value">Apr 29, 2014</td><td class="patent-data-table-td ">Kyorin Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Treatment of influenza</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8710104">US8710104</a></td><td class="patent-data-table-td patent-date-value">Nov 6, 2009</td><td class="patent-data-table-td patent-date-value">Apr 29, 2014</td><td class="patent-data-table-td ">Triact Therapeutics, Inc.</td><td class="patent-data-table-td ">Catecholic butanes and use thereof for cancer therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8716557">US8716557</a></td><td class="patent-data-table-td patent-date-value">Jan 17, 2007</td><td class="patent-data-table-td patent-date-value">May 6, 2014</td><td class="patent-data-table-td ">Synthon Biopharmaceuticals B.V.</td><td class="patent-data-table-td ">Compositions and methods for inhibition of fucosyltransferase and xylosyltransferase expression in plants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8729036">US8729036</a></td><td class="patent-data-table-td patent-date-value">Aug 7, 2003</td><td class="patent-data-table-td patent-date-value">May 20, 2014</td><td class="patent-data-table-td ">University Of Massachusetts</td><td class="patent-data-table-td ">Compositions for RNA interference and methods of use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8734853">US8734853</a></td><td class="patent-data-table-td patent-date-value">Nov 17, 2009</td><td class="patent-data-table-td patent-date-value">May 27, 2014</td><td class="patent-data-table-td ">University Of North Texas Health Science Center At Fort Worth</td><td class="patent-data-table-td ">HDL particles for delivery of nucleic acids</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8742092">US8742092</a></td><td class="patent-data-table-td patent-date-value">Oct 4, 2010</td><td class="patent-data-table-td patent-date-value">Jun 3, 2014</td><td class="patent-data-table-td ">University Of Massachusetts</td><td class="patent-data-table-td ">RNA sequence-specific mediators of RNA interference</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8759102">US8759102</a></td><td class="patent-data-table-td patent-date-value">Dec 17, 2004</td><td class="patent-data-table-td patent-date-value">Jun 24, 2014</td><td class="patent-data-table-td ">Plant Bioscience Limited</td><td class="patent-data-table-td ">Short RNA producing gene silencing in cells</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8759306">US8759306</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 31, 2006</td><td class="patent-data-table-td patent-date-value">Jun 24, 2014</td><td class="patent-data-table-td ">Devgen N.V.</td><td class="patent-data-table-td ">RNAi for the control of insects and arachnids</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8759611">US8759611</a></td><td class="patent-data-table-td patent-date-value">Dec 20, 2010</td><td class="patent-data-table-td patent-date-value">Jun 24, 2014</td><td class="patent-data-table-td ">Monsanto Technology Llc</td><td class="patent-data-table-td ">Methods for genetic control of insect infestation in plants and compositions thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8765709">US8765709</a></td><td class="patent-data-table-td patent-date-value">Aug 28, 2013</td><td class="patent-data-table-td patent-date-value">Jul 1, 2014</td><td class="patent-data-table-td ">Asuragen, Inc.</td><td class="patent-data-table-td ">Methods and compositions involving miRNA and miRNA inhibitor molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8765930">US8765930</a></td><td class="patent-data-table-td patent-date-value">Jun 4, 2010</td><td class="patent-data-table-td patent-date-value">Jul 1, 2014</td><td class="patent-data-table-td ">MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.</td><td class="patent-data-table-td ">RNA interference mediating small RNA molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8778902">US8778902</a></td><td class="patent-data-table-td patent-date-value">Jul 13, 2010</td><td class="patent-data-table-td patent-date-value">Jul 15, 2014</td><td class="patent-data-table-td ">MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.</td><td class="patent-data-table-td ">RNA interference mediating small RNA molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8779116">US8779116</a></td><td class="patent-data-table-td patent-date-value">Nov 5, 2012</td><td class="patent-data-table-td patent-date-value">Jul 15, 2014</td><td class="patent-data-table-td ">University Of Iowa Research Foundation</td><td class="patent-data-table-td ">SiRNA-mediated gene silencing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8779236">US8779236</a></td><td class="patent-data-table-td patent-date-value">Jul 23, 2009</td><td class="patent-data-table-td patent-date-value">Jul 15, 2014</td><td class="patent-data-table-td ">Plant Bioscience Limited</td><td class="patent-data-table-td ">Gene silencing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20090081790">US20090081790</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 30, 2008</td><td class="patent-data-table-td patent-date-value">Mar 26, 2009</td><td class="patent-data-table-td ">Otsuka Pharmaceutical Co., Ltd</td><td class="patent-data-table-td ">Polynucleotide for Target Gene</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20100011654">US20100011654</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 31, 2006</td><td class="patent-data-table-td patent-date-value">Jan 21, 2010</td><td class="patent-data-table-td ">Devgen N.V.</td><td class="patent-data-table-td ">Rnai for the control of insects and arachnids</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20110166058">US20110166058</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 16, 2010</td><td class="patent-data-table-td patent-date-value">Jul 7, 2011</td><td class="patent-data-table-td ">Novartis Ag</td><td class="patent-data-table-td ">Organic compositions to treat hsf1-related diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20120029051">US20120029051</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 26, 2011</td><td class="patent-data-table-td patent-date-value">Feb 2, 2012</td><td class="patent-data-table-td ">Alcon Research, Ltd.</td><td class="patent-data-table-td ">siRNA Targeting VEGFA and Methods for Treatment In Vivo</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20120135517">US20120135517</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 7, 2011</td><td class="patent-data-table-td patent-date-value">May 31, 2012</td><td class="patent-data-table-td ">Commonwealth Scientific And Industrial Research Organisation</td><td class="patent-data-table-td ">Synthetic genes and genetic constructs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20120232128">US20120232128</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 11, 2012</td><td class="patent-data-table-td patent-date-value">Sep 13, 2012</td><td class="patent-data-table-td ">Kyorin Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Treatment of influenza</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1693470A1?cl=en">EP1693470A1</a></td><td class="patent-data-table-td patent-date-value">Feb 15, 2006</td><td class="patent-data-table-td patent-date-value">Aug 23, 2006</td><td class="patent-data-table-td ">Agilent Technologies, Inc.</td><td class="patent-data-table-td ">Methods and compositions for determining cytotoxicity of transfection agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2172549A2?cl=en">EP2172549A2</a></td><td class="patent-data-table-td patent-date-value">Feb 3, 2006</td><td class="patent-data-table-td patent-date-value">Apr 7, 2010</td><td class="patent-data-table-td ">Benitec, Inc.</td><td class="patent-data-table-td ">RNAi expression constructs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2201982A1?cl=en">EP2201982A1</a></td><td class="patent-data-table-td patent-date-value">Dec 24, 2008</td><td class="patent-data-table-td patent-date-value">Jun 30, 2010</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Histamine H4 receptor antagonists for the treatment of vestibular disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2253316A1?cl=en">EP2253316A1</a></td><td class="patent-data-table-td patent-date-value">May 20, 2009</td><td class="patent-data-table-td patent-date-value">Nov 24, 2010</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Medicale)</td><td class="patent-data-table-td ">serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of vestibular deficits</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2292739A1?cl=en">EP2292739A1</a></td><td class="patent-data-table-td patent-date-value">Mar 19, 2007</td><td class="patent-data-table-td patent-date-value">Mar 9, 2011</td><td class="patent-data-table-td ">Institut National De La Recherche Agronomique</td><td class="patent-data-table-td ">Method for preparing differentiated avian cells and genes involved in the maintenance of pluripotency</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2322650A1?cl=en">EP2322650A1</a></td><td class="patent-data-table-td patent-date-value">May 14, 2005</td><td class="patent-data-table-td patent-date-value">May 18, 2011</td><td class="patent-data-table-td ">Rosetta Genomics Ltd</td><td class="patent-data-table-td ">MicroRNAs and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2322651A1?cl=en">EP2322651A1</a></td><td class="patent-data-table-td patent-date-value">May 14, 2005</td><td class="patent-data-table-td patent-date-value">May 18, 2011</td><td class="patent-data-table-td ">Rosetta Genomics Ltd</td><td class="patent-data-table-td ">MicroRNAs and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2322652A1?cl=en">EP2322652A1</a></td><td class="patent-data-table-td patent-date-value">May 14, 2005</td><td class="patent-data-table-td patent-date-value">May 18, 2011</td><td class="patent-data-table-td ">Rosetta Genomics Ltd</td><td class="patent-data-table-td ">MicroRNAs and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2322653A1?cl=en">EP2322653A1</a></td><td class="patent-data-table-td patent-date-value">May 14, 2005</td><td class="patent-data-table-td patent-date-value">May 18, 2011</td><td class="patent-data-table-td ">Rosetta Genomics Ltd</td><td class="patent-data-table-td ">MicroRNAs and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2322654A1?cl=en">EP2322654A1</a></td><td class="patent-data-table-td patent-date-value">May 14, 2005</td><td class="patent-data-table-td patent-date-value">May 18, 2011</td><td class="patent-data-table-td ">Rosetta Genomics Ltd</td><td class="patent-data-table-td ">MicroRNAs and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2322660A1?cl=en">EP2322660A1</a></td><td class="patent-data-table-td patent-date-value">May 14, 2005</td><td class="patent-data-table-td patent-date-value">May 18, 2011</td><td class="patent-data-table-td ">Rosetta Genomics Ltd</td><td class="patent-data-table-td ">MicroRNAs and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2322662A1?cl=en">EP2322662A1</a></td><td class="patent-data-table-td patent-date-value">May 14, 2005</td><td class="patent-data-table-td patent-date-value">May 18, 2011</td><td class="patent-data-table-td ">Rosetta Genomics Ltd</td><td class="patent-data-table-td ">MicroRNAs and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2322665A1?cl=en">EP2322665A1</a></td><td class="patent-data-table-td patent-date-value">May 14, 2005</td><td class="patent-data-table-td patent-date-value">May 18, 2011</td><td class="patent-data-table-td ">Rosetta Genomics Ltd</td><td class="patent-data-table-td ">MicroRNAs and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2325331A1?cl=en">EP2325331A1</a></td><td class="patent-data-table-td patent-date-value">May 14, 2005</td><td class="patent-data-table-td patent-date-value">May 25, 2011</td><td class="patent-data-table-td ">Rosetta Genomics Ltd</td><td class="patent-data-table-td ">MicroRNAs and Uses Thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2325333A1?cl=en">EP2325333A1</a></td><td class="patent-data-table-td patent-date-value">May 14, 2005</td><td class="patent-data-table-td patent-date-value">May 25, 2011</td><td class="patent-data-table-td ">Rosetta Genomics Ltd</td><td class="patent-data-table-td ">MicrorRNAs and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2325340A1?cl=en">EP2325340A1</a></td><td class="patent-data-table-td patent-date-value">May 14, 2005</td><td class="patent-data-table-td patent-date-value">May 25, 2011</td><td class="patent-data-table-td ">Rosetta Genomics Ltd</td><td class="patent-data-table-td ">MicroRNAs and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2327798A1?cl=en">EP2327798A1</a></td><td class="patent-data-table-td patent-date-value">May 14, 2005</td><td class="patent-data-table-td patent-date-value">Jun 1, 2011</td><td class="patent-data-table-td ">Rosetta Genomics Ltd</td><td class="patent-data-table-td ">MicroRNAs and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2336363A1?cl=en">EP2336363A1</a></td><td class="patent-data-table-td patent-date-value">May 14, 2005</td><td class="patent-data-table-td patent-date-value">Jun 22, 2011</td><td class="patent-data-table-td ">Rosetta Genomics Ltd</td><td class="patent-data-table-td ">MicroRNAs and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2372363A1?cl=en">EP2372363A1</a></td><td class="patent-data-table-td patent-date-value">Sep 19, 2006</td><td class="patent-data-table-td patent-date-value">Oct 5, 2011</td><td class="patent-data-table-td ">OSI Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Biological markers predictive of anti-cancer response to insulin-like growth factor-1</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2394662A2?cl=en">EP2394662A2</a></td><td class="patent-data-table-td patent-date-value">Mar 30, 2005</td><td class="patent-data-table-td patent-date-value">Dec 14, 2011</td><td class="patent-data-table-td ">The Regents of The University of California</td><td class="patent-data-table-td ">Methods and compositions for treating and preventing disease associated with AlphavBeta5 intergrin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2399575A2?cl=en">EP2399575A2</a></td><td class="patent-data-table-td patent-date-value">Aug 8, 2007</td><td class="patent-data-table-td patent-date-value">Dec 28, 2011</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Medicale)</td><td class="patent-data-table-td ">Methods, uses and compositions for treatment of an infection by a virus of the family of flaviviridae through the farnesoid X receptor (FXR) inhibition</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2399988A2?cl=en">EP2399988A2</a></td><td class="patent-data-table-td patent-date-value">Aug 8, 2007</td><td class="patent-data-table-td patent-date-value">Dec 28, 2011</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Medicale)</td><td class="patent-data-table-td ">Cell culture system for replication of HCV through the farnesoid X receptor (FXR) activation or inhibition and diagnostic method for HCV infection</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2412816A2?cl=en">EP2412816A2</a></td><td class="patent-data-table-td patent-date-value">Jul 26, 2005</td><td class="patent-data-table-td patent-date-value">Feb 1, 2012</td><td class="patent-data-table-td ">Pfenex, Inc.</td><td class="patent-data-table-td ">Process for improved protein expression by strain engineering</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2444496A1?cl=en">EP2444496A1</a></td><td class="patent-data-table-td patent-date-value">Apr 17, 2006</td><td class="patent-data-table-td patent-date-value">Apr 25, 2012</td><td class="patent-data-table-td ">Del Monte Fresh Produce Company</td><td class="patent-data-table-td ">Plant promoters, terminators, genes, vectors and related transformed plants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2447371A1?cl=en">EP2447371A1</a></td><td class="patent-data-table-td patent-date-value">Apr 17, 2006</td><td class="patent-data-table-td patent-date-value">May 2, 2012</td><td class="patent-data-table-td ">Del Monte Fresh Produce Company</td><td class="patent-data-table-td ">Plant promoters, terminators, genes, vectors and related transformed plants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2567693A1?cl=en">EP2567693A1</a></td><td class="patent-data-table-td patent-date-value">Jul 16, 2004</td><td class="patent-data-table-td patent-date-value">Mar 13, 2013</td><td class="patent-data-table-td ">Protiva Biotherapeutics Inc.</td><td class="patent-data-table-td ">Lipid encapsulated interfering RNA</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2615172A1?cl=en">EP2615172A1</a></td><td class="patent-data-table-td patent-date-value">Apr 25, 2008</td><td class="patent-data-table-td patent-date-value">Jul 17, 2013</td><td class="patent-data-table-td ">Pfenex Inc.</td><td class="patent-data-table-td ">Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2659771A1?cl=en">EP2659771A1</a></td><td class="patent-data-table-td patent-date-value">Jul 20, 2010</td><td class="patent-data-table-td patent-date-value">Nov 6, 2013</td><td class="patent-data-table-td ">Ceres, Inc.</td><td class="patent-data-table-td ">Transgenic plants having increased biomass</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2003057840A2?cl=en">WO2003057840A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 26, 2002</td><td class="patent-data-table-td patent-date-value">Jul 17, 2003</td><td class="patent-data-table-td ">Allele Biotechnology &amp; Pharmac</td><td class="patent-data-table-td ">Compositions for dna mediated gene silencing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004001000A2?cl=en">WO2004001000A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 20, 2003</td><td class="patent-data-table-td patent-date-value">Dec 31, 2003</td><td class="patent-data-table-td ">Monsanto Technology Llc</td><td class="patent-data-table-td ">Intron double stranded rna constructs and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004001013A2?cl=en">WO2004001013A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 24, 2003</td><td class="patent-data-table-td patent-date-value">Dec 31, 2003</td><td class="patent-data-table-td ">Baylor College Medicine</td><td class="patent-data-table-td ">Inhibition of gene expression in vertebrates using double-stranded rna (rnai)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004013355A1?cl=en">WO2004013355A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 26, 2003</td><td class="patent-data-table-td patent-date-value">Feb 12, 2004</td><td class="patent-data-table-td ">Beverly L Davidson</td><td class="patent-data-table-td ">Sirna-mediated gene silencing with viral vectors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004050895A2?cl=en">WO2004050895A2</a></td><td class="patent-data-table-td patent-date-value">Nov 25, 2003</td><td class="patent-data-table-td patent-date-value">Jun 17, 2004</td><td class="patent-data-table-td ">Pedro Aza-Blanc</td><td class="patent-data-table-td ">Methods and compositions for inducing apoptosis in cancer cells</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2005007196A2?cl=en">WO2005007196A2</a></td><td class="patent-data-table-td patent-date-value">Jul 16, 2004</td><td class="patent-data-table-td patent-date-value">Jan 27, 2005</td><td class="patent-data-table-td ">Protiva Biotherapeutics Inc</td><td class="patent-data-table-td ">Lipid encapsulated interfering rna</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2005081714A2?cl=en">WO2005081714A2</a></td><td class="patent-data-table-td patent-date-value">Nov 22, 2004</td><td class="patent-data-table-td patent-date-value">Sep 9, 2005</td><td class="patent-data-table-td ">Revivicor Inc</td><td class="patent-data-table-td ">Use of interfering rna in the production of transgenic animals</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007035744A1?cl=en">WO2007035744A1</a></td><td class="patent-data-table-td patent-date-value">Sep 19, 2006</td><td class="patent-data-table-td patent-date-value">Mar 29, 2007</td><td class="patent-data-table-td ">Osi Pharm Inc</td><td class="patent-data-table-td ">Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008089243A2?cl=en">WO2008089243A2</a></td><td class="patent-data-table-td patent-date-value">Jan 16, 2008</td><td class="patent-data-table-td patent-date-value">Jul 24, 2008</td><td class="patent-data-table-td ">Tiefei Dong</td><td class="patent-data-table-td ">The redox/fyn/c-cbl pathway</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008112218A2?cl=en">WO2008112218A2</a></td><td class="patent-data-table-td patent-date-value">Mar 10, 2008</td><td class="patent-data-table-td patent-date-value">Sep 18, 2008</td><td class="patent-data-table-td ">Antigen Express Inc</td><td class="patent-data-table-td ">Li-rnai involved li suppression in cancer immunotherapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010061393A1?cl=en">WO2010061393A1</a></td><td class="patent-data-table-td patent-date-value">Nov 30, 2009</td><td class="patent-data-table-td patent-date-value">Jun 3, 2010</td><td class="patent-data-table-td ">Compugen Ltd.</td><td class="patent-data-table-td ">He4 variant nucleotide and amino acid sequences, and methods of use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010065437A1?cl=en">WO2010065437A1</a></td><td class="patent-data-table-td patent-date-value">Nov 30, 2009</td><td class="patent-data-table-td patent-date-value">Jun 10, 2010</td><td class="patent-data-table-td ">Research Development Foundation</td><td class="patent-data-table-td ">Modulation of olfml-3 mediated angiogenesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010072829A1?cl=en">WO2010072829A1</a></td><td class="patent-data-table-td patent-date-value">Dec 23, 2009</td><td class="patent-data-table-td patent-date-value">Jul 1, 2010</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Selective histamine h4 receptor antagonists for the treatment of vestibular disorders.</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010099138A2?cl=en">WO2010099138A2</a></td><td class="patent-data-table-td patent-date-value">Feb 24, 2010</td><td class="patent-data-table-td patent-date-value">Sep 2, 2010</td><td class="patent-data-table-td ">Osi Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010099363A1?cl=en">WO2010099363A1</a></td><td class="patent-data-table-td patent-date-value">Feb 26, 2010</td><td class="patent-data-table-td patent-date-value">Sep 2, 2010</td><td class="patent-data-table-td ">Osi Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010099364A2?cl=en">WO2010099364A2</a></td><td class="patent-data-table-td patent-date-value">Feb 26, 2010</td><td class="patent-data-table-td patent-date-value">Sep 2, 2010</td><td class="patent-data-table-td ">Osi Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010106187A2?cl=en">WO2010106187A2</a></td><td class="patent-data-table-td patent-date-value">Mar 22, 2010</td><td class="patent-data-table-td patent-date-value">Sep 23, 2010</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Inhibitors of cathepsin s for prevention or treatment of obesity-associated disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010108108A2?cl=en">WO2010108108A2</a></td><td class="patent-data-table-td patent-date-value">Mar 19, 2010</td><td class="patent-data-table-td patent-date-value">Sep 23, 2010</td><td class="patent-data-table-td ">Egen, Inc.</td><td class="patent-data-table-td ">Polyamine derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010115874A1?cl=en">WO2010115874A1</a></td><td class="patent-data-table-td patent-date-value">Apr 6, 2010</td><td class="patent-data-table-td patent-date-value">Oct 14, 2010</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods for the treatment and the diagnosis ofpulmonary arterial hypertension</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010133663A1?cl=en">WO2010133663A1</a></td><td class="patent-data-table-td patent-date-value">May 20, 2010</td><td class="patent-data-table-td patent-date-value">Nov 25, 2010</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Serotonin 5-ht3 receptor antagonists for use in the treatment of lesional vestibular disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010149765A1?cl=en">WO2010149765A1</a></td><td class="patent-data-table-td patent-date-value">Jun 25, 2010</td><td class="patent-data-table-td patent-date-value">Dec 29, 2010</td><td class="patent-data-table-td ">Inserm (Institut National De La Sante Et De La Recherche Medicale)</td><td class="patent-data-table-td ">Non human animal models for increased retinal vascular permeability</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011020874A1?cl=en">WO2011020874A1</a></td><td class="patent-data-table-td patent-date-value">Aug 19, 2010</td><td class="patent-data-table-td patent-date-value">Feb 24, 2011</td><td class="patent-data-table-td ">Inserm (Institut National De La Sante Et De La Recherche Medicale)</td><td class="patent-data-table-td ">Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011048070A1?cl=en">WO2011048070A1</a></td><td class="patent-data-table-td patent-date-value">Oct 19, 2010</td><td class="patent-data-table-td patent-date-value">Apr 28, 2011</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods and pharmaceutical compositions for the treatment of disorders of glucose homeostasis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011054916A1?cl=en">WO2011054916A1</a></td><td class="patent-data-table-td patent-date-value">Nov 5, 2010</td><td class="patent-data-table-td patent-date-value">May 12, 2011</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods and pharmaceutical composition for the treatment of atherosclerosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011070049A1?cl=en">WO2011070049A1</a></td><td class="patent-data-table-td patent-date-value">Dec 8, 2010</td><td class="patent-data-table-td patent-date-value">Jun 16, 2011</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011080261A1?cl=en">WO2011080261A1</a></td><td class="patent-data-table-td patent-date-value">Dec 28, 2010</td><td class="patent-data-table-td patent-date-value">Jul 7, 2011</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Method for improved cardiomyogenic differentiation of pluripotent cells</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011083124A1?cl=en">WO2011083124A1</a></td><td class="patent-data-table-td patent-date-value">Jan 5, 2011</td><td class="patent-data-table-td patent-date-value">Jul 14, 2011</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Flt3 receptor antagonists for the treatment or the prevention of pain disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011086126A1?cl=en">WO2011086126A1</a></td><td class="patent-data-table-td patent-date-value">Jan 13, 2011</td><td class="patent-data-table-td patent-date-value">Jul 21, 2011</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Compounds for the treatment of autism</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011109572A2?cl=en">WO2011109572A2</a></td><td class="patent-data-table-td patent-date-value">Mar 3, 2011</td><td class="patent-data-table-td patent-date-value">Sep 9, 2011</td><td class="patent-data-table-td ">OSI Pharmaceuticals, LLC</td><td class="patent-data-table-td ">Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011109584A2?cl=en">WO2011109584A2</a></td><td class="patent-data-table-td patent-date-value">Mar 3, 2011</td><td class="patent-data-table-td patent-date-value">Sep 9, 2011</td><td class="patent-data-table-td ">OSI Pharmaceuticals, LLC</td><td class="patent-data-table-td ">Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011120474A1?cl=en">WO2011120474A1</a></td><td class="patent-data-table-td patent-date-value">Apr 1, 2011</td><td class="patent-data-table-td patent-date-value">Oct 6, 2011</td><td class="patent-data-table-td ">Centro De Ingeniería Genética Y Biotecnología</td><td class="patent-data-table-td ">Method for inhibiting hiv replication in mammal and human cells</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011141456A1?cl=en">WO2011141456A1</a></td><td class="patent-data-table-td patent-date-value">May 10, 2011</td><td class="patent-data-table-td patent-date-value">Nov 17, 2011</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods and compositions for the treatment of fluid accumulation in and/ or under the retina</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011157798A1?cl=en">WO2011157798A1</a></td><td class="patent-data-table-td patent-date-value">Jun 16, 2011</td><td class="patent-data-table-td patent-date-value">Dec 22, 2011</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods and compositions for stimulating reepithelialisation during wound healing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012000904A1?cl=en">WO2012000904A1</a></td><td class="patent-data-table-td patent-date-value">Jun 24, 2011</td><td class="patent-data-table-td patent-date-value">Jan 5, 2012</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Pharmaceutical composition for use in the treatment of glaucoma</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012010696A1?cl=en">WO2012010696A1</a></td><td class="patent-data-table-td patent-date-value">Jul 22, 2011</td><td class="patent-data-table-td patent-date-value">Jan 26, 2012</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods for cancer management targeting co-029</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012019991A1?cl=en">WO2012019991A1</a></td><td class="patent-data-table-td patent-date-value">Aug 8, 2011</td><td class="patent-data-table-td patent-date-value">Feb 16, 2012</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods and pharmaceutical compositions for the treatment of hiv-1 infections</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012028703A1?cl=en">WO2012028703A1</a></td><td class="patent-data-table-td patent-date-value">Sep 2, 2011</td><td class="patent-data-table-td patent-date-value">Mar 8, 2012</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Method for the prognosis of the progression of cancer</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012042061A1?cl=en">WO2012042061A1</a></td><td class="patent-data-table-td patent-date-value">Oct 3, 2011</td><td class="patent-data-table-td patent-date-value">Apr 5, 2012</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods for predicting the progression and treating a chronic kidney disease in a patient</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012042289A1?cl=en">WO2012042289A1</a></td><td class="patent-data-table-td patent-date-value">Sep 28, 2010</td><td class="patent-data-table-td patent-date-value">Apr 5, 2012</td><td class="patent-data-table-td ">Inserm ( Institut National De La Sante Et De La Recherche Medicale)</td><td class="patent-data-table-td ">Methods and pharmaceutical compositions for the treatment of bone density related diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012058072A1?cl=en">WO2012058072A1</a></td><td class="patent-data-table-td patent-date-value">Oct 19, 2011</td><td class="patent-data-table-td patent-date-value">May 3, 2012</td><td class="patent-data-table-td ">Harrisvaccines, Inc</td><td class="patent-data-table-td ">Method of rapidly producing vaccines for animals</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012058073A2?cl=en">WO2012058073A2</a></td><td class="patent-data-table-td patent-date-value">Oct 19, 2011</td><td class="patent-data-table-td patent-date-value">May 3, 2012</td><td class="patent-data-table-td ">Harrisvaccines, Inc.</td><td class="patent-data-table-td ">Methods and compositions to protect aquatic invertebrates from disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012072681A1?cl=en">WO2012072681A1</a></td><td class="patent-data-table-td patent-date-value">Nov 30, 2011</td><td class="patent-data-table-td patent-date-value">Jun 7, 2012</td><td class="patent-data-table-td ">Inserm (Institut National De La Sante Et De La Recherche Medicale)</td><td class="patent-data-table-td ">Diagnostic and treatment of chronic heart failure</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012072820A1?cl=en">WO2012072820A1</a></td><td class="patent-data-table-td patent-date-value">Dec 5, 2011</td><td class="patent-data-table-td patent-date-value">Jun 7, 2012</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods and pharmaceutical compositions for the treatment of heart failure</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012074868A2?cl=en">WO2012074868A2</a></td><td class="patent-data-table-td patent-date-value">Nov 23, 2011</td><td class="patent-data-table-td patent-date-value">Jun 7, 2012</td><td class="patent-data-table-td ">Ms Technologies, Llc</td><td class="patent-data-table-td ">Optimized expression of glyphosate resistance encoding nucleic acid molecules in plant cells</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012107589A1?cl=en">WO2012107589A1</a></td><td class="patent-data-table-td patent-date-value">Feb 13, 2012</td><td class="patent-data-table-td patent-date-value">Aug 16, 2012</td><td class="patent-data-table-td ">Centre Hospitalier Universitaire D&#39;amiens</td><td class="patent-data-table-td ">Methods and pharmaceutical compositions for the treatment and prevention of hcv infections</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012112586A1?cl=en">WO2012112586A1</a></td><td class="patent-data-table-td patent-date-value">Feb 14, 2012</td><td class="patent-data-table-td patent-date-value">Aug 23, 2012</td><td class="patent-data-table-td ">Revivicor, Inc.</td><td class="patent-data-table-td ">Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012120130A1?cl=en">WO2012120130A1</a></td><td class="patent-data-table-td patent-date-value">Mar 9, 2012</td><td class="patent-data-table-td patent-date-value">Sep 13, 2012</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods to characterize patients suffering from hemolysis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012128946A1?cl=en">WO2012128946A1</a></td><td class="patent-data-table-td patent-date-value">Mar 7, 2012</td><td class="patent-data-table-td patent-date-value">Sep 27, 2012</td><td class="patent-data-table-td ">Ms Technologies Llc</td><td class="patent-data-table-td ">Regulatory regions preferentially expressing in non-pollen plant tissue</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012129145A1?cl=en">WO2012129145A1</a></td><td class="patent-data-table-td patent-date-value">Mar 19, 2012</td><td class="patent-data-table-td patent-date-value">Sep 27, 2012</td><td class="patent-data-table-td ">OSI Pharmaceuticals, LLC</td><td class="patent-data-table-td ">Nscle combination therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012140208A1?cl=en">WO2012140208A1</a></td><td class="patent-data-table-td patent-date-value">Apr 13, 2012</td><td class="patent-data-table-td patent-date-value">Oct 18, 2012</td><td class="patent-data-table-td ">Inserm (Institut National De La Sante Et De La Recherche Medicale)</td><td class="patent-data-table-td ">Screening methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012146702A1?cl=en">WO2012146702A1</a></td><td class="patent-data-table-td patent-date-value">Apr 27, 2012</td><td class="patent-data-table-td patent-date-value">Nov 1, 2012</td><td class="patent-data-table-td ">Centre Hospitalier Universitaire De Montpellier</td><td class="patent-data-table-td ">Methods for preparing accessory cells and uses thereof for preparing activated nk cells</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012160130A1?cl=en">WO2012160130A1</a></td><td class="patent-data-table-td patent-date-value">May 24, 2012</td><td class="patent-data-table-td patent-date-value">Nov 29, 2012</td><td class="patent-data-table-td ">Universite Paris Descartes</td><td class="patent-data-table-td ">Erk inhibitors for use in treating spinal muscular atrophy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012163848A1?cl=en">WO2012163848A1</a></td><td class="patent-data-table-td patent-date-value">May 25, 2012</td><td class="patent-data-table-td patent-date-value">Dec 6, 2012</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods and pharmaceutical compositions for the treatment of crohn&#39;s disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012170304A2?cl=en">WO2012170304A2</a></td><td class="patent-data-table-td patent-date-value">Jun 1, 2012</td><td class="patent-data-table-td patent-date-value">Dec 13, 2012</td><td class="patent-data-table-td ">The Regents Of The University Of California</td><td class="patent-data-table-td ">Plants with elevated levels of glucan</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012175711A1?cl=en">WO2012175711A1</a></td><td class="patent-data-table-td patent-date-value">Jun 22, 2012</td><td class="patent-data-table-td patent-date-value">Dec 27, 2012</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Method for predicting the responsiveness of a patient affected with an osteosarcoma to a chemotherapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013014262A1?cl=en">WO2013014262A1</a></td><td class="patent-data-table-td patent-date-value">Jul 27, 2012</td><td class="patent-data-table-td patent-date-value">Jan 31, 2013</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods for diagnosing and treating myhre syndrome</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013022594A1?cl=en">WO2013022594A1</a></td><td class="patent-data-table-td patent-date-value">Jul 23, 2012</td><td class="patent-data-table-td patent-date-value">Feb 14, 2013</td><td class="patent-data-table-td ">The Regents Of The University Of California</td><td class="patent-data-table-td ">Transcription factors for the production of cellulose degrading enzymes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013024022A1?cl=en">WO2013024022A1</a></td><td class="patent-data-table-td patent-date-value">Aug 10, 2012</td><td class="patent-data-table-td patent-date-value">Feb 21, 2013</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods and pharmaceutical compositions for treatment of pulmonary hypertension</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013033380A1?cl=en">WO2013033380A1</a></td><td class="patent-data-table-td patent-date-value">Aug 30, 2012</td><td class="patent-data-table-td patent-date-value">Mar 7, 2013</td><td class="patent-data-table-td ">Genentech, Inc.</td><td class="patent-data-table-td ">Diagnostic markers</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013050405A1?cl=en">WO2013050405A1</a></td><td class="patent-data-table-td patent-date-value">Oct 3, 2012</td><td class="patent-data-table-td patent-date-value">Apr 11, 2013</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods and pharmaceutical compositions for the treatment of th2 mediated diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013053919A2?cl=en">WO2013053919A2</a></td><td class="patent-data-table-td patent-date-value">Oct 12, 2012</td><td class="patent-data-table-td patent-date-value">Apr 18, 2013</td><td class="patent-data-table-td ">Inserm</td><td class="patent-data-table-td ">Biomarkers of renal disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013055530A1?cl=en">WO2013055530A1</a></td><td class="patent-data-table-td patent-date-value">Sep 28, 2012</td><td class="patent-data-table-td patent-date-value">Apr 18, 2013</td><td class="patent-data-table-td ">Genentech, Inc.</td><td class="patent-data-table-td ">Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013057313A1?cl=en">WO2013057313A1</a></td><td class="patent-data-table-td patent-date-value">Oct 22, 2012</td><td class="patent-data-table-td patent-date-value">Apr 25, 2013</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods for the detection and the treatment of cardiac remodeling</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013066665A1?cl=en">WO2013066665A1</a></td><td class="patent-data-table-td patent-date-value">Oct 23, 2012</td><td class="patent-data-table-td patent-date-value">May 10, 2013</td><td class="patent-data-table-td ">Harrisvaccines, Inc</td><td class="patent-data-table-td ">Method of rapidly producing improved vaccines for animals</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013068836A1?cl=en">WO2013068836A1</a></td><td class="patent-data-table-td patent-date-value">Nov 6, 2012</td><td class="patent-data-table-td patent-date-value">May 16, 2013</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013076194A1?cl=en">WO2013076194A1</a></td><td class="patent-data-table-td patent-date-value">Nov 22, 2012</td><td class="patent-data-table-td patent-date-value">May 30, 2013</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods and pharmaceutical compositions for reducing airway hyperresponse</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013103434A1?cl=en">WO2013103434A1</a></td><td class="patent-data-table-td patent-date-value">Oct 23, 2012</td><td class="patent-data-table-td patent-date-value">Jul 11, 2013</td><td class="patent-data-table-td ">Harrisvaccines, Inc.</td><td class="patent-data-table-td ">Methods and compositions to protect aquatic invertebrates from disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013113762A1?cl=en">WO2013113762A1</a></td><td class="patent-data-table-td patent-date-value">Jan 30, 2013</td><td class="patent-data-table-td patent-date-value">Aug 8, 2013</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods and kits for predicting the risk of having a cutaneous melanoma in a subject</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013121034A1?cl=en">WO2013121034A1</a></td><td class="patent-data-table-td patent-date-value">Feb 18, 2013</td><td class="patent-data-table-td patent-date-value">Aug 22, 2013</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods and pharmaceutical compositions for reducing adipose tissue inflammation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013135745A1?cl=en">WO2013135745A1</a></td><td class="patent-data-table-td patent-date-value">Mar 13, 2013</td><td class="patent-data-table-td patent-date-value">Sep 19, 2013</td><td class="patent-data-table-td ">F. Hoffmann-La Roche Ag</td><td class="patent-data-table-td ">Methods of treating melanoma with pak1 inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013164444A1?cl=en">WO2013164444A1</a></td><td class="patent-data-table-td patent-date-value">May 3, 2013</td><td class="patent-data-table-td patent-date-value">Nov 7, 2013</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Method and pharmaceutical composition for use in the treatment and diagnotic of anemia of inflammation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013167582A1?cl=en">WO2013167582A1</a></td><td class="patent-data-table-td patent-date-value">May 7, 2013</td><td class="patent-data-table-td patent-date-value">Nov 14, 2013</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013171296A1?cl=en">WO2013171296A1</a></td><td class="patent-data-table-td patent-date-value">May 16, 2013</td><td class="patent-data-table-td patent-date-value">Nov 21, 2013</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Diagnostic and treatment of sarcoidosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013174834A1?cl=en">WO2013174834A1</a></td><td class="patent-data-table-td patent-date-value">May 22, 2013</td><td class="patent-data-table-td patent-date-value">Nov 28, 2013</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods for diagnosing and treating focal segmental glomerulosclerosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013182711A1?cl=en">WO2013182711A1</a></td><td class="patent-data-table-td patent-date-value">Jun 10, 2013</td><td class="patent-data-table-td patent-date-value">Dec 12, 2013</td><td class="patent-data-table-td ">Sensorion</td><td class="patent-data-table-td ">H4 receptor inhibitors for treating tinnitus</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2014006025A2?cl=en">WO2014006025A2</a></td><td class="patent-data-table-td patent-date-value">Jul 2, 2013</td><td class="patent-data-table-td patent-date-value">Jan 9, 2014</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Marker of pathogenicity in salmonella</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2014013005A1?cl=en">WO2014013005A1</a></td><td class="patent-data-table-td patent-date-value">Jul 18, 2013</td><td class="patent-data-table-td patent-date-value">Jan 23, 2014</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods for preventing and treating chronic kidney disease (ckd)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2014018375A1?cl=en">WO2014018375A1</a></td><td class="patent-data-table-td patent-date-value">Jul 18, 2013</td><td class="patent-data-table-td patent-date-value">Jan 30, 2014</td><td class="patent-data-table-td ">Xenon Pharmaceuticals Inc.</td><td class="patent-data-table-td ">Cyp8b1 and uses thereof in therapeutic and diagnostic methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2014053871A1?cl=en">WO2014053871A1</a></td><td class="patent-data-table-td patent-date-value">Oct 4, 2012</td><td class="patent-data-table-td patent-date-value">Apr 10, 2014</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">A method for screening a compound capable of inhibiting the notch1 transcriptional activity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2014057045A1?cl=en">WO2014057045A1</a></td><td class="patent-data-table-td patent-date-value">Oct 10, 2013</td><td class="patent-data-table-td patent-date-value">Apr 17, 2014</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods and pharmaceutical compositions for treatment of gastrointestinal stromal tumors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2014064192A1?cl=en">WO2014064192A1</a></td><td class="patent-data-table-td patent-date-value">Oct 24, 2013</td><td class="patent-data-table-td patent-date-value">May 1, 2014</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Method and pharmaceutical composition for use in the treatment and prediction of myocardial infraction</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2014064203A1?cl=en">WO2014064203A1</a></td><td class="patent-data-table-td patent-date-value">Oct 24, 2013</td><td class="patent-data-table-td patent-date-value">May 1, 2014</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2014064215A1?cl=en">WO2014064215A1</a></td><td class="patent-data-table-td patent-date-value">Oct 24, 2013</td><td class="patent-data-table-td patent-date-value">May 1, 2014</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2014068070A1?cl=en">WO2014068070A1</a></td><td class="patent-data-table-td patent-date-value">Oct 31, 2013</td><td class="patent-data-table-td patent-date-value">May 8, 2014</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods for preventing antiphospholipid syndrome (aps)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2014072416A1?cl=en">WO2014072416A1</a></td><td class="patent-data-table-td patent-date-value">Nov 7, 2013</td><td class="patent-data-table-td patent-date-value">May 15, 2014</td><td class="patent-data-table-td ">INSERM (Institut National de la Santé et de la Recherche Médicale)</td><td class="patent-data-table-td ">Methods and pharmaceutical compositions for the treatment of bone metastases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2014076235A1?cl=en">WO2014076235A1</a></td><td class="patent-data-table-td patent-date-value">Nov 15, 2013</td><td class="patent-data-table-td patent-date-value">May 22, 2014</td><td class="patent-data-table-td ">Neurochlore</td><td class="patent-data-table-td ">Modulators of intracellular chloride concentration for treating fragile x syndrome</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S455000">435/455</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S325000">435/325</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S320100">435/320.1</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S093200">424/93.2</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc536/defs536.htm&usg=AFQjCNHex3TR9tihVxBKQnsQg6n8YmdVYg#C536S024500">536/24.5</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S093210">424/93.21</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S04400R">514/44.00R</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0009500000">C12N9/50</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0015850000">C12N15/85</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0009100000">C12N9/10</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0009120000">C12N9/12</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0015820000">C12N15/82</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0015630000">C12N15/63</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0015690000">C12N15/69</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N9/127">C12N9/127</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N15/69">C12N15/69</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N15/8218">C12N15/8218</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N15/113">C12N15/113</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N9/1051">C12N9/1051</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2830/00">C12N2830/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2830/002">C12N2830/002</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2830/60">C12N2830/60</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2800/108">C12N2800/108</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N9/503">C12N9/503</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2840/20">C12N2840/20</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2830/55">C12N2830/55</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N15/8283">C12N15/8283</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2840/102">C12N2840/102</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2830/38">C12N2830/38</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2830/15">C12N2830/15</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N15/8216">C12N15/8216</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N15/63">C12N15/63</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2830/42">C12N2830/42</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=CWtgBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N15/85">C12N15/85</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">C12N9/10D1</span>, <span class="nested-value">C12N9/12J48</span>, <span class="nested-value">C12N15/69</span>, <span class="nested-value">C12N15/82B4</span>, <span class="nested-value">C12N9/50A</span>, <span class="nested-value">C12N15/85</span>, <span class="nested-value">C12N15/63</span>, <span class="nested-value">C12N15/82B</span>, <span class="nested-value">C12N15/82C8B6C</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Feb 14, 2012</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Apr 29, 2011</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH OR</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20110209</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WATERHOUSE, PETER MICHAEL;REEL/FRAME:026204/0782</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 8, 2011</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CLAIMS 1-3 AND 8-9 ARE CANCELLED. CLAIMS 4-7 AND 10-22 ARE DETERMINED TO BE PATENTABLE AS AMENDED. NEW CLAIMS 23-41 ARE ADDED AND DETERMINED TO BE PATENTABLE.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 3, 2010</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Apr 6, 2009</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH OR</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STATE OF QUEENSLAND THROUGH ITS DEPARTMENT OF PRIMARY INDUSTRIES;REEL/FRAME:022482/0882</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20031208</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 20, 2009</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH OR</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BENITEC AUSTRALIA LIMITED;REEL/FRAME:022427/0228</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20090320</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 13, 2008</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">BENITEC AUSTRALIA LTD., AUSTRALIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CORRECT ERROR MADE IN PREVIOUSLY RECORDED DOCUMENT AT REEL 018406 FRAME 0188;ASSIGNOR:BENITEC LIMITED;REEL/FRAME:021651/0131</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20060622</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 4, 2006</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 18, 2006</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">BENITEC LIMITED, AUSTRALIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:BENITEC AUSTRALIA LTD.;REEL/FRAME:018406/0188</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20060622</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 23, 2004</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20041004</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 13, 2004</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH OR</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STATE OF QUEENSLAND THROUGH ITS DEPARTMENT OF PRIMARY INDUSTRIES;REEL/FRAME:014337/0535</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20031208</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STATE OF QUEENSLAND THROUGH ITS DEPARTMENT OF PRIMARY INDUSTRIES /AR;REEL/FRAME:014337/0535</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 10, 2003</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">BENITEC AUSTRALIA LIMITED, AUSTRALIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRAHAM, MICHAEL WAYNE;RICE, ROBERT NORMAN;REEL/FRAME:013782/0915;SIGNING DATES FROM 20030617 TO 20030630</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">STATE OF QUEENSLAND THROUGH ITS DEPARTMENT OF PRIM</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRAHAM, MICHAEL WAYNE;RICE, ROBERT NORMAN;REEL/FRAME:013782/0915;SIGNING DATES FROM 20030617 TO 20030630</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">BENITEC AUSTRALIA LIMITED P.O. BOX 4193ST. LUCIA S</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 27, 2001</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">BENITEC AUSTRALIA LTD., AUSTRALIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF ADDRESS;ASSIGNOR:AG-GENE AUSTRALIA LTD.;REEL/FRAME:012116/0897</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20000502</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">BENITEC AUSTRALIA LTD. PRIMARY INDUSTRIES BLDG., 8</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF ADDRESS;ASSIGNOR:AG-GENE AUSTRALIA LTD. /AR;REEL/FRAME:012116/0897</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 23, 2000</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">BENITEC AUSTRALIA LTD., AUSTRALIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:AG-GENE AUSTRALIA LTD.;REEL/FRAME:011197/0523</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20000502</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">PRIMARY INDUSTRIES, AUSTRALIA</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">BENITEC AUSTRALIA LTD. QUEEN STREET BRISBANE AUSTR</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">PRIMARY INDUSTRIES 80 ANN ST. PRIMARY INDUSTRIES B</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 20, 1998</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">AG-GENE AUSTRALIA LTD., AUSTRALIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GRAHAM, MICHAEL WAYNE;REEL/FRAME:009403/0133</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">19980717</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">STATE OF QUEENSLAND THROUGH ITS DEPT. OF PRIMARY I</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U13c0W7qcPqvrp-5SVdnBiwOl0_IA\u0026id=CWtgBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U2he2w030fNodTerZpy8j4YZ6eeqA\u0026id=CWtgBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U2IpDZz14LDyfD_3KvhGVJXdNvjew","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Genetic_constructs_for_delaying_or_repre.pdf?id=CWtgBAABERAJ\u0026output=pdf\u0026sig=ACfU3U0iT5B09Q4CAwsXVjZwUcSf5xUtOw"},"sample_url":"http://www.google.com/patents/reader?id=CWtgBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>